propafenone has been researched along with Atrial Fibrillation in 357 studies
Propafenone: An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity.
propafenone : An aromatic ketone that is 3-(propylamino)propane-1,2-diol in which the hydrogen of the primary hydroxy group is replaced by a 2-(3-phenylpropanoyl)phenyl group. It is a class 1C antiarrhythmic drug with local anesthetic effects, and is used as the hydrochloride salt in the management of supraventricular and ventricular arrhythmias.
Atrial Fibrillation: Abnormal cardiac rhythm that is characterized by rapid, uncoordinated firing of electrical impulses in the upper chambers of the heart (HEART ATRIA). In such case, blood cannot be effectively pumped into the lower chambers of the heart (HEART VENTRICLES). It is caused by abnormal impulse generation.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Propafenone is a class IC antiarrhythmic agent that is commonly used as the first-line therapy for patients with paroxysmal atrial fibrillation (AF) in Taiwan." | 9.69 | An open-label randomized noninferior study of generic name and brand name of propafenone for rhythm control in patients with paroxysmal atrial fibrillation. ( Chang, SL; Chin, CG; Chiou, CW; Hsieh, MH; Hsieh, YC; Huang, CL; Hung, Y; Lai, WT; Lee, HC; Lin, TH; Lin, WS; Lin, YJ; Lin, YK; Yeh, TC, 2023) |
| "Amiodarone and propafenone are commonly used to maintain sinus rhythm in patients with atrial fibrillation (AF)." | 9.34 | Comparison of Amiodarone and Propafenone in Blanking Period after Radiofrequency Catheter Ablation in Patients with Atrial Fibrillation: A Propensity Score-Matched Study. ( Chen, L; Chen, X; Fan, L; Gong, K; Huang, R; Lin, J; Xu, Z; Zhang, F; Zhang, Y, 2020) |
| "Our objective was to compare the efficacy of dronedarone and propafenone in maintaining sinus rhythm in patients with atrial fibrillation (AF) after electrical cardioversion." | 9.19 | Efficacy of dronedarone versus propafenone in the maintenance of sinus rhythm in patients with atrial fibrillation after electrical cardioversion. ( Byeon, K; Chun, KJ; Im, SI; Kim, JS; On, YK; Park, KM; Park, SJ, 2014) |
| "To investigate the efficacy and safety of intravenous ibutilide for conversion of atrial fibrillation (AF) and flutter (AFL) to sinus rhythm." | 9.17 | [Efficacy and safety of ibutilide for conversion of atrial fibrillation/flutter]. ( Ma, C; Xiang, M; Yang, Y; Yu, Z; Zhang, S, 2013) |
| "An oral loading dose of propafenone 600 mg is used in our center as in other places around the world for conversion of recent-onset atrial fibrillation (AF) in patients without structural heart disease." | 9.17 | Propafenone versus vernakalant for conversion of recent-onset atrial fibrillation. ( Aragon, M; Conde, D; Corrales Barbosa, A; Costabel, JP; Giniger, A; Klein, A; Lambardi, F; Trivi, M, 2013) |
| "To investigate effects of IV administration of propafenone for naturally occurring and experimentally induced chronic atrial fibrillation in horses." | 9.14 | Use of propafenone for conversion of chronic atrial fibrillation in horses. ( De Clercq, D; Deprez, P; Tavernier, R; van Loon, G; Verbesselt, R, 2009) |
| "A prospective, randomized study was conducted to evaluate the efficacy and tolerability of oral propafenone and quinidine for the conversion of paroxysmal atrial fibrillation (AF)." | 9.14 | Efficacy and tolerability of oral propafenone versus quinidine in the treatment of recent onset atrial fibrillation: A randomized, prospective study. ( Kochanowski, J; Kosior, DA; Opolski, G; Piatkowski, R; Postuła, M; Rabczenko, D; Scisło, P, 2009) |
| "We studied the efficacy of propafenone in preventing atrial tachyarrhythmias after cardiac surgery, and the possible relationships between CYP2D6 polymorphism and the efficacy, pharmacokinetics, and tolerability of propafenone." | 9.13 | Propafenone for the prevention of atrial tachyarrhythmias after cardiac surgery: a randomized, double-blind placebo-controlled trial. ( Bail, D; Böhm, JO; Delabar, U; Drescher, S; Eichelbaum, M; Engel, C; Fux, R; Gleiter, CH; Hellberg, KD; Hofmann, U; Igel, S; Jägle, C; Kivistö, KT; Marx, C; Meisner, C; Mörike, K; Rein, JG; Schaeffeler, E; Schwab, M; Wagner, F; Ziemer, G, 2008) |
| "The aim of this study was to compare the effect of valsartan/amlodipine and atenolol/amlodipine combination in preventing the recurrence of atrial fibrillation (AF) in hypertensive diabetic patients with a history of recent paroxysmal atrial fibrillation." | 9.13 | Comparative evaluation of effect of valsartan/amlodipine and atenolol/amlodipine combinations on atrial fibrillation recurrence in hypertensive patients with type 2 diabetes mellitus. ( Corradi, L; Derosa, G; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Zoppi, A, 2008) |
| "To assess the effectiveness and safety of pharmacological conversion of persistent atrial fibrillation (AF) with a combined propafenone plus ibutilide regimen." | 9.12 | Propafenone added to ibutilide increases conversion rates of persistent atrial fibrillation. ( Draganigos, A; Goudevenos, JA; Katsouras, CS; Kolettis, TM; Kolios, P; Korantzopoulos, P; Leontaridis, I; Naka, KK; Papathanasiou, A, 2006) |
| "To compare the efficacy and safety of amiodarone and propafenone when used for the prevention of atrial fibrillation (AF) and maintenance of normal sinus rhythm in patients with refractory AF." | 9.11 | Long-term maintenance of normal sinus rhythm in patients with current symptomatic atrial fibrillation: amiodarone vs propafenone, both in low doses. ( Hamilos, MI; Igoumenidis, NE; Klapsinos, NC; Kochiadakis, GE; Tzerakis, PG; Vardas, PE; Zacharis, EA, 2004) |
| "The aim of this study was to investigate the efficacy and safety of propafenone in the prevention of atrial fibrillation (AF) relapse after restoration of sinus rhythm." | 9.11 | Efficacy of propafenone for maintaining sinus rhythm in patients with recent onset or persistent atrial fibrillation after conversion: a randomized, placebo-controlled study. ( Altinbas, A; Dogan, A; Ergene, O; Ergene, U; Gedikli, O; Kinay, O; Nazli, C; Ozaydin, M; Ucarci, Y, 2004) |
| "We evaluated the safety and efficacy of ibutilide when added to propafenone in treating both paroxysmal and chronic atrial fibrillation (AF) and atrial flutter (AFL)." | 9.11 | Ibutilide added to propafenone for the conversion of atrial fibrillation and atrial flutter. ( Chiladakis, JA; Kalogeropoulos, A; Manolis, AS; Patsouras, N, 2004) |
| "We sought to assess the efficacy and safety of ibutilide cardioversion for those with atrial fibrillation (AF) or atrial flutter (AFL) receiving long-term treatmentwith class IC agents." | 9.11 | Use of ibutilide in cardioversion of patients with atrial fibrillation or atrial flutter treated with class IC agents. ( Bonso, A; Glatter, KA; Hongo, RH; Raviele, A; Rossillo, A; Scheinman, MM; Themistoclakis, S; Yang, Y, 2004) |
| "The efficacy and safety of oral propafenone for the prevention of atrial fibrillation (AF) were tested in a group of 293 patients who underwent coronary artery bypass grafting." | 9.11 | Effectiveness of oral propafenone for the prevention of atrial fibrillation after coronary artery bypass grafting. ( Amsterdam, E; Kowey, PR; Yannicelli, D, 2004) |
| "This prospective, randomized, single-blinded, placebo-controlled study compared the efficacy and safety of sotalol and propafenone when used for long-term prevention of atrial fibrillation." | 9.11 | Sotalol versus propafenone for long-term maintenance of normal sinus rhythm in patients with recurrent symptomatic atrial fibrillation. ( Chlouverakis, GI; Hamilos, ME; Igoumenidis, NE; Klapsinos, NC; Kochiadakis, GE; Tzerakis, PG; Vardas, PE, 2004) |
| "To compare the efficacy and safety of ibutilide versus propafenone in immediate cardioversion of atrial fibrillation (AF) and atrial flutter (AFL) lasted less than 90 days." | 9.11 | [Immediate cardioversion of atrial fibrillation and atrial flutter lasting less than 90 days by ibutilide versus propafenone: a multicenter study]. ( Fang, Q; Ge, JB; Guo, JH; Guo, JX; Han, SM; Sun, YM; Wan, Z; Zhang, HC; Zheng, YA; Zhu, WQ, 2005) |
| "This study was to evaluate the efficacy and safety of ibutilide and propafenone given intravenously in converting recent onset atrial fibrillation (AF)." | 9.11 | Comparison of intravenous ibutilide vs. propafenone for rapid termination of recent onset atrial fibrillation. ( Guo, JH; Li, XB; Xn, Y; Zhang, HCh; Zhang, N; Zhang, P, 2005) |
| "We report a double-blind, multicenter, multinational, placebo-controlled, and well-controlled trial to prove that the sustained-release (SR) formulation of propafenone is superior to placebo in preventing symptoms of paroxysmal atrial fibrillation (AF)." | 9.10 | Efficacy and safety of propafenone sustained release in the prophylaxis of symptomatic paroxysmal atrial fibrillation (The European Rythmol/Rytmonorm Atrial Fibrillation Trial [ERAFT] Study). ( Camez, A; Eberle, S; Hewkin, A; Kalsch, B; Lip, GY; Lombardi, F; Meinertz, T; Sadowski, ZP, 2002) |
| "The objective of this randomized, double-blind, placebo-controlled clinical trial was to test the efficacy and safety of a new sustained-release preparation of the antiarrhythmic drug propafenone (propafenone SR) in reducing the frequency of symptomatic arrhythmia recurrences in patients with atrial fibrillation (AF)." | 9.10 | Efficacy and safety of sustained-release propafenone (propafenone SR) for patients with atrial fibrillation. ( Carlson, M; Fava, G; Page, RL; Pritchett, EL; Undesser, K, 2003) |
| "For patients in whom antiarrhythmic drug therapy is indicated, low dose amiodarone significantly reduces atrial fibrillation-related costs by reducing the number of atrial fibrillation-related procedures." | 9.10 | Amiodarone reduces procedures and costs related to atrial fibrillation in a controlled clinical trial. ( Couturier, A; Dubuc, M; Frasure-Smith, N; Gagné, P; Lambert, J; Lumer, GB; Nattel, S; Roy, D; Talajic, M; Thibault, B, 2002) |
| "The purpose of this study was to investigate the efficacy and safety of amiodarone and propafenone in the conversion of chronic atrial fibrillation in a prospective, randomized, placebo-controlled study." | 9.09 | Amiodarone versus propafenone for conversion of chronic atrial fibrillation: results of a randomized, controlled study. ( Chlouverakis, GI; Igoumenidis, NE; Kochiadakis, GE; Parthenakis, FI; Vardas, PE, 1999) |
| "Propafenone in a single oral loading dose is safe and promptly effective in patients with recent onset atrial fibrillation." | 9.09 | Safety of oral propafenone in the conversion of recent onset atrial fibrillation to sinus rhythm: a prospective parallel placebo-controlled multicentre study. ( Aschieri, D; Capucci, A; Piepoli, M; Villani, GQ, 1999) |
| "To evaluate, in a prospective and randomized fashion, the efficacy of a pretreatment with verapamil (V) in reducing recurrences of atrial fibrillation (AF) after electrical cardioversion (C)." | 9.09 | Pretreatment with verapamil in patients with persistent or chronic atrial fibrillation who underwent electrical cardioversion. ( De Matteis, C; De Simone, A; Di Napoli, T; Di Stasio, M; Gasparini, M; Petrazzuoli, F; Rotunno, R; Stabile, G; Turco, P; Vitale, DF, 1999) |
| "A prospective, randomized, double-blind study to compare the efficacy in terminating postoperative atrial fibrillation of the class Ic drug propafenone versus class Ia drug procainamide was conducted." | 9.09 | Comparison of propafenone versus procainamide for the acute treatment of atrial fibrillation after cardiac surgery. ( Geelen, P; O'Hara, GE; Plante, S; Roy, D; Roy, N; Talajic, M; Turgeon, J, 1999) |
| "We undertook a prospective, multicenter trial to test the hypothesis that low doses of amiodarone would be more efficacious in preventing recurrent atrial fibrillation than therapy with sotalol or propafenone." | 9.09 | Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. ( Connolly, S; Dorian, P; Dubuc, M; Eisenberg, MJ; Gagné, P; Green, M; Kus, T; Lambert, J; Nattel, S; Roy, D; Talajic, M; Thibault, B, 2000) |
| "We consecutively randomized all emergency patients with non-valvular atrial fibrillation lasting no more than 48 hours to either intravenous or oral initial load of propafenone." | 9.09 | Intravenous versus oral initial load of propafenone for conversion of recent-onset atrial fibrillation in the emergency room: a randomized trial. ( Brai, G; De Simone, M; Geraci, E; Gozzo, D; Gristina, A; Luciano, L; Madonia, S; Maisano, S; Migliore, G; Mineo, R; Muzzo, MP; Nicchi, F; Randazzo, A; Raspanti, G; Rotolo, G; Russo, A; Sagona, F; Schirosa, M; Spinello, M; Stancampiano, R, 2000) |
| "Paroxysmal atrial fibrillation (AF), a frequent cause of repeated hospitalization, is effectively treated with propafenone." | 9.09 | [Propafenone dose for emergency room conversion of paroxysmal atrial fibrillation]. ( Antonelli, D; Darawsha, A; Freedberg, NA; Rimbrot, S; Rosenfeld, T, 1999) |
| "In a prospective, single-blind trial, we randomized 150 consecutive symptomatic patients with acute (< or = 48 hours' duration) atrial fibrillation to receive intravenous flecainide, propafenone, or amiodarone." | 9.09 | Comparison of intravenous flecainide, propafenone, and amiodarone for conversion of acute atrial fibrillation to sinus rhythm. ( Camacho, C; Fernández-Gómez, JM; García-Garmendia, JL; Martínez-Marcos, FJ; Ortega-Carpio, A; Santos, JM, 2000) |
| "This randomized study compared the efficacy and safety of amiodarone, propafenone and sotalol in the prevention of atrial fibrillation." | 9.09 | Amiodarone, sotalol, or propafenone in atrial fibrillation: which is preferred to maintain normal sinus rhythm? ( Chrysostomakis, SI; Igoumenidis, NE; Kaleboubas, MD; Kochiadakis, GE; Marketou, ME; Mavrakis, HE; Vardas, PE, 2000) |
| "The authors report their experience in recent-onset atrial fibrillation treated with intravenous flecainide and propafenone, in comparison with the placebo group." | 9.09 | [Effectiveness and side effects of the treatment with propafenone and flecainide for recent-onset atrial fibrillation]. ( Caccavale, F; Catanzaro, M; Coppo, A; Corsini, F; Corsini, G; Di Maggio, O; Fattore, L; Iodice, E; Martone, A; Romano, A; Romano, S; Toscano, G, 2001) |
| "This study was performed to evaluate, using a randomized double-blind, placebo-controlled protocol, the long-term efficacy and safety of propafenone and sotalol in maintaining sinus rhythm after conversion of recurrent symptomatic atrial fibrillation (AF)." | 9.09 | Long-term efficacy and safety of propafenone and sotalol for the maintenance of sinus rhythm after conversion of recurrent symptomatic atrial fibrillation. ( Bellandi, F; Dabizzi, RP; Frascarelli, F; Giovannini, T; Leoncini, M; Maioli, M; Simonetti, I, 2001) |
| "The purpose of this study was to investigate the efficacy, safety and cost-effectiveness of intravenous and oral propafenone in the conversion of paroxysmal atrial fibrillation propafenone to sinus rhythm." | 9.09 | [Comparison of efficacy, safety and cost-effectiveness of intravenous versus oral propafenone in paroxysmal atrial fibrillation]. ( Grossmann, G; Klecha, T; Klepacka, H; Modrzewska, A; Rumiński, W; Zadura, M, 2001) |
| "A double-blind, placebo-controlled trial of the efficacy and tolerability of propafenone was undertaken in 100 patients with paroxysmal supraventricular tachycardia ([PSVT] n = 52) or atrial fibrillation/flutter ([PAF] n = 48) who had recorded two or more symptomatic arrhythmia recurrences by transtelephonic ECG monitoring during a 3-month drug-free observation period." | 9.08 | A randomized, placebo-controlled trial of propafenone in the prophylaxis of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation. UK Propafenone PSVT Study Group. ( , 1995) |
| "To compare placebo vs two different regimens of propafenone administration--intravenous administration or short-term oral loading--in converting recent-onset atrial fibrillation to sinus rhythm." | 9.08 | Propafenone for conversion of recent-onset atrial fibrillation. A controlled comparison between oral loading dose and intravenous administration. ( Boriani, G; Capucci, A; Lenzi, T; Magnani, B; Sanguinetti, M, 1995) |
| "The safety and efficacy of amiodarone and propafenone in converting atrial fibrillation or flutter after cardiac surgery were compared in a randomized double-blind trial." | 9.08 | Intravenous amiodarone vs propafenone for atrial fibrillation and flutter after cardiac operation. ( Cappiello, E; Di Biasi, P; Mangini, A; Paje, A; Santoli, C; Scrofani, R, 1995) |
| "To evaluate the efficacy of propafenone in converting recent-onset atrial fibrillation (AF) lasting < 7 days, 182 patients were treated intravenously with propafenone (Group 1, n = 98) and with placebo 0." | 9.08 | Effectiveness of intravenous propafenone for conversion of recent-onset atrial fibrillation: a placebo-controlled study. ( Bamoshmoosh, M; Bellandi, F; Cantini, F; Dabizzi, RP; Palchetti, R; Pedone, T, 1995) |
| "Oral propafenone hydrochloride effect was studied on atrial signal-averaged ECG (ASAECG) during time- and frequency-domain analysis in patients with paroxysmal atrial fibrillation (PAF) during ischemic heart disease (IHD)." | 9.08 | [Effect of propafenone hydrochloride on atrial signal-averaged ECG in patients with paroxysmal atrial fibrillation]. ( Banasiak, W; Fuglewicz, A; Kałka, D; Lacheta, W; Molenda, W; Pieróg, M; Ponikowski, P; Telichowski, A; Wiech, K; Zebrowski, J, 1995) |
| "To compare the relative safety of flecainide acetate to propafenone HCl during long-term treatment (12 months), we conducted a randomized, open-label, comparative, parallel, multicenter trial in 200 patients with paroxysmal atrial fibrillation (AF) and no history of heart disease." | 9.08 | Safety of long-term flecainide and propafenone in the management of patients with symptomatic paroxysmal atrial fibrillation: report from the Flecainide and Propafenone Italian Study Investigators. ( Casadei, G; Chimienti, M; Cullen, MT, 1996) |
| "To assess the cardiac and extracardiac safety and efficacy of flecainide versus propafenone in patients suffering from episodes of paroxysmal atrial fibrillation (AF) or atrial flutter, 97 patients were enrolled in a randomized, open-label, long-term, parallel, comparative multicenter study." | 9.08 | Comparison of the safety and efficacy of flecainide versus propafenone in hospital out-patients with symptomatic paroxysmal atrial fibrillation/flutter. The Flecainide AF French Study Group. ( Aliot, E; Denjoy, I, 1996) |
| "In order to compare the long-term safety of flecainide and propafenone, an open label, randomized, parallel group study was performed in 335 patients with paroxysmal atrial fibrillation (n = 200) or paroxysmal supraventricular tachycardia (n = 135), and no history of heart disease." | 9.08 | Safety of flecainide versus propafenone for the long-term management of symptomatic paroxysmal supraventricular tachyarrhythmias. Report from the Flecainide and Propafenone Italian Study (FAPIS) Group. ( Casadei, G; Chimienti, M; Cullen, MT, 1995) |
| "To assess the propafenone and sotalol efficacy in the prevention of paroxysmal atrial fibrillation (FA) we enrolled, in a double blind placebo controlled study over 1 year, 300 patients (168 males); mean age 52." | 9.08 | [Propafenone and sotalol: long-term efficacy and tolerability in the prevention of paroxysmal atrial fibrillation. A placebo-controlled double-blind study]. ( Bellandi, F; Cantini, F; Dabizzi, RP; Niccoli, L; Palchetti, R, 1996) |
| "The aim of this study was to assess the effectiveness of propafenone and quinidine to restore sinus rhythm in patients with paroxysmal atrial fibrillation." | 9.08 | [A comparison between propafenone and hydroquinidine perorally in the treatment of recent-onset atrial fibrillation]. ( Arrigo, F; Cavallaro, L; Coglitore, A; Fazio, F; Oreto, G; Saporito, F; Satullo, G; Sorrenti, S, 1996) |
| "The main aim of the study was to evaluate the safety and efficacy of propafenone versus quinidine as an initial choice in treatment of symptomatic paroxysmal atrial fibrillation." | 9.08 | Comparisons of oral propafenone and quinidine as an initial treatment option in patients with symptomatic paroxysmal atrial fibrillation: a double-blind, randomized trial. ( Chang, MS; Chen, SA; Chiang, CE; Lee, SH; Tai, CT; Wang, SP; Wen, ZC, 1996) |
| "Propafenone, given before electrical cardioversion for chronic atrial fibrillation does not affect the mean defibrillation threshold or the rate of successful arrhythmia conversion." | 9.08 | Effects of oral propafenone administration before electrical cardioversion of chronic atrial fibrillation: a placebo-controlled study. ( Bianconi, L; Castro, A; Chieffi, M; Lukic, V; Mennuni, M; Santini, M, 1996) |
| "Safety and efficacy of propafenone and disopyramide for long-term maintenance of sinus rhythm after electrical cardioversion was studied in 56 patients with chronic atrial fibrillation (median arrhythmia duration, 5 months)." | 9.08 | Propafenone versus disopyramide for maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation: a randomized, double-blind study. PRODIS Study Group. ( Crijns, HJ; Gosselink, AT; Lie, KI, 1996) |
| "The effectiveness of intravenous propafenone for conversion to sinus rhythm (SR) of paroxysmal atrial fibrillation (AF), lasting less than 7 days, was evaluated with a single-blind, randomized, placebo-controlled study, given the possible spontaneous conversion of this arrhythmia." | 9.08 | Intravenous propafenone: efficacy and safety in the conversion to sinus rhythm of recent onset atrial fibrillation--a single-blind placebo-controlled study. ( Bellandi, F; Cantini, F; Dabizzi, RP; Natale, MD; Niccoli, L, 1996) |
| "The primary objective was to evaluate the efficacy of propafenone compared with amiodarone in the reversion of atrial fibrillation or flutter." | 9.08 | The efficacy and safety of intravenous propafenone versus intravenous amiodarone in the conversion of atrial fibrillation or flutter after cardiac surgery. ( Larbuisson, R; Stiels, B; Venneman, I, 1996) |
| "This multicentre, randomized, double-blind study, conducted in parallel groups, was designed to compare the efficacy and safety of cibenzoline (C) and oral propafenone (P) in the prevention of recurrent atrial arrhythmias (M) over a 6-month period." | 9.08 | [Cibenzoline versus propafenone by the oral route for preventing recurrence of atrial arrhythmia: multicenter, randomized, double-blind study]. ( Bleinc, D; Canler, A; Lardoux, H; Maison Blanche, P; Marchand, X; Péraudeau, P; Rouesnel, P; Scheck, F, 1996) |
| "A population of 105 patients with recent onset (< 72 h) atrial fibrillation was randomly treated with propafenone as a single oral loading dose of 450 mg (Regimen A) or 600 mg (Regimen B) or with placebo." | 9.08 | Conversion of recent onset atrial fibrillation to sinus rhythm using a single oral loading dose of propafenone: comparison of two regimens. ( Barone, P; Bonini, W; Boriani, G; Botto, GL; Broffoni, T; Capucci, A; Espureo, M; Ferrari, G; Lombardi, R; Molteni, S, 1997) |
| "The effectiveness of oral propafenone in converting recent-onset atrial fibrillation to sinus rhythm has been established by controlled trials." | 9.08 | Oral propafenone to convert recent-onset atrial fibrillation in patients with and without underlying heart disease. A randomized, controlled trial. ( Biffi, M; Boriani, G; Botto, GL; Broffoni, T; Capucci, A; Della Casa, S; Magnani, B; Rubino, I; Sanguinetti, M, 1997) |
| "The main goal of this study is to evaluate the safety and efficacy of propafenone versus sotalol as an initial choice of treatment in patients with symptomatic paroxysmal atrial fibrillation (AF), according to a double-blind randomized system." | 9.08 | Comparisons of oral propafenone and sotalol as an initial treatment in patients with symptomatic paroxysmal atrial fibrillation. ( Chang, MS; Chen, SA; Chen, YJ; Cheng, JJ; Chiang, CE; Fong, AN; Huang, JL; Lee, SH; Tai, CT; Wen, ZC; Yu, WC, 1997) |
| "To evaluate the efficacy and safety of a single loading oral dose of propafenone in the interruption of recent-onset atrial fibrillation." | 9.08 | Value of single oral loading dose of propafenone in converting recent-onset atrial fibrillation. Results of a randomized, double-blind, controlled study. ( Alvarez, M; Azpitarte, J; Baún, O; Fernández, R; García, R; Martín, F; Moreno, E; Tercedor, L, 1997) |
| "In recent-onset atrial fibrillation, intravenous propafenone has been shown to effectively restore sinus rhythm, whereas the efficacy of intravenous digoxin has been questioned." | 9.08 | Comparison between propafenone and digoxin administered intravenously to patients with acute atrial fibrillation. PAFIT-3 Investigators. The Propafenone in Atrial Fibrillation Italian Trial. ( Bianconi, L; Mennuni, M, 1998) |
| "The efficacy and safety of propafenone as an oral loading dose (600-mg single oral dose) in converting recent-onset atrial fibrillation (< or = 7 days duration) to sinus rhythm were evaluated in a single-blind, placebo-controlled study according to patients' age." | 9.08 | Oral loading with propafenone: a placebo-controlled study in elderly and nonelderly patients with recent onset atrial fibrillation. ( Biffi, M; Boriani, G; Botto, GL; Branzi, A; Broffoni, T; Capucci, A; Della Casa, S; Magnani, B; Rubino, I; Sanguinetti, M, 1998) |
| "The efficacy and safety of intravenous propafenone, amiodarone, or placebo were compared in the treatment of atrial fibrillation (AF) of recent onset (duration < or = 48 hours)." | 9.08 | Intravenous propafenone versus intravenous amiodarone in the management of atrial fibrillation of recent onset: a placebo-controlled study. ( Igoumenidis, NE; Kochiadakis, GE; Marketou, ME; Mezilis, NE; Parthenakis, FI; Simantirakis, EN; Vardas, PE, 1998) |
| "A population of 123 patients with recent-onset (< 72 hours) atrial fibrillation (AF) without heart failure was randomly treated with propafenone (PFN) intravenously (i." | 9.08 | Randomized, crossover, controlled comparison of oral loading versus intravenous infusion of propafenone in recent-onset atrial fibrillation. ( Bonini, W; Botto, GL; Broffoni, T; Cappelletti, G; Espureo, M; Ferrari, G; Lombardi, R; Molteni, S; Pedraglio, E, 1998) |
| "The effectiveness of propafenone versus amiodarone for conversion to sinus rhythm of paroxysmal atrial fibrillation was compared." | 9.07 | [A comparison between propafenone and amiodarone in the conversion to sinus rhythm of atrial fibrillation of recent onset]. ( Alfano, C; Rossini, E; Treglia, A, 1994) |
| "Eighty-seven patients with recent onset atrial fibrillation (< or = 8 days) without clinical signs of heart failure were randomly allocated to one of the following treatments: (i) oral propafenone (600 mg as a loading dose followed after 8 h by 300 mg t." | 9.07 | A controlled study on oral propafenone versus digoxin plus quinidine in converting recent onset atrial fibrillation to sinus rhythm. ( Boriani, G; Capucci, A; Della Casa, S; Magnani, B; Rubino, I; Sanguinetti, M, 1994) |
| "The antiarrhythmic agent propafenone has been reported to prolong atrioventricular node conduction and may be suitable for rate control in atrial fibrillation (AF)." | 9.07 | The inefficacy of intravenous propafenone for rate control in atrial fibrillation. ( Klein, GJ; Leather, RA; Leitch, JW; Murdoch, C; Yee, R, 1994) |
| "The effects of intravenous flecainide and propafenone (2 mg/kg) administered in random order were compared in 16 patients with Wolff-Parkinson-White syndrome." | 9.07 | Effects of flecainide on atrial electrophysiology in the Wolff-Parkinson-White syndrome. ( Camm, AJ; Katritsis, D; Nunain, SO, 1992) |
| "Efficacy and safety of intravenous flecainide (2 mg/kg body weight in 10 minutes), verapamil (10 mg in 1 minute), and propafenone (2 mg/kg body weight in 10 minutes) were investigated in 90 consecutive patients with atrial fibrillation (AF) or flutter (AFL)." | 9.07 | Acute pharmacologic conversion of atrial fibrillation and flutter: the role of flecainide, propafenone, and verapamil. ( Kingma, JH; Suttorp, MJ, 1992) |
| "In 34 patients with a symptomatic accessory atrioventricular connection the reversible protective effect of orally administered flecainide (300 mg/day) and of propafenone (900 mg/day) in control of ventricular response during atrial fibrillation by exercise was assessed." | 9.07 | Reversible protective effect of propafenone or flecainide during atrial fibrillation in patients with an accessory atrioventricular connection. ( Auricchio, A, 1992) |
| "New antiarrhythmic class 1C agents have been proposed in the last few years in an attempt to suppress paroxysmal atrial fibrillation at long-term, as the most commonly used class 1A agents such as quinidine gave highly variable results as regards both side-effects and efficacy." | 9.07 | [Propafenone versus hydroquinidine in long-term pharmacological prophylaxis of atrial fibrillation]. ( Brusca, A; Comba Costa, G; Gaita, F; Gaschino, G; Greco, C; Richiardi, E; Rosettani, E, 1992) |
| "We compared the electrophysiological effects of intravenous propafenone and flecainide on accessory pathway conduction by a randomized crossover study in 16 patients with Wolff-Parkinson-White syndrome." | 9.07 | A comparison of intravenous propafenone and flecainide in the treatment of tachycardias associated with the Wolff-Parkinson-White syndrome. ( Camm, AJ; Garratt, CJ; Gill, J; Linker, NJ; O'Nunain, S; Ward, DE, 1991) |
| "We present our experience on the efficacy of propafenone in ten symptomatic patients with Wolff-Parkinson-White syndrome." | 9.06 | Propafenone in Wolff-Parkinson-White syndrome at risk. ( Chiariello, M; Condorelli, M; De Paola, M; Giasi, M; Santinelli, C; Santinelli, V; Smimmo, D; Turco, P, 1990) |
| "In 69 consecutive patients with recent-onset atrial fibrillation, we compared the usefulness of verapamil, flecainide and propafenone for the acute conversion to sinus rhythm within 1 hour of the start of intravenous infusion." | 9.06 | Comparative evaluation of verapamil, flecainide and propafenone for the acute conversion of atrial fibrillation to sinus rhythm. ( Kastrati, A; Kondili, A; Popa, Y, 1990) |
| "The effects of intravenous procainamide (n = 30) or propafenone (n = 25) were evaluated in 55 patients with acute atrial fibrillation and the Wolff-Parkinson-White syndrome." | 9.06 | Termination of acute atrial fibrillation in the Wolff-Parkinson-White syndrome by procainamide and propafenone: importance of atrial fibrillatory cycle length. ( Boahene, KA; Fujimura, O; Klein, GJ; Sharma, AD; Yee, R, 1990) |
| "To evaluate the efficacy of propafenone for suppression of recurrent paroxysmal symptomatic atrial fibrillation (AF), patients with frequent episodes of AF entered an open-label, dose-ranging study to determine the maximal tolerated dose of propafenone and were subsequently randomized to alternate between propafenone and placebo every month for 4 months." | 9.06 | Usefulness of propafenone for recurrent paroxysmal atrial fibrillation. ( Connolly, SJ; Hoffert, DL, 1989) |
| "The efficacy of intravenous propafenone (2 mg/kg) was assessed in 83 consecutive patients: 68 with atrial fibrillation (AF) and 15 with atrial flutter lasting less than 15 days." | 9.06 | Effectiveness of intravenous propafenone for conversion of atrial fibrillation and flutter of recent onset. ( Bianconi, L; Boccadamo, R; Gentili, C; Pappalardo, A; Pistolese, M, 1989) |
| "The efficacy and safety of intravenous propafenone was studied in 10 patients with Wolff-Parkinson-White syndrome and in 2 patients with a concealed accessory pathway." | 9.06 | Efficacy of propafenone in Wolff-Parkinson-White syndrome: electrophysiologic findings and long-term follow-up. ( Antman, EM; Friedman, PL; Ludmer, PL; McGowan, NE, 1987) |
| " We also performed a literature search to find publications that report propafenone-associated gross hematuria." | 9.01 | Propafenone-associated Gross Hematuria: A Case Report and Review of the Literature. ( Chen, S; Cui, Y; Ding, W; Wang, Z; Ye, J; Zhao, X, 2019) |
| "The efficacy and safety of the single dose oral loading regimen of propafenone for pharmacological cardioversion of recent-onset atrial fibrillation (AFib) was evaluated by analyzing the trials on the subject identified through a comprehensive literature search." | 8.81 | Single oral loading dose of propafenone for pharmacological cardioversion of recent-onset atrial fibrillation. ( Khan, IA, 2001) |
| "This review summarizes the results of placebo-controlled trials of propafenone, a class IC antiarrhythmic drug, in patients with supraventricular tachycardia, atrial fibrillation (AF), and atrial flutter." | 8.80 | Placebo-controlled evaluations of propafenone for atrial tachyarrhythmias. ( Rae, AP, 1998) |
| "To review comparative studies evaluating oral propafenone for restoring sinus rhythm in recent onset atrial fibrillation." | 8.79 | Oral propafenone for rapid conversion of recent onset atrial fibrillation--a review. ( Gin, K; Hughes, C; Sunderji, R, 1997) |
| "Flecainide and propafenone are Class Ic antiarrhythmic drugs that block the cardiac fast inwards Na+ current and are used for rhythm control in patients with atrial fibrillation (AF)." | 8.31 | Medical therapy with flecainide and propafenone in atrial fibrillation: Long-term clinical experience in the tertiary care setting. ( Duru, F; Eriksson, U; Kovacs, B; Krasniqi, N; Yakupoglu, HY, 2023) |
| "Rivaroxaban reduces the risk of thromboembolism in atrial fibrillation (AF) patients, who often also receive antiarrhythmic drugs (AADs) to maintain sinus rhythm." | 8.02 | Safety and Effectiveness of Rivaroxaban in Combination with Various Antiarrhythmic Drugs in Patients with Non-Permanent Atrial Fibrillation. ( Chen, CY; Chiou, WR; Chuang, JY; Huang, CC; Kuo, JY; Lee, YH; Liao, FC; Lin, PL; Liu, LY; Su, MI; Tsai, CT; Wu, YJ, 2021) |
| "Our objective was to evaluate the efficacy and safety of intravenous (IV) sotalol in the treatment of incessant tachyarrhythmias in children with normal cardiac function." | 7.85 | Efficacy of Intravenous Sotalol for Treatment of Incessant Tachyarrhythmias in Children. ( Ge, H; Jiang, H; Li, X; Liu, H; Zhang, Y, 2017) |
| "INTRODUCTION Numerous studies described the effectiveness and safety of antazoline in pharmacological cardioversion of short‑duration atrial fibrillation (AF)." | 7.83 | Comparative effectiveness and safety of antazoline‑based and propafenone‑based strategies for pharmacological cardioversion of short‑duration atrial fibrillation in the emergency department. ( Farkowski, MM; Kowalik, I; Maciąg, A; Pytkowski, M; Sterliński, M; Szwed, H; Woźniak, J; Żurawska, M, 2016) |
| "To estimate cost-effectiveness of dronedarone versus amiodarone, propafenone, and sotalol in patients with atrial fibrillation (AF)." | 7.81 | Analysis of the cost-effectiveness of dronedarone versus amiodarone, propafenone, and sotalol in patients with atrial fibrillation: results for Serbia. ( Jankovic, SM; Kostic, M; Paunovic, D; Tesic, D, 2015) |
| "Vernakalant is a new, safe and effective drug used intravenously, which has proved to be more rapid in converting recent onset atrial fibrillation (AF) to sinus rhythm compared to placebo, amiodarone, propafenone, and flecainide in clinical studies." | 7.80 | Vernakalant: Perception of state of health in patients with a recent-onset atrial fibrillation. ( Aragon, M; Conde, D; Costabel, JP; Lambardi, F; Trivi, M, 2014) |
| "Ranolazine has been shown to produce atrial-selective depression of sodium channel-dependent parameters and suppress atrial fibrillation (AF) in a variety of experimental models." | 7.78 | Atrial-selective sodium channel block strategy to suppress atrial fibrillation: ranolazine versus propafenone. ( Antzelevitch, C; Belardinelli, L; Burashnikov, A, 2012) |
| " We report a case of hidden ECG Brugada pattern, revealed after oral propafenone administration in the setting of pharmaceutical atrial fibrillation cardioversion." | 7.77 | Likelihood of Brugada ECG pattern confirmed after propafenone administration for atrial fibrillation cardioversion. ( Dragios, TD; Kyriakides, ZS; Manolis, AG, 2011) |
| "We report the case of a 46-year-old man who developed syncope, a widened QRS interval, and depressed left ventricular systolic function during propafenone therapy for atrial fibrillation." | 7.76 | Syncope, widened QRS interval, and left ventricular systolic depression: coincident with propafenone therapy for atrial fibrillation. ( Grodman, R; Isber, N; Samaan, RA; Sobamowo, HO; Tamburrino, F, 2010) |
| "We present two cases of proarrhythmia after propafenone treatment." | 7.74 | [Proarrhythmic effect of propafenone in patients with atrial fibrillation and atrial flutter]. ( Jastrzebski, M, 2008) |
| " The case history is reported of a patient with atrial flutter and atrial fibrillation who developed Brugada-like ECG changes when treated with propafenone." | 7.74 | Propafenone-induced Brugada-like ECG changes mistaken as acute myocardial infarction. ( Chutani, S; Grubb, B; Imran, N; Kanjwal, Y, 2008) |
| "The effectiveness and safety of ibutilide (IB) use in patients receiving amiodarone or propafenone for atrial flutter (AFL) and atrial fibrillation (AF) were compared to IB alone." | 7.73 | Efficacy and safety of ibutilide for cardioversion of atrial flutter and fibrillation in patients receiving amiodarone or propafenone. ( Fragakis, N; Katsaris, G; Kozirakis, M; Maligkos, G; Papadopoulos, N; Papanastasiou, S; Tsaritsaniotis, E, 2005) |
| "This is the first study to demonstrate the reproducibility of an oral propafenone loading dose in converting paroxysmal atrial fibrillation in patients without significant cardiac disease or hypertension." | 7.72 | Reproducible efficacy of loading oral propafenone in restoring sinus rhythm in patients with paroxysmal atrial fibrillation. ( Capucci, A; Piepoli, MF; Villani, GQ, 2003) |
| "The clinical outcomes of 114 patients with atrial fibrillation who had been treated with the innovator propafenone, and in whom the drug was then replaced with generic propafenone because of cost containment, were compared." | 7.72 | Efficacy of substituting innovator propafenone for its generic formulation in patients with atrial fibrillation. ( Amit, G; Bonneh, DY; Grosbard, A; Ilia, R; Katz, A; Liss, T; Rosen, A; Wagshal, AB, 2004) |
| "The aim of the study was to evaluate the efficacy of intravenous and oral propafenone for termination of recent onset (<48 hrs) atrial fibrillation." | 7.71 | [Pharmacological cardioversion of atrial fibrillation with intravenous and oral propafenone]. ( Lukoseviciūte, A; Peciuliene, I, 2002) |
| "The objective of this study was to determine the percentage of patients with paroxysmal atrial fibrillation who were poor metabolizers of CYP2D6 in a Chinese population from Hong Kong and to assess the relationship between the dextromethorphan/dextrorphan ratio and the propafenone/5-hydroxypropafenone ratio or the steady-state propafenone concentration." | 7.71 | Evaluation of CYP2D6 oxidation of dextromethorphan and propafenone in a Chinese population with atrial fibrillation. ( Chow, MS; Fan, C; Lau, CP; Tang, MO; White, CM, 2001) |
| "The effects of pilsicainide on vagally induced atrial fibrillation and on electrophysiological parameters were compared with those of propafenone in alpha-chloralose-anesthetized dogs." | 7.70 | Effects of pilsicainide and propafenone on vagally induced atrial fibrillation: role of suppressant effect in conductivity. ( Iwasa, A; Matsunaga, T; Okumura, K; Tabuchi, T; Tayama, S; Tsuchiya, T; Tsunoda, R; Yasue, H, 1998) |
| "We describe a case of 1:1 atrial flutter in a patient with coronary disease taking propafenone." | 7.70 | Atrial flutter with 1:1 atrioventricular conduction caused by propafenone. ( Adams, PC; el-Harari, MB, 1998) |
| "We have investigated the relationship of clinical variables to successful cardioversion of atrial fibrillation (AF) to sinus rhythm using an oral loading dose of propafenone." | 7.70 | Predictors of success in the conversion of new-onset atrial fibrillation using oral propafenone. ( Cete, Y; Ergene, O; Ergene, U; Fowler, J; Nazli, C; Oktay, C, 1998) |
| "(1) To investigate the electrophysiological effects of flecainide and propafenone during atrial fibrillation, and their relation to arrhythmia termination; (2) to investigate the effects of isoprenaline on atrial fibrillation in basal conditions and during treatment with class 1C drugs to evaluate the role of adrenergic stimulation on proarrhythmic events occurring during this treatment." | 7.70 | Electrophysiological effects of flecainide and propafenone on atrial fibrillation cycle and relation with arrhythmia termination. ( Biffi, M; Boriani, G; Branzi, A; Bronzetti, G; Capucci, A; Magnani, B, 1999) |
| "Among the 136 patients treated for atrial fibrillation with amiodarone (n = 96) or propafenone (n = 40), 15 (11%, mean age 65." | 7.70 | Persistent atrial flutter in patients treated for atrial fibrillation with amiodarone and propafenone: electrophysiologic characteristics, radiofrequency catheter ablation, and risk prediction. ( Chang, MS; Chen, SA; Chen, YJ; Chiang, CE; Ding, YA; Feng, AN; Lee, SH; Tai, CT; Yu, WC, 1999) |
| "We studied left atrial function in 55 patients undergoing electrical (n = 23) or chemical (intravenous administration of propafenone, n = 32) attempts at cardioversion from atrial fibrillation." | 7.70 | Transesophageal echocardiographic evidence of more pronounced left atrial stunning after chemical (propafenone) rather than electrical attempts at cardioversion from atrial fibrillation. ( Antonielli, E; Baralis, G; Bassignana, A; Di Leo, M; Pizzuti, A; Rovere, ME; Tanga, M, 1999) |
| "To describe a probable case of transient global amnesia caused by propafenone." | 7.69 | Probable propafenone-induced transient global amnesia. ( Brace, SR; Jones, RJ; Vander Tuin, EL, 1995) |
| " In order to prevent/terminate fibrillation propafenone (Rytmonorm, 450-600 mg/day) was started, however this therapy resulted in permanent atrial flutter of 230-270/min mainly with 2:1 antrioventricular conduction." | 7.69 | [Persistent atrial flutter induced by propafenone (Rytmonorm)]. ( Fazekas, T; Kiss, J; Pap, I; Rudas, L, 1994) |
| "The efficacy and safety of quinidine, as a rapid oral loading therapy, and propafenone in the conversion of atrial fibrillation of <6 months duration to sinus rhythm were compared." | 7.69 | Quinidine versus propafenone for conversion of atrial fibrillation to sinus rhythm. ( Di Benedetto, S, 1997) |
| "One hundred and ninety-six patients with stable atrial fibrillation of recent onset received propafenone (98 patients) or Amiodarone (98 patients) intravenously." | 7.68 | [The efficacy of intravenous propafenone and amiodarone in the conversion of recent-onset atrial fibrillation. A 1-year follow-up with oral treatment]. ( Bellandi, F; Cantini, F; Dabizzi, RP; Palchetti, R; Pedone, T, 1993) |
| "The efficacy of propafenone in the treatment of paroxysmal atrial fibrillation was investigated in 16 patients presenting with frequent and/or poorly tolerated paroxysmal atrial fibrillation despite prophylactic treatment in 13 patients." | 7.68 | [Intravenous and oral propafenone in the treatment and prevention of paroxysmal atrial fibrillation]. ( Bru, P; Cointe, R; Gerard, R; Lévy, S; Metge, M; Paganelli, F; Vrancea, F, 1993) |
| "Propafenone efficacy in conversion of atrial fibrillation to sinus rhythm has been well documented." | 7.68 | [Efficacy of intravenous and per os propafenone in the ambulatory treatment of recent-onset atrial fibrillation]. ( Bartoli, P; Bonechi, F; Brandinelli, A; Fradella, G; Maioli, M; Margheri, M; Mazza, F; Paterni, M; Sansoni, M; Zipoli, A, 1992) |
| "A 77-year-old female with new onset atrial fibrillation occurring in the absence of structural heart disease developed torsade de pointes during therapy with quinidine bisulfate 500 mg orally every 8 hours." | 7.68 | Propafenone-induced torsade de pointes: cross-reactivity with quinidine. ( Cohen, JM; Gillis, AM; Hii, JT; Mitchell, LB; Wyse, DG, 1991) |
| "Propafenone was given to 81 patients (49 males and 32 females, mean age 61 +/- 16 years) with recurrent atrial fibrillation." | 7.68 | Long term efficacy of propafenone for prevention of atrial fibrillation. ( Kerr, CR; Kyles, AE; Murdock, CJ; Vorderbrugge, S; Yeung-Lai-Wah, JA, 1991) |
| "The antiarrhythmic effect of oral propafenone was evaluated in 10 patients with Wolff-Parkinson-White syndrome presenting with non-ventricular arrhythmias (paroxysmal supraventricular tachycardia n = 7, atrial fibrillation or flutter n = 3)." | 7.68 | Propafenone in the prevention of non-ventricular arrhythmias associated with the Wolff-Parkinson-White syndrome. ( Kallikazaros, I; Papoutsakis, P; Stefanadis, C; Vassiliadis, I, 1990) |
| "We describe a case of acute myocardial infarction complicated by atrial and ventricular arrhythmias in which it was possible to verify the effectiveness of lidocaine, mexiletine and propafenone." | 7.67 | Lidocaine, mexiletine and propafenone in the treatment of arrhythmias complicating myocardial infarction. A case report. ( Aguglia, F; De Marzio, P; Gnecchi, M, 1985) |
| "Intravenous propafenone (1 mg/Kg in 3 min) has been administered to 14 patients with recent atrial fibrillation." | 7.67 | [Treatment of recent atrial fibrillation with intravenous propafenone]. ( Arrigo, F; Carerj, B; Carerj, S; Cavalli, G; Cento, D; Consolo, F; Magazù, A; Oreto, G, 1989) |
| "Sixty patients who had recurrent episodes of symptomatic atrial fibrillation or flutter, or both, and who had failed one to five prior drug trials were treated with open label oral propafenone hydrochloride." | 7.67 | Long-term oral propafenone therapy for suppression of refractory symptomatic atrial fibrillation and atrial flutter. ( Antman, EM; Beamer, AD; Cantillon, C; Friedman, PL; Goldman, L; McGowan, N, 1988) |
| "The safety and efficacy of intravenous Propafenone, in the treatment of atrial fibrillation (a." | 7.67 | [Fibrillation and atrial flutter. Immediate control and conversion to sinus rhythm with intravenous propafenone]. ( Bianconi, L; Boccadamo, R; Broglia, R; Pappalardo, A; Pistolese, M, 1987) |
| "The electrophysiologic effects of diprafenone were evaluated in 31 patients (9 X AV nodal reentrant tachycardia, 9 X Wolff-Parkinson-White syndrome, 4 X paroxysmal atrial fibrillation, 10 X recurrent ventricular tachycardia)." | 7.67 | [Electrophysiologic effects of diprafenone in supraventricular and ventricular tachycardia]. ( Beermann, J; Gerckens, U; Lüderitz, B; Manz, M, 1986) |
| "Forty-seven patients with chronic atrial fibrillation and (or) flutter in whom the clinical picture and the length of arrhythmia indicated that drug-mediated cardioversion should be tried were treated with a combination of lidoflazine and propafenon." | 7.66 | [Combined use of propafenon and lidoflazine in chronic atrial fibrillation and flutter (author's transl)]. ( Beck, OA; Hochrein, H, 1980) |
| "Propafenone (PPF) is an antiarrhythmic, Class Ic agent." | 6.70 | The influence of CYP2D6 polymorphism on the antiarrhythmic efficacy of propafenone in patients with paroxysmal atrial fibrillation during 3 months propafenone prophylactic treatment. ( Dmochowska-Perz, M; Jazwinska-Tarnawska, E; Loboz-Grudzien, K; Niewinski, P; Orzechowska-Juzwenko, K; Rzemislawska, Z; Slawin, J, 2001) |
| "Propafenone was given at a dose of 2 mg/kg body weight intravenously (i." | 6.69 | Propafenone versus procainamide for conversion of atrial fibrillation to sinus rhythm. ( Lucchi, GR; Mattioli, AV; Mattioli, G; Vivoli, D, 1998) |
| "The frequent recurrence of paroxysmal atrial fibrillation (PAF) despite the use of standard antiarrhythmic agents prompted the use of new therapeutic approaches." | 6.69 | Control of paroxysmal atrial fibrillation recurrence using combined administration of propafenone and quinidine. ( Chow, MS; Fan, C; Lau, CP; Tang, MO; Tse, HF, 2000) |
| "Pharmacological conversion of paroxysmal atrial fibrillation is frequently necessary." | 6.68 | Intravenous propafenone in paroxysmal atrial fibrillation: a randomized, placebo-controlled, double-blind, multicenter clinical trial. Paroxysmal Atrial Fibrillation Italian Trial (PAFIT)-2 Investigators. ( Buia, G; Fresco, C; Morgera, T; Pavan, A; Pavan, D; Proclemer, A; Vicentini, A, 1996) |
| "Propafenone was clinically effective (complete relief of symptoms) in 26 (74%) patients." | 6.68 | The incidence of asymptomatic paroxysmal atrial fibrillation in patients treated with propranolol or propafenone. ( Ceremuzynski, L; Czepiel, A; Karczmarewicz, S; Karpinski, G; Kulakowski, P; Makowska, E; Wolk, R, 1996) |
| "Previous bradyarrhythmias or sick sinus syndrome (SSS), and concomitant use of antiarrhythmic drugs were exclusion criteria." | 6.68 | Conversion of recent onset atrial fibrillation with single loading oral dose of propafenone: is in-hospital admission absolutely necessary? ( Alfieri, G; Barone, P; Bernasconi, G; Bonini, W; Botto, GL; Broffoni, T; Ferrari, G; Lombardi, R; Molteni, S, 1996) |
| " Oral propafenone at a low dosage 150 mg 3 times daily is well tolerated and effective in maintaining sinus rhythm for 6 months after pharmacologic or electrical restoration of sinus rhythm." | 6.68 | Propafenone for conversion and prophylaxis of atrial fibrillation. Propafenone Atrial Fibrillation Trial Investigators. ( Hoebrechts, R; Stiels, B; Stroobandt, R, 1997) |
| "Propafenone is a class Ic agent for the treatment of atrial arrhythmias with a main hepatic metabolism." | 6.68 | Propafenone in the conversion of atrial fibrillation in patients suffering from chronic renal failure. ( Di Benedetto, A; Di Ieso, N; Liguori, A; Napoli, C; Sorice, P, 1997) |
| "Propafenone is a class 1c antiarrhythmic agent that has an electrophysiologic profile suggesting that it might be potentially effective in recent-onset AF." | 6.67 | Clinical course of recent-onset atrial fibrillation treated with oral propafenone. ( Ganam, R; Ganem, R; Rabner, M; Weiner, P; Zidan, F, 1994) |
| " Consecutive patients were treated with P replacing previous therapy with amiodarone (A) withdrawn on account of adverse side effects occurring on average after 1." | 6.67 | [Prevention of paroxysmal atrial fibrillation with propafenone after withdrawal of amiodarone because of side effects]. ( Foscoli, M; Giofrè, R; Labriola, E; Lolli, C; Tarquinii, M; Toschi, GP, 1993) |
| "The development of a sustained-release formulation of propafenone allowed to reduce the wide fluctuations in plasma levels observed with the immediate release preparation, improving compliance and adherence to therapy, by simplifying the dosing regimen from 3 to 2 daily doses." | 6.48 | Atrial fibrillation and the pharmacological treatment: the role of propafenone. ( Molina, E; Sestito, A, 2012) |
| "Amiodarone was associated with the highest rate of patients experiencing at least one serious adverse event (OR 2." | 6.47 | Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation. ( Eckert, L; Freemantle, N; Lafuente-Lafuente, C; Mitchell, S; Reynolds, M, 2011) |
| "Propafenone is a class IC antiarrhythmic agent that is suitable for oral loading as it reaches peak plasma concentrations within 2 to 4 hours of administration." | 6.41 | Oral loading with propafenone for conversion of recent-onset atrial fibrillation: a review on in-hospital treatment. ( Biffi, M; Boriani, G; Branzi, A; Capucci, A; Martignani, C, 2002) |
| "Propafenone was effective in suppressing recurrences of AF in 55." | 6.40 | Propafenone for the treatment of supraventricular tachycardia and atrial fibrillation: a meta-analysis. ( Antman, EM; Maisel, WH; Reimold, SC, 1998) |
| "Propafenone is a sodium channel blocking agent with a mild beta- and calcium channel-blocking activity." | 6.39 | Guidelines for the use of propafenone in treating supraventricular arrhythmias. ( Camm, AJ; Kishore, AG, 1995) |
| "Antazoline appears to be an efficacious agent for termination of AF in real‑world setting." | 5.72 | Efficacy and safety of antazoline for cardioversion of atrial fibrillation: propensity score matching analysis of a multicenter registry (CANT II Study). ( Balsam, P; Bula, K; Błaszczyk, R; Ceynowa-Sielawko, B; Ćwiek-Rębowska, E; Dembowski, T; Farkowski, M; Kasprzak, JD; Koziński, M; Krzowski, B; Maciąg, A; Miśkowiec, D; Mizia-Stec, K; Ozierański, K; Peller, M; Szołkiewicz, M; Szwed, H; Wańha, W; Wójcik, M; Wróbel, W; Wybraniec, MT, 2022) |
| "No sustained ventricular tachycardia, ventricular fibrillation, sudden cardiac death, or cardiovascular mortality were observed." | 5.72 | Propafenone use in coronary artery disease patients undergoing atrial fibrillation ablation. ( Aksu, T; Aras, D; Cay, S; Kara, M; Ozcan, F; Ozeke, O; Topaloglu, S, 2022) |
| "Propafenone is a class IC antiarrhythmic agent that is commonly used as the first-line therapy for patients with paroxysmal atrial fibrillation (AF) in Taiwan." | 5.69 | An open-label randomized noninferior study of generic name and brand name of propafenone for rhythm control in patients with paroxysmal atrial fibrillation. ( Chang, SL; Chin, CG; Chiou, CW; Hsieh, MH; Hsieh, YC; Huang, CL; Hung, Y; Lai, WT; Lee, HC; Lin, TH; Lin, WS; Lin, YJ; Lin, YK; Yeh, TC, 2023) |
| "When verapamil treatment was stopped, the patient experienced AF recurrence." | 5.51 | Treatment with verapamil for restoration of sinus rhythm in atrial fibrillation with rapid ventricular response: A case report. ( Chen, L; Liang, D; Lin, J; Lin, Y; Qi, G; Tian, W; Wang, X, 2019) |
| " We analysed the differences between amiodarone and class IC group in terms of efficacy and safety that is conversion to sinus rhythm rates within 12 and 48 h after starting treatment, time to conversion, and adverse drug effects." | 5.46 | Efficacy and safety in pharmacological cardioversion of recent-onset atrial fibrillation: a propensity score matching to compare amiodarone vs class IC antiarrhythmic drugs. ( Bonora, A; Dilda, A; Franchi, E; Maccagnani, A; Olivieri, O; Pistorelli, C; Taioli, G; Turcato, G; Zerman, G, 2017) |
| " Therefore, oral loading with propafenone (as "pill-in-the-pocket" treatment of recent-onset atrial fibrillation) in a patient on concurrent carvedilol treatment may lead to a pharmacokinetic interaction, with high plasma levels of propafenone and potential drug-related adverse effects." | 5.36 | Atrial fibrillation: adverse effects of "pill-in-the-pocket" treatment and propafenone-carvedilol interaction. ( Biffi, M; Boriani, G; Diemberger, I; Domenichini, G; Martignani, C; Marziali, A, 2010) |
| "Pill-in-the-pocket treatment should be prescribed only if the administration of a loading oral dose of flecainide or propafenone has been proved safe in hospital, since major adverse effects have been reported in 5% of patients during in-hospital treatment." | 5.36 | Intravenous administration of flecainide or propafenone in patients with recent-onset atrial fibrillation does not predict adverse effects during 'pill-in-the-pocket' treatment. ( Alboni, P; Boriani, G; Botto, GL; Capucci, A; Iori, M; Mancini, M; Mariconti, B; Pacchioni, F; Pasanisi, G; Russo, G, 2010) |
| "Amiodarone and propafenone are commonly used to maintain sinus rhythm in patients with atrial fibrillation (AF)." | 5.34 | Comparison of Amiodarone and Propafenone in Blanking Period after Radiofrequency Catheter Ablation in Patients with Atrial Fibrillation: A Propensity Score-Matched Study. ( Chen, L; Chen, X; Fan, L; Gong, K; Huang, R; Lin, J; Xu, Z; Zhang, F; Zhang, Y, 2020) |
| "Propafenone was prescribed at the initial dose of 600 mg/day in 65% of patients." | 5.31 | [Efficacy and tolerance of propafenone after correction of atrial fibrillation: PEPS pharmaco-epidemiologic study]. ( Davy, JM; Funck-Brentano, C; Jaillon, P; Mary-Krause, M; Simon, T; Weingrod, M, 2002) |
| "Propafenone is an effective antiarrhythmic drug used widely for the treatment of supraventricular and ventricular arrhythmias." | 5.31 | Propafenone-induced ataxia: report of three cases. ( Odeh, M; Oliven, A; Seligmann, H, 2000) |
| "Three patients experienced recurrence of AF in the early follow-up." | 5.29 | Role of transesophageal pacing in recurrent atrial fibrillation. Experience with propafenone. ( Bellizzi, G; Candelmo, F; Foffa, A; Guarino, P; Martino, DF; Morella, A; Parente, A; Turco, P; Viola, V, 1994) |
| "Propafenone was less effective (mean effect 3." | 5.27 | European experience with the antiarrhythmic efficacy of propafenone for supraventricular and ventricular arrhythmias. ( Assayag, P; Coumel, P; Leclercq, JF, 1984) |
| "Our objective was to compare the efficacy of dronedarone and propafenone in maintaining sinus rhythm in patients with atrial fibrillation (AF) after electrical cardioversion." | 5.19 | Efficacy of dronedarone versus propafenone in the maintenance of sinus rhythm in patients with atrial fibrillation after electrical cardioversion. ( Byeon, K; Chun, KJ; Im, SI; Kim, JS; On, YK; Park, KM; Park, SJ, 2014) |
| "To investigate the efficacy and safety of intravenous ibutilide for conversion of atrial fibrillation (AF) and flutter (AFL) to sinus rhythm." | 5.17 | [Efficacy and safety of ibutilide for conversion of atrial fibrillation/flutter]. ( Ma, C; Xiang, M; Yang, Y; Yu, Z; Zhang, S, 2013) |
| "An oral loading dose of propafenone 600 mg is used in our center as in other places around the world for conversion of recent-onset atrial fibrillation (AF) in patients without structural heart disease." | 5.17 | Propafenone versus vernakalant for conversion of recent-onset atrial fibrillation. ( Aragon, M; Conde, D; Corrales Barbosa, A; Costabel, JP; Giniger, A; Klein, A; Lambardi, F; Trivi, M, 2013) |
| "In this study, we randomly compared single oral doses of flecainide, amiodarone and propafenone versus placebo for the conversion of recent atrial fibrillation (AF) (within 48 hours)." | 5.15 | Pharmacological conversion of recent atrial fibrillation: a randomized, placebo-controlled study of three antiarrhythmic drugs. ( Balla, I; Kondili, A; Petrela, E, 2011) |
| "Total of 349 cases of paroxysmal atrial fibrillation, which 117 cases in shensongyangxin group, 115 cases in propafenone group; 117 cases in shensongyangxin + propafenone group." | 5.15 | [Evaluation of shensongyangxin capsules in the treatment of paroxysmal atrial fibrillation: a randomized, double-blind and controlled multicenter trial]. ( Cong, HL; Han, QH; Hou, ZS; Li, SM; Liu, XF; Liu, YJ; Miao, WL; Pu, JL; Qi, XY; Wang, AH; Yang, XC; Zhou, JZ, 2011) |
| "To investigate effects of IV administration of propafenone for naturally occurring and experimentally induced chronic atrial fibrillation in horses." | 5.14 | Use of propafenone for conversion of chronic atrial fibrillation in horses. ( De Clercq, D; Deprez, P; Tavernier, R; van Loon, G; Verbesselt, R, 2009) |
| "A prospective, randomized study was conducted to evaluate the efficacy and tolerability of oral propafenone and quinidine for the conversion of paroxysmal atrial fibrillation (AF)." | 5.14 | Efficacy and tolerability of oral propafenone versus quinidine in the treatment of recent onset atrial fibrillation: A randomized, prospective study. ( Kochanowski, J; Kosior, DA; Opolski, G; Piatkowski, R; Postuła, M; Rabczenko, D; Scisło, P, 2009) |
| "Patients received intravenous flecainide, propafenone, or amiodarone on presentation and a second dose after 6 hours if atrial fibrillation persisted." | 5.14 | Management of patients with acute atrial fibrillation in the ED. ( Abbate, R; Conti, A; Del Taglia, B; Gensini, GF; Grifoni, S; Mariannini, Y; Michelucci, A; Padeletti, L; Pepe, G; Vanni, S, 2010) |
| "We studied the efficacy of propafenone in preventing atrial tachyarrhythmias after cardiac surgery, and the possible relationships between CYP2D6 polymorphism and the efficacy, pharmacokinetics, and tolerability of propafenone." | 5.13 | Propafenone for the prevention of atrial tachyarrhythmias after cardiac surgery: a randomized, double-blind placebo-controlled trial. ( Bail, D; Böhm, JO; Delabar, U; Drescher, S; Eichelbaum, M; Engel, C; Fux, R; Gleiter, CH; Hellberg, KD; Hofmann, U; Igel, S; Jägle, C; Kivistö, KT; Marx, C; Meisner, C; Mörike, K; Rein, JG; Schaeffeler, E; Schwab, M; Wagner, F; Ziemer, G, 2008) |
| "The aim of this study was to compare the effect of valsartan/amlodipine and atenolol/amlodipine combination in preventing the recurrence of atrial fibrillation (AF) in hypertensive diabetic patients with a history of recent paroxysmal atrial fibrillation." | 5.13 | Comparative evaluation of effect of valsartan/amlodipine and atenolol/amlodipine combinations on atrial fibrillation recurrence in hypertensive patients with type 2 diabetes mellitus. ( Corradi, L; Derosa, G; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Zoppi, A, 2008) |
| "To assess the effectiveness and safety of pharmacological conversion of persistent atrial fibrillation (AF) with a combined propafenone plus ibutilide regimen." | 5.12 | Propafenone added to ibutilide increases conversion rates of persistent atrial fibrillation. ( Draganigos, A; Goudevenos, JA; Katsouras, CS; Kolettis, TM; Kolios, P; Korantzopoulos, P; Leontaridis, I; Naka, KK; Papathanasiou, A, 2006) |
| " Separate studies have demonstrated the utility of single oral bolus propafenone for conversion of recent-onset atrial fibrillation (AF); however, most patients were hospitalized, had no structural heart disease, were taking no other antiarrhythmic drugs, and were not exposed to concomitant shock." | 5.12 | Utility of adjunctive single oral bolus propafenone therapy in patients with atrial defibrillators. ( Euler, DE; Harvey, MN; Hoyt, RH; Koehler, JL; Schwartzman, D; Ujhelyi, MR, 2006) |
| "To compare the efficacy and safety of amiodarone and propafenone when used for the prevention of atrial fibrillation (AF) and maintenance of normal sinus rhythm in patients with refractory AF." | 5.11 | Long-term maintenance of normal sinus rhythm in patients with current symptomatic atrial fibrillation: amiodarone vs propafenone, both in low doses. ( Hamilos, MI; Igoumenidis, NE; Klapsinos, NC; Kochiadakis, GE; Tzerakis, PG; Vardas, PE; Zacharis, EA, 2004) |
| "The aim of this study was to investigate the efficacy and safety of propafenone in the prevention of atrial fibrillation (AF) relapse after restoration of sinus rhythm." | 5.11 | Efficacy of propafenone for maintaining sinus rhythm in patients with recent onset or persistent atrial fibrillation after conversion: a randomized, placebo-controlled study. ( Altinbas, A; Dogan, A; Ergene, O; Ergene, U; Gedikli, O; Kinay, O; Nazli, C; Ozaydin, M; Ucarci, Y, 2004) |
| "We evaluated the safety and efficacy of ibutilide when added to propafenone in treating both paroxysmal and chronic atrial fibrillation (AF) and atrial flutter (AFL)." | 5.11 | Ibutilide added to propafenone for the conversion of atrial fibrillation and atrial flutter. ( Chiladakis, JA; Kalogeropoulos, A; Manolis, AS; Patsouras, N, 2004) |
| "We sought to assess the efficacy and safety of ibutilide cardioversion for those with atrial fibrillation (AF) or atrial flutter (AFL) receiving long-term treatmentwith class IC agents." | 5.11 | Use of ibutilide in cardioversion of patients with atrial fibrillation or atrial flutter treated with class IC agents. ( Bonso, A; Glatter, KA; Hongo, RH; Raviele, A; Rossillo, A; Scheinman, MM; Themistoclakis, S; Yang, Y, 2004) |
| "The efficacy and safety of oral propafenone for the prevention of atrial fibrillation (AF) were tested in a group of 293 patients who underwent coronary artery bypass grafting." | 5.11 | Effectiveness of oral propafenone for the prevention of atrial fibrillation after coronary artery bypass grafting. ( Amsterdam, E; Kowey, PR; Yannicelli, D, 2004) |
| "In-hospital administration of flecainide and propafenone in a single oral loading dose has been shown to be effective and superior to placebo in terminating atrial fibrillation." | 5.11 | Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach. ( Alboni, P; Baldi, N; Baroffio, R; Botto, GL; Calzolari, M; Gaggioli, G; Gianfranchi, L; Luzi, M; Marchi, P; Russo, V; Solano, A, 2004) |
| "This prospective, randomized, single-blinded, placebo-controlled study compared the efficacy and safety of sotalol and propafenone when used for long-term prevention of atrial fibrillation." | 5.11 | Sotalol versus propafenone for long-term maintenance of normal sinus rhythm in patients with recurrent symptomatic atrial fibrillation. ( Chlouverakis, GI; Hamilos, ME; Igoumenidis, NE; Klapsinos, NC; Kochiadakis, GE; Tzerakis, PG; Vardas, PE, 2004) |
| "To compare the efficacy and safety of ibutilide versus propafenone in immediate cardioversion of atrial fibrillation (AF) and atrial flutter (AFL) lasted less than 90 days." | 5.11 | [Immediate cardioversion of atrial fibrillation and atrial flutter lasting less than 90 days by ibutilide versus propafenone: a multicenter study]. ( Fang, Q; Ge, JB; Guo, JH; Guo, JX; Han, SM; Sun, YM; Wan, Z; Zhang, HC; Zheng, YA; Zhu, WQ, 2005) |
| "This study was to evaluate the efficacy and safety of ibutilide and propafenone given intravenously in converting recent onset atrial fibrillation (AF)." | 5.11 | Comparison of intravenous ibutilide vs. propafenone for rapid termination of recent onset atrial fibrillation. ( Guo, JH; Li, XB; Xn, Y; Zhang, HCh; Zhang, N; Zhang, P, 2005) |
| "We report a double-blind, multicenter, multinational, placebo-controlled, and well-controlled trial to prove that the sustained-release (SR) formulation of propafenone is superior to placebo in preventing symptoms of paroxysmal atrial fibrillation (AF)." | 5.10 | Efficacy and safety of propafenone sustained release in the prophylaxis of symptomatic paroxysmal atrial fibrillation (The European Rythmol/Rytmonorm Atrial Fibrillation Trial [ERAFT] Study). ( Camez, A; Eberle, S; Hewkin, A; Kalsch, B; Lip, GY; Lombardi, F; Meinertz, T; Sadowski, ZP, 2002) |
| "The objective of this randomized, double-blind, placebo-controlled clinical trial was to test the efficacy and safety of a new sustained-release preparation of the antiarrhythmic drug propafenone (propafenone SR) in reducing the frequency of symptomatic arrhythmia recurrences in patients with atrial fibrillation (AF)." | 5.10 | Efficacy and safety of sustained-release propafenone (propafenone SR) for patients with atrial fibrillation. ( Carlson, M; Fava, G; Page, RL; Pritchett, EL; Undesser, K, 2003) |
| "In this multicentre randomized controlled trial, 68 patients affected by severely symptomatic paroxysmal atrial fibrillation were assigned, after successful atrioventricular junction ablation and pacing treatment, to antiarrhythmic drug therapy with amiodarone, propafenone, flecainide or sotalol and were compared with 69 patients assigned, after successful AV junction ablation and pacing treatment, to no antiarrhythmic drug therapy." | 5.10 | An evaluation of the strategy of maintenance of sinus rhythm by antiarrhythmic drug therapy after ablation and pacing therapy in patients with paroxysmal atrial fibrillation. ( Alboni, P; Bongiorni, MG; Botto, GL; Brignole, M; Bruna, C; Gasparini, M; Menozzi, C; Ometto, R; Verlato, R; Vincenti, A, 2002) |
| "For patients in whom antiarrhythmic drug therapy is indicated, low dose amiodarone significantly reduces atrial fibrillation-related costs by reducing the number of atrial fibrillation-related procedures." | 5.10 | Amiodarone reduces procedures and costs related to atrial fibrillation in a controlled clinical trial. ( Couturier, A; Dubuc, M; Frasure-Smith, N; Gagné, P; Lambert, J; Lumer, GB; Nattel, S; Roy, D; Talajic, M; Thibault, B, 2002) |
| "The purpose of this study was to investigate the efficacy and safety of amiodarone and propafenone in the conversion of chronic atrial fibrillation in a prospective, randomized, placebo-controlled study." | 5.09 | Amiodarone versus propafenone for conversion of chronic atrial fibrillation: results of a randomized, controlled study. ( Chlouverakis, GI; Igoumenidis, NE; Kochiadakis, GE; Parthenakis, FI; Vardas, PE, 1999) |
| "Propafenone in a single oral loading dose is safe and promptly effective in patients with recent onset atrial fibrillation." | 5.09 | Safety of oral propafenone in the conversion of recent onset atrial fibrillation to sinus rhythm: a prospective parallel placebo-controlled multicentre study. ( Aschieri, D; Capucci, A; Piepoli, M; Villani, GQ, 1999) |
| "To evaluate, in a prospective and randomized fashion, the efficacy of a pretreatment with verapamil (V) in reducing recurrences of atrial fibrillation (AF) after electrical cardioversion (C)." | 5.09 | Pretreatment with verapamil in patients with persistent or chronic atrial fibrillation who underwent electrical cardioversion. ( De Matteis, C; De Simone, A; Di Napoli, T; Di Stasio, M; Gasparini, M; Petrazzuoli, F; Rotunno, R; Stabile, G; Turco, P; Vitale, DF, 1999) |
| "A prospective, randomized, double-blind study to compare the efficacy in terminating postoperative atrial fibrillation of the class Ic drug propafenone versus class Ia drug procainamide was conducted." | 5.09 | Comparison of propafenone versus procainamide for the acute treatment of atrial fibrillation after cardiac surgery. ( Geelen, P; O'Hara, GE; Plante, S; Roy, D; Roy, N; Talajic, M; Turgeon, J, 1999) |
| "We undertook a prospective, multicenter trial to test the hypothesis that low doses of amiodarone would be more efficacious in preventing recurrent atrial fibrillation than therapy with sotalol or propafenone." | 5.09 | Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. ( Connolly, S; Dorian, P; Dubuc, M; Eisenberg, MJ; Gagné, P; Green, M; Kus, T; Lambert, J; Nattel, S; Roy, D; Talajic, M; Thibault, B, 2000) |
| "We consecutively randomized all emergency patients with non-valvular atrial fibrillation lasting no more than 48 hours to either intravenous or oral initial load of propafenone." | 5.09 | Intravenous versus oral initial load of propafenone for conversion of recent-onset atrial fibrillation in the emergency room: a randomized trial. ( Brai, G; De Simone, M; Geraci, E; Gozzo, D; Gristina, A; Luciano, L; Madonia, S; Maisano, S; Migliore, G; Mineo, R; Muzzo, MP; Nicchi, F; Randazzo, A; Raspanti, G; Rotolo, G; Russo, A; Sagona, F; Schirosa, M; Spinello, M; Stancampiano, R, 2000) |
| "Paroxysmal atrial fibrillation (AF), a frequent cause of repeated hospitalization, is effectively treated with propafenone." | 5.09 | [Propafenone dose for emergency room conversion of paroxysmal atrial fibrillation]. ( Antonelli, D; Darawsha, A; Freedberg, NA; Rimbrot, S; Rosenfeld, T, 1999) |
| "In a prospective, single-blind trial, we randomized 150 consecutive symptomatic patients with acute (< or = 48 hours' duration) atrial fibrillation to receive intravenous flecainide, propafenone, or amiodarone." | 5.09 | Comparison of intravenous flecainide, propafenone, and amiodarone for conversion of acute atrial fibrillation to sinus rhythm. ( Camacho, C; Fernández-Gómez, JM; García-Garmendia, JL; Martínez-Marcos, FJ; Ortega-Carpio, A; Santos, JM, 2000) |
| "This randomized study compared the efficacy and safety of amiodarone, propafenone and sotalol in the prevention of atrial fibrillation." | 5.09 | Amiodarone, sotalol, or propafenone in atrial fibrillation: which is preferred to maintain normal sinus rhythm? ( Chrysostomakis, SI; Igoumenidis, NE; Kaleboubas, MD; Kochiadakis, GE; Marketou, ME; Mavrakis, HE; Vardas, PE, 2000) |
| "The authors report their experience in recent-onset atrial fibrillation treated with intravenous flecainide and propafenone, in comparison with the placebo group." | 5.09 | [Effectiveness and side effects of the treatment with propafenone and flecainide for recent-onset atrial fibrillation]. ( Caccavale, F; Catanzaro, M; Coppo, A; Corsini, F; Corsini, G; Di Maggio, O; Fattore, L; Iodice, E; Martone, A; Romano, A; Romano, S; Toscano, G, 2001) |
| "This study was performed to evaluate, using a randomized double-blind, placebo-controlled protocol, the long-term efficacy and safety of propafenone and sotalol in maintaining sinus rhythm after conversion of recurrent symptomatic atrial fibrillation (AF)." | 5.09 | Long-term efficacy and safety of propafenone and sotalol for the maintenance of sinus rhythm after conversion of recurrent symptomatic atrial fibrillation. ( Bellandi, F; Dabizzi, RP; Frascarelli, F; Giovannini, T; Leoncini, M; Maioli, M; Simonetti, I, 2001) |
| "The purpose of this study was to investigate the efficacy, safety and cost-effectiveness of intravenous and oral propafenone in the conversion of paroxysmal atrial fibrillation propafenone to sinus rhythm." | 5.09 | [Comparison of efficacy, safety and cost-effectiveness of intravenous versus oral propafenone in paroxysmal atrial fibrillation]. ( Grossmann, G; Klecha, T; Klepacka, H; Modrzewska, A; Rumiński, W; Zadura, M, 2001) |
| "A double-blind, placebo-controlled trial of the efficacy and tolerability of propafenone was undertaken in 100 patients with paroxysmal supraventricular tachycardia ([PSVT] n = 52) or atrial fibrillation/flutter ([PAF] n = 48) who had recorded two or more symptomatic arrhythmia recurrences by transtelephonic ECG monitoring during a 3-month drug-free observation period." | 5.08 | A randomized, placebo-controlled trial of propafenone in the prophylaxis of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation. UK Propafenone PSVT Study Group. ( , 1995) |
| "To compare placebo vs two different regimens of propafenone administration--intravenous administration or short-term oral loading--in converting recent-onset atrial fibrillation to sinus rhythm." | 5.08 | Propafenone for conversion of recent-onset atrial fibrillation. A controlled comparison between oral loading dose and intravenous administration. ( Boriani, G; Capucci, A; Lenzi, T; Magnani, B; Sanguinetti, M, 1995) |
| "The safety and efficacy of amiodarone and propafenone in converting atrial fibrillation or flutter after cardiac surgery were compared in a randomized double-blind trial." | 5.08 | Intravenous amiodarone vs propafenone for atrial fibrillation and flutter after cardiac operation. ( Cappiello, E; Di Biasi, P; Mangini, A; Paje, A; Santoli, C; Scrofani, R, 1995) |
| "To evaluate the efficacy of propafenone in converting recent-onset atrial fibrillation (AF) lasting < 7 days, 182 patients were treated intravenously with propafenone (Group 1, n = 98) and with placebo 0." | 5.08 | Effectiveness of intravenous propafenone for conversion of recent-onset atrial fibrillation: a placebo-controlled study. ( Bamoshmoosh, M; Bellandi, F; Cantini, F; Dabizzi, RP; Palchetti, R; Pedone, T, 1995) |
| "Oral propafenone hydrochloride effect was studied on atrial signal-averaged ECG (ASAECG) during time- and frequency-domain analysis in patients with paroxysmal atrial fibrillation (PAF) during ischemic heart disease (IHD)." | 5.08 | [Effect of propafenone hydrochloride on atrial signal-averaged ECG in patients with paroxysmal atrial fibrillation]. ( Banasiak, W; Fuglewicz, A; Kałka, D; Lacheta, W; Molenda, W; Pieróg, M; Ponikowski, P; Telichowski, A; Wiech, K; Zebrowski, J, 1995) |
| "To compare the relative safety of flecainide acetate to propafenone HCl during long-term treatment (12 months), we conducted a randomized, open-label, comparative, parallel, multicenter trial in 200 patients with paroxysmal atrial fibrillation (AF) and no history of heart disease." | 5.08 | Safety of long-term flecainide and propafenone in the management of patients with symptomatic paroxysmal atrial fibrillation: report from the Flecainide and Propafenone Italian Study Investigators. ( Casadei, G; Chimienti, M; Cullen, MT, 1996) |
| "To assess the cardiac and extracardiac safety and efficacy of flecainide versus propafenone in patients suffering from episodes of paroxysmal atrial fibrillation (AF) or atrial flutter, 97 patients were enrolled in a randomized, open-label, long-term, parallel, comparative multicenter study." | 5.08 | Comparison of the safety and efficacy of flecainide versus propafenone in hospital out-patients with symptomatic paroxysmal atrial fibrillation/flutter. The Flecainide AF French Study Group. ( Aliot, E; Denjoy, I, 1996) |
| "In order to compare the long-term safety of flecainide and propafenone, an open label, randomized, parallel group study was performed in 335 patients with paroxysmal atrial fibrillation (n = 200) or paroxysmal supraventricular tachycardia (n = 135), and no history of heart disease." | 5.08 | Safety of flecainide versus propafenone for the long-term management of symptomatic paroxysmal supraventricular tachyarrhythmias. Report from the Flecainide and Propafenone Italian Study (FAPIS) Group. ( Casadei, G; Chimienti, M; Cullen, MT, 1995) |
| "To assess the propafenone and sotalol efficacy in the prevention of paroxysmal atrial fibrillation (FA) we enrolled, in a double blind placebo controlled study over 1 year, 300 patients (168 males); mean age 52." | 5.08 | [Propafenone and sotalol: long-term efficacy and tolerability in the prevention of paroxysmal atrial fibrillation. A placebo-controlled double-blind study]. ( Bellandi, F; Cantini, F; Dabizzi, RP; Niccoli, L; Palchetti, R, 1996) |
| "The aim of this study was to assess the effectiveness of propafenone and quinidine to restore sinus rhythm in patients with paroxysmal atrial fibrillation." | 5.08 | [A comparison between propafenone and hydroquinidine perorally in the treatment of recent-onset atrial fibrillation]. ( Arrigo, F; Cavallaro, L; Coglitore, A; Fazio, F; Oreto, G; Saporito, F; Satullo, G; Sorrenti, S, 1996) |
| "The main aim of the study was to evaluate the safety and efficacy of propafenone versus quinidine as an initial choice in treatment of symptomatic paroxysmal atrial fibrillation." | 5.08 | Comparisons of oral propafenone and quinidine as an initial treatment option in patients with symptomatic paroxysmal atrial fibrillation: a double-blind, randomized trial. ( Chang, MS; Chen, SA; Chiang, CE; Lee, SH; Tai, CT; Wang, SP; Wen, ZC, 1996) |
| "Propafenone, given before electrical cardioversion for chronic atrial fibrillation does not affect the mean defibrillation threshold or the rate of successful arrhythmia conversion." | 5.08 | Effects of oral propafenone administration before electrical cardioversion of chronic atrial fibrillation: a placebo-controlled study. ( Bianconi, L; Castro, A; Chieffi, M; Lukic, V; Mennuni, M; Santini, M, 1996) |
| "Safety and efficacy of propafenone and disopyramide for long-term maintenance of sinus rhythm after electrical cardioversion was studied in 56 patients with chronic atrial fibrillation (median arrhythmia duration, 5 months)." | 5.08 | Propafenone versus disopyramide for maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation: a randomized, double-blind study. PRODIS Study Group. ( Crijns, HJ; Gosselink, AT; Lie, KI, 1996) |
| "The effectiveness of intravenous propafenone for conversion to sinus rhythm (SR) of paroxysmal atrial fibrillation (AF), lasting less than 7 days, was evaluated with a single-blind, randomized, placebo-controlled study, given the possible spontaneous conversion of this arrhythmia." | 5.08 | Intravenous propafenone: efficacy and safety in the conversion to sinus rhythm of recent onset atrial fibrillation--a single-blind placebo-controlled study. ( Bellandi, F; Cantini, F; Dabizzi, RP; Natale, MD; Niccoli, L, 1996) |
| "The primary objective was to evaluate the efficacy of propafenone compared with amiodarone in the reversion of atrial fibrillation or flutter." | 5.08 | The efficacy and safety of intravenous propafenone versus intravenous amiodarone in the conversion of atrial fibrillation or flutter after cardiac surgery. ( Larbuisson, R; Stiels, B; Venneman, I, 1996) |
| "This multicentre, randomized, double-blind study, conducted in parallel groups, was designed to compare the efficacy and safety of cibenzoline (C) and oral propafenone (P) in the prevention of recurrent atrial arrhythmias (M) over a 6-month period." | 5.08 | [Cibenzoline versus propafenone by the oral route for preventing recurrence of atrial arrhythmia: multicenter, randomized, double-blind study]. ( Bleinc, D; Canler, A; Lardoux, H; Maison Blanche, P; Marchand, X; Péraudeau, P; Rouesnel, P; Scheck, F, 1996) |
| "A population of 105 patients with recent onset (< 72 h) atrial fibrillation was randomly treated with propafenone as a single oral loading dose of 450 mg (Regimen A) or 600 mg (Regimen B) or with placebo." | 5.08 | Conversion of recent onset atrial fibrillation to sinus rhythm using a single oral loading dose of propafenone: comparison of two regimens. ( Barone, P; Bonini, W; Boriani, G; Botto, GL; Broffoni, T; Capucci, A; Espureo, M; Ferrari, G; Lombardi, R; Molteni, S, 1997) |
| "The effectiveness of oral propafenone in converting recent-onset atrial fibrillation to sinus rhythm has been established by controlled trials." | 5.08 | Oral propafenone to convert recent-onset atrial fibrillation in patients with and without underlying heart disease. A randomized, controlled trial. ( Biffi, M; Boriani, G; Botto, GL; Broffoni, T; Capucci, A; Della Casa, S; Magnani, B; Rubino, I; Sanguinetti, M, 1997) |
| "The main goal of this study is to evaluate the safety and efficacy of propafenone versus sotalol as an initial choice of treatment in patients with symptomatic paroxysmal atrial fibrillation (AF), according to a double-blind randomized system." | 5.08 | Comparisons of oral propafenone and sotalol as an initial treatment in patients with symptomatic paroxysmal atrial fibrillation. ( Chang, MS; Chen, SA; Chen, YJ; Cheng, JJ; Chiang, CE; Fong, AN; Huang, JL; Lee, SH; Tai, CT; Wen, ZC; Yu, WC, 1997) |
| "To evaluate the efficacy and safety of a single loading oral dose of propafenone in the interruption of recent-onset atrial fibrillation." | 5.08 | Value of single oral loading dose of propafenone in converting recent-onset atrial fibrillation. Results of a randomized, double-blind, controlled study. ( Alvarez, M; Azpitarte, J; Baún, O; Fernández, R; García, R; Martín, F; Moreno, E; Tercedor, L, 1997) |
| "In recent-onset atrial fibrillation, intravenous propafenone has been shown to effectively restore sinus rhythm, whereas the efficacy of intravenous digoxin has been questioned." | 5.08 | Comparison between propafenone and digoxin administered intravenously to patients with acute atrial fibrillation. PAFIT-3 Investigators. The Propafenone in Atrial Fibrillation Italian Trial. ( Bianconi, L; Mennuni, M, 1998) |
| "The efficacy and safety of propafenone as an oral loading dose (600-mg single oral dose) in converting recent-onset atrial fibrillation (< or = 7 days duration) to sinus rhythm were evaluated in a single-blind, placebo-controlled study according to patients' age." | 5.08 | Oral loading with propafenone: a placebo-controlled study in elderly and nonelderly patients with recent onset atrial fibrillation. ( Biffi, M; Boriani, G; Botto, GL; Branzi, A; Broffoni, T; Capucci, A; Della Casa, S; Magnani, B; Rubino, I; Sanguinetti, M, 1998) |
| "The efficacy and safety of intravenous propafenone, amiodarone, or placebo were compared in the treatment of atrial fibrillation (AF) of recent onset (duration < or = 48 hours)." | 5.08 | Intravenous propafenone versus intravenous amiodarone in the management of atrial fibrillation of recent onset: a placebo-controlled study. ( Igoumenidis, NE; Kochiadakis, GE; Marketou, ME; Mezilis, NE; Parthenakis, FI; Simantirakis, EN; Vardas, PE, 1998) |
| "A population of 123 patients with recent-onset (< 72 hours) atrial fibrillation (AF) without heart failure was randomly treated with propafenone (PFN) intravenously (i." | 5.08 | Randomized, crossover, controlled comparison of oral loading versus intravenous infusion of propafenone in recent-onset atrial fibrillation. ( Bonini, W; Botto, GL; Broffoni, T; Cappelletti, G; Espureo, M; Ferrari, G; Lombardi, R; Molteni, S; Pedraglio, E, 1998) |
| "The incidence of fast atrial tachycardias with regular ventricular rhythm was assessed in a population of 243 patients with recent onset (< 72 hours) atrial fibrillation (AF), without heart failure, randomly treated with single loading oral dose of propafenone (600 mg), flecainide (300 mg), digoxin (1 mg), or placebo for acute conversion to sinus rhythm (SR)." | 5.07 | Regular ventricular rhythms before conversion of recent onset atrial fibrillation to sinus rhythm. ( Bonini, W; Botto, GL; Broffoni, T; Cappelletti, G; Falcone, C; Ferrari, G; Lombardi, R; Paulesu, A; Pedraglio, E, 1994) |
| "The effectiveness of propafenone versus amiodarone for conversion to sinus rhythm of paroxysmal atrial fibrillation was compared." | 5.07 | [A comparison between propafenone and amiodarone in the conversion to sinus rhythm of atrial fibrillation of recent onset]. ( Alfano, C; Rossini, E; Treglia, A, 1994) |
| "Eighty-seven patients with recent onset atrial fibrillation (< or = 8 days) without clinical signs of heart failure were randomly allocated to one of the following treatments: (i) oral propafenone (600 mg as a loading dose followed after 8 h by 300 mg t." | 5.07 | A controlled study on oral propafenone versus digoxin plus quinidine in converting recent onset atrial fibrillation to sinus rhythm. ( Boriani, G; Capucci, A; Della Casa, S; Magnani, B; Rubino, I; Sanguinetti, M, 1994) |
| "The antiarrhythmic agent propafenone has been reported to prolong atrioventricular node conduction and may be suitable for rate control in atrial fibrillation (AF)." | 5.07 | The inefficacy of intravenous propafenone for rate control in atrial fibrillation. ( Klein, GJ; Leather, RA; Leitch, JW; Murdoch, C; Yee, R, 1994) |
| "The effects of intravenous flecainide and propafenone (2 mg/kg) administered in random order were compared in 16 patients with Wolff-Parkinson-White syndrome." | 5.07 | Effects of flecainide on atrial electrophysiology in the Wolff-Parkinson-White syndrome. ( Camm, AJ; Katritsis, D; Nunain, SO, 1992) |
| "Efficacy and safety of intravenous flecainide (2 mg/kg body weight in 10 minutes), verapamil (10 mg in 1 minute), and propafenone (2 mg/kg body weight in 10 minutes) were investigated in 90 consecutive patients with atrial fibrillation (AF) or flutter (AFL)." | 5.07 | Acute pharmacologic conversion of atrial fibrillation and flutter: the role of flecainide, propafenone, and verapamil. ( Kingma, JH; Suttorp, MJ, 1992) |
| "In 34 patients with a symptomatic accessory atrioventricular connection the reversible protective effect of orally administered flecainide (300 mg/day) and of propafenone (900 mg/day) in control of ventricular response during atrial fibrillation by exercise was assessed." | 5.07 | Reversible protective effect of propafenone or flecainide during atrial fibrillation in patients with an accessory atrioventricular connection. ( Auricchio, A, 1992) |
| "New antiarrhythmic class 1C agents have been proposed in the last few years in an attempt to suppress paroxysmal atrial fibrillation at long-term, as the most commonly used class 1A agents such as quinidine gave highly variable results as regards both side-effects and efficacy." | 5.07 | [Propafenone versus hydroquinidine in long-term pharmacological prophylaxis of atrial fibrillation]. ( Brusca, A; Comba Costa, G; Gaita, F; Gaschino, G; Greco, C; Richiardi, E; Rosettani, E, 1992) |
| "We compared the electrophysiological effects of intravenous propafenone and flecainide on accessory pathway conduction by a randomized crossover study in 16 patients with Wolff-Parkinson-White syndrome." | 5.07 | A comparison of intravenous propafenone and flecainide in the treatment of tachycardias associated with the Wolff-Parkinson-White syndrome. ( Camm, AJ; Garratt, CJ; Gill, J; Linker, NJ; O'Nunain, S; Ward, DE, 1991) |
| "We present our experience on the efficacy of propafenone in ten symptomatic patients with Wolff-Parkinson-White syndrome." | 5.06 | Propafenone in Wolff-Parkinson-White syndrome at risk. ( Chiariello, M; Condorelli, M; De Paola, M; Giasi, M; Santinelli, C; Santinelli, V; Smimmo, D; Turco, P, 1990) |
| "In a single-blind randomized study, the efficacy and safety of intravenous propafenone (2 mg/kg body weight per 10 min) versus flecainide (2 mg/kg per 10 min) were assessed in 50 patients with atrial fibrillation or flutter." | 5.06 | The value of class IC antiarrhythmic drugs for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. ( Jessurun, ER; Kingma, JH; Lie, KI; Lie-A-Huen, L; Suttorp, MJ; van Hemel, NM, 1990) |
| "In 69 consecutive patients with recent-onset atrial fibrillation, we compared the usefulness of verapamil, flecainide and propafenone for the acute conversion to sinus rhythm within 1 hour of the start of intravenous infusion." | 5.06 | Comparative evaluation of verapamil, flecainide and propafenone for the acute conversion of atrial fibrillation to sinus rhythm. ( Kastrati, A; Kondili, A; Popa, Y, 1990) |
| "The effects of intravenous procainamide (n = 30) or propafenone (n = 25) were evaluated in 55 patients with acute atrial fibrillation and the Wolff-Parkinson-White syndrome." | 5.06 | Termination of acute atrial fibrillation in the Wolff-Parkinson-White syndrome by procainamide and propafenone: importance of atrial fibrillatory cycle length. ( Boahene, KA; Fujimura, O; Klein, GJ; Sharma, AD; Yee, R, 1990) |
| "To evaluate the efficacy of propafenone for suppression of recurrent paroxysmal symptomatic atrial fibrillation (AF), patients with frequent episodes of AF entered an open-label, dose-ranging study to determine the maximal tolerated dose of propafenone and were subsequently randomized to alternate between propafenone and placebo every month for 4 months." | 5.06 | Usefulness of propafenone for recurrent paroxysmal atrial fibrillation. ( Connolly, SJ; Hoffert, DL, 1989) |
| "The efficacy of intravenous propafenone (2 mg/kg) was assessed in 83 consecutive patients: 68 with atrial fibrillation (AF) and 15 with atrial flutter lasting less than 15 days." | 5.06 | Effectiveness of intravenous propafenone for conversion of atrial fibrillation and flutter of recent onset. ( Bianconi, L; Boccadamo, R; Gentili, C; Pappalardo, A; Pistolese, M, 1989) |
| "The efficacy and safety of intravenous propafenone was studied in 10 patients with Wolff-Parkinson-White syndrome and in 2 patients with a concealed accessory pathway." | 5.06 | Efficacy of propafenone in Wolff-Parkinson-White syndrome: electrophysiologic findings and long-term follow-up. ( Antman, EM; Friedman, PL; Ludmer, PL; McGowan, NE, 1987) |
| " We also performed a literature search to find publications that report propafenone-associated gross hematuria." | 5.01 | Propafenone-associated Gross Hematuria: A Case Report and Review of the Literature. ( Chen, S; Cui, Y; Ding, W; Wang, Z; Ye, J; Zhao, X, 2019) |
| "The efficacy and safety of the single dose oral loading regimen of propafenone for pharmacological cardioversion of recent-onset atrial fibrillation (AFib) was evaluated by analyzing the trials on the subject identified through a comprehensive literature search." | 4.81 | Single oral loading dose of propafenone for pharmacological cardioversion of recent-onset atrial fibrillation. ( Khan, IA, 2001) |
| "This review summarizes the results of placebo-controlled trials of propafenone, a class IC antiarrhythmic drug, in patients with supraventricular tachycardia, atrial fibrillation (AF), and atrial flutter." | 4.80 | Placebo-controlled evaluations of propafenone for atrial tachyarrhythmias. ( Rae, AP, 1998) |
| " These antiarrhythmics, prescribed to prevent atrial fibrillation (3 patients) and atrial flutter (5 patients), were flecainide in 4 cases, propafenone in 2 cases and cibenzoline and hydroquinidine respectively associated with digitoxine and propranolol." | 4.79 | [Supraventricular tachycardia with wide QRS complexes during Vaughan-Williams class I anti-arrhythmic treatment. Diagnostic and therapeutic implications]. ( Aouate, P; Benassar, A; Fontaine, G; Frank, R; Jacquemin, M; Laborde, JP; Tageddine, R; Tonet, J; Turlure, A, 1995) |
| "To review comparative studies evaluating oral propafenone for restoring sinus rhythm in recent onset atrial fibrillation." | 4.79 | Oral propafenone for rapid conversion of recent onset atrial fibrillation--a review. ( Gin, K; Hughes, C; Sunderji, R, 1997) |
| "Among the drugs recommended to prevent recurrences of atrial fibrillation after external electric shock, antiarrhythmic agents of classes Ia (quinidine, disopyramide), Ic (cibenzoline, flecainide, propafenone) and III (sotalol) seem to have the same effectiveness in maintaining the sinus rhythm in about 50 percent of the cases after 6 months and one year." | 4.78 | [Antiarrhythmic treatment after reduction of atrial fibrillation by external shock]. ( Brechenmacher, C; Chauvin, M; Koenig, A; Theolade, R, 1993) |
| "Flecainide and propafenone are Class Ic antiarrhythmic drugs that block the cardiac fast inwards Na+ current and are used for rhythm control in patients with atrial fibrillation (AF)." | 4.31 | Medical therapy with flecainide and propafenone in atrial fibrillation: Long-term clinical experience in the tertiary care setting. ( Duru, F; Eriksson, U; Kovacs, B; Krasniqi, N; Yakupoglu, HY, 2023) |
| "The use of flecainide and propafenone for medical cardioversion of atrial fibrillation (AF) and atrial flutter/intra-atrial reentrant tachycardia (IART) is well-described in adults without congenital heart disease (CHD)." | 4.31 | Medical cardioversion of atrial fibrillation and flutter with class IC antiarrhythmic drugs in young patients with and without congenital heart disease. ( Alexander, ME; Bezzerides, VJ; DeWitt, ES; Dionne, A; Eberly, LM; Mah, DY; O'Leary, ET; Przybylski, R; Triedman, JK; Walsh, EP, 2023) |
| "Rivaroxaban reduces the risk of thromboembolism in atrial fibrillation (AF) patients, who often also receive antiarrhythmic drugs (AADs) to maintain sinus rhythm." | 4.02 | Safety and Effectiveness of Rivaroxaban in Combination with Various Antiarrhythmic Drugs in Patients with Non-Permanent Atrial Fibrillation. ( Chen, CY; Chiou, WR; Chuang, JY; Huang, CC; Kuo, JY; Lee, YH; Liao, FC; Lin, PL; Liu, LY; Su, MI; Tsai, CT; Wu, YJ, 2021) |
| " The purpose of this study was to assess the efficacy of the AADs disopyramide, quinidine, and propafenone on human atrial arrhythmias mediated by Pitx2-induced remodelling, from a single cell to the tissue level, using drug binding models with multi-channel pharmacology." | 4.02 | In Silico Assessment of Class I Antiarrhythmic Drug Effects on ( Bai, J; Gao, M; Lo, A; Lu, Y; Zhang, H; Zhao, J; Zhu, Y, 2021) |
| " He was being treated with propafenone twice daily (450 mg) for paroxysmal atrial fibrillation." | 3.85 | Severe cardiac toxicity following alcohol intake in a patient using therapeutic dose of propafenone. ( Bayram, Z; Doğan, C; Güner, A; Özdemir, N; Yılmaz, F, 2017) |
| "Our objective was to evaluate the efficacy and safety of intravenous (IV) sotalol in the treatment of incessant tachyarrhythmias in children with normal cardiac function." | 3.85 | Efficacy of Intravenous Sotalol for Treatment of Incessant Tachyarrhythmias in Children. ( Ge, H; Jiang, H; Li, X; Liu, H; Zhang, Y, 2017) |
| "INTRODUCTION Numerous studies described the effectiveness and safety of antazoline in pharmacological cardioversion of short‑duration atrial fibrillation (AF)." | 3.83 | Comparative effectiveness and safety of antazoline‑based and propafenone‑based strategies for pharmacological cardioversion of short‑duration atrial fibrillation in the emergency department. ( Farkowski, MM; Kowalik, I; Maciąg, A; Pytkowski, M; Sterliński, M; Szwed, H; Woźniak, J; Żurawska, M, 2016) |
| "To estimate cost-effectiveness of dronedarone versus amiodarone, propafenone, and sotalol in patients with atrial fibrillation (AF)." | 3.81 | Analysis of the cost-effectiveness of dronedarone versus amiodarone, propafenone, and sotalol in patients with atrial fibrillation: results for Serbia. ( Jankovic, SM; Kostic, M; Paunovic, D; Tesic, D, 2015) |
| "Ventricular arrhythmia (VA) can occur during propafenone therapy in atrial fibrillation (AF) patients with structurally normal heart." | 3.81 | Factors predisposing to ventricular proarrhythmia during antiarrhythmic drug therapy for atrial fibrillation in patients with structurally normal heart. ( Chang, SL; Chang, Y; Chao, TF; Chen, SA; Chen, YY; Chien, KL; Chiou, CW; Chong, E; Chung, FP; Hu, YF; Liao, JN; Lin, CY; Lin, YJ; Lo, LW; Tuan, TC, 2015) |
| "Vernakalant is a new, safe and effective drug used intravenously, which has proved to be more rapid in converting recent onset atrial fibrillation (AF) to sinus rhythm compared to placebo, amiodarone, propafenone, and flecainide in clinical studies." | 3.80 | Vernakalant: Perception of state of health in patients with a recent-onset atrial fibrillation. ( Aragon, M; Conde, D; Costabel, JP; Lambardi, F; Trivi, M, 2014) |
| "Ranolazine has been shown to produce atrial-selective depression of sodium channel-dependent parameters and suppress atrial fibrillation (AF) in a variety of experimental models." | 3.78 | Atrial-selective sodium channel block strategy to suppress atrial fibrillation: ranolazine versus propafenone. ( Antzelevitch, C; Belardinelli, L; Burashnikov, A, 2012) |
| " We report a case of hidden ECG Brugada pattern, revealed after oral propafenone administration in the setting of pharmaceutical atrial fibrillation cardioversion." | 3.77 | Likelihood of Brugada ECG pattern confirmed after propafenone administration for atrial fibrillation cardioversion. ( Dragios, TD; Kyriakides, ZS; Manolis, AG, 2011) |
| "We report the case of a 46-year-old man who developed syncope, a widened QRS interval, and depressed left ventricular systolic function during propafenone therapy for atrial fibrillation." | 3.76 | Syncope, widened QRS interval, and left ventricular systolic depression: coincident with propafenone therapy for atrial fibrillation. ( Grodman, R; Isber, N; Samaan, RA; Sobamowo, HO; Tamburrino, F, 2010) |
| " Three months after starting citalopram, she experienced episodes of chest tightness and dizziness." | 3.74 | Adverse effects of propafenone after long-term therapy with the addition of citalopram. ( Garcia, A, 2008) |
| "We present two cases of proarrhythmia after propafenone treatment." | 3.74 | [Proarrhythmic effect of propafenone in patients with atrial fibrillation and atrial flutter]. ( Jastrzebski, M, 2008) |
| " The abilities of TAEA and ISQ-1 to terminate AF, with comparison to the rapidly activating component of delayed rectifier potassium current blocker (+)-N-[1'-(6-cyano-1,2,3,4-tetrahydro-2(R)-naphthalenyl)-3,4-dihydro-4(R)-hydroxyspiro(2H-1-benzopyran-2,4'-piperidin)-6-yl]methanesulfonamide] monohydrochloride (MK-499) and the class IC 1-[2-[2-hydroxy-3-(propylamino)-propoxy]phenyl]-3-phenyl-1-propanone (propafenone), were assessed in conscious dogs with heart failure and inducible AF (entry criterion)." | 3.74 | Atrial antifibrillatory effects of structurally distinct IKur blockers 3-[(dimethylamino)methyl]-6-methoxy-2-methyl-4-phenylisoquinolin-1(2H)-one and 2-phenyl-1,1-dipyridin-3-yl-2-pyrrolidin-1-yl-ethanol in dogs with underlying heart failure. ( Beshore, DC; Dinsmore, CJ; Kiss, L; Liverton, NJ; Lynch, JJ; McIntyre, CJ; Regan, CP; Stump, GL, 2008) |
| " The case history is reported of a patient with atrial flutter and atrial fibrillation who developed Brugada-like ECG changes when treated with propafenone." | 3.74 | Propafenone-induced Brugada-like ECG changes mistaken as acute myocardial infarction. ( Chutani, S; Grubb, B; Imran, N; Kanjwal, Y, 2008) |
| "The effectiveness and safety of ibutilide (IB) use in patients receiving amiodarone or propafenone for atrial flutter (AFL) and atrial fibrillation (AF) were compared to IB alone." | 3.73 | Efficacy and safety of ibutilide for cardioversion of atrial flutter and fibrillation in patients receiving amiodarone or propafenone. ( Fragakis, N; Katsaris, G; Kozirakis, M; Maligkos, G; Papadopoulos, N; Papanastasiou, S; Tsaritsaniotis, E, 2005) |
| "Amiodarone and cedilanid may be the proper drugs for the treatment of paroxysmal atrial fibrillation in the elderly." | 3.73 | Drug therapy of paroxysmal atrial fibrillation in the elderly over 75 years old. ( Cao, J; Chen, DY; Zhu, BP, 2006) |
| "This is the first study to demonstrate the reproducibility of an oral propafenone loading dose in converting paroxysmal atrial fibrillation in patients without significant cardiac disease or hypertension." | 3.72 | Reproducible efficacy of loading oral propafenone in restoring sinus rhythm in patients with paroxysmal atrial fibrillation. ( Capucci, A; Piepoli, MF; Villani, GQ, 2003) |
| "The clinical outcomes of 114 patients with atrial fibrillation who had been treated with the innovator propafenone, and in whom the drug was then replaced with generic propafenone because of cost containment, were compared." | 3.72 | Efficacy of substituting innovator propafenone for its generic formulation in patients with atrial fibrillation. ( Amit, G; Bonneh, DY; Grosbard, A; Ilia, R; Katz, A; Liss, T; Rosen, A; Wagshal, AB, 2004) |
| " We tested the efficacy and proarrhythmic potential of KCB-328, dofetilide and propafenone in the pacing induced canine model of atrial fibrillation (AF)." | 3.72 | Evaluation of KCB-328, a new IKr blocking antiarrhythmic agent in pacing induced canine atrial fibrillation. ( Chandra, P; Danilo, P; Kim, HY; Lee, K; Rosen, MR; Rosen, TS; Yeom, ZH, 2004) |
| "A 74-year-old man with a structurally normal heart presented with typical atrial flutter, after treatment of atrial fibrillation with propafenone." | 3.72 | Typical counterclockwise atrial flutter occurring despite absence of the inferior vena cava. ( Gilkeson, RC; Varma, N; Waldo, AL, 2004) |
| " The tachycardia was felt to be focal atrial fibrillation, and the patient was placed on propafenone with good results." | 3.71 | Paroxysmal supraventricular tachycardia induced by oral stimulation: a case report and review of swallow-induced dysrhythmias. ( Chock, JG; Gill, MR, 2002) |
| " In view of recent atrial fibrillation with inadequate heart rate control, digoxin and propafenone were included in the therapeutic regimen." | 3.71 | [Proarrhythmic effects of propafenone in a woman with hepatopathy: is it always a simple drug in clinical practice?]. ( Brieda, M; Burelli, C; Cassin, M; Dametto, E; Hrovatin, E; Nicolosi, GL; Piazza, R; Zardo, F, 2002) |
| "The aim of the study was to evaluate the efficacy of intravenous and oral propafenone for termination of recent onset (<48 hrs) atrial fibrillation." | 3.71 | [Pharmacological cardioversion of atrial fibrillation with intravenous and oral propafenone]. ( Lukoseviciūte, A; Peciuliene, I, 2002) |
| "The objective of this study was to determine the percentage of patients with paroxysmal atrial fibrillation who were poor metabolizers of CYP2D6 in a Chinese population from Hong Kong and to assess the relationship between the dextromethorphan/dextrorphan ratio and the propafenone/5-hydroxypropafenone ratio or the steady-state propafenone concentration." | 3.71 | Evaluation of CYP2D6 oxidation of dextromethorphan and propafenone in a Chinese population with atrial fibrillation. ( Chow, MS; Fan, C; Lau, CP; Tang, MO; White, CM, 2001) |
| "24 consecutive patients with atrial fibrillation (age 54 (12) years; 5 female, 19 male) developing atrial flutter while taking propafenone (n = 12) or flecainide (n = 12)." | 3.71 | Class IC antiarrhythmic drug induced atrial flutter: electrocardiographic and electrophysiological findings and their importance for long term outcome after right atrial isthmus ablation. ( Nabar, A; Rodriguez, LM; Timmermans, C; van Mechelen, R; Wellens, HJ, 2001) |
| "The effects of pilsicainide on vagally induced atrial fibrillation and on electrophysiological parameters were compared with those of propafenone in alpha-chloralose-anesthetized dogs." | 3.70 | Effects of pilsicainide and propafenone on vagally induced atrial fibrillation: role of suppressant effect in conductivity. ( Iwasa, A; Matsunaga, T; Okumura, K; Tabuchi, T; Tayama, S; Tsuchiya, T; Tsunoda, R; Yasue, H, 1998) |
| "We describe a case of 1:1 atrial flutter in a patient with coronary disease taking propafenone." | 3.70 | Atrial flutter with 1:1 atrioventricular conduction caused by propafenone. ( Adams, PC; el-Harari, MB, 1998) |
| "We have investigated the relationship of clinical variables to successful cardioversion of atrial fibrillation (AF) to sinus rhythm using an oral loading dose of propafenone." | 3.70 | Predictors of success in the conversion of new-onset atrial fibrillation using oral propafenone. ( Cete, Y; Ergene, O; Ergene, U; Fowler, J; Nazli, C; Oktay, C, 1998) |
| "(1) To investigate the electrophysiological effects of flecainide and propafenone during atrial fibrillation, and their relation to arrhythmia termination; (2) to investigate the effects of isoprenaline on atrial fibrillation in basal conditions and during treatment with class 1C drugs to evaluate the role of adrenergic stimulation on proarrhythmic events occurring during this treatment." | 3.70 | Electrophysiological effects of flecainide and propafenone on atrial fibrillation cycle and relation with arrhythmia termination. ( Biffi, M; Boriani, G; Branzi, A; Bronzetti, G; Capucci, A; Magnani, B, 1999) |
| "Among the 136 patients treated for atrial fibrillation with amiodarone (n = 96) or propafenone (n = 40), 15 (11%, mean age 65." | 3.70 | Persistent atrial flutter in patients treated for atrial fibrillation with amiodarone and propafenone: electrophysiologic characteristics, radiofrequency catheter ablation, and risk prediction. ( Chang, MS; Chen, SA; Chen, YJ; Chiang, CE; Ding, YA; Feng, AN; Lee, SH; Tai, CT; Yu, WC, 1999) |
| "We studied left atrial function in 55 patients undergoing electrical (n = 23) or chemical (intravenous administration of propafenone, n = 32) attempts at cardioversion from atrial fibrillation." | 3.70 | Transesophageal echocardiographic evidence of more pronounced left atrial stunning after chemical (propafenone) rather than electrical attempts at cardioversion from atrial fibrillation. ( Antonielli, E; Baralis, G; Bassignana, A; Di Leo, M; Pizzuti, A; Rovere, ME; Tanga, M, 1999) |
| "To describe a probable case of transient global amnesia caused by propafenone." | 3.69 | Probable propafenone-induced transient global amnesia. ( Brace, SR; Jones, RJ; Vander Tuin, EL, 1995) |
| "We assessed the safety and efficacy of intravenous propafenone in the treatment of atrial fibrillation and flutter of recent onset (1-10 days)." | 3.69 | [Efficacy of intravenous propafenone in the management of arterial flutter and fibrillation of recent onset]. ( Minutiello, L, 1994) |
| " In order to prevent/terminate fibrillation propafenone (Rytmonorm, 450-600 mg/day) was started, however this therapy resulted in permanent atrial flutter of 230-270/min mainly with 2:1 antrioventricular conduction." | 3.69 | [Persistent atrial flutter induced by propafenone (Rytmonorm)]. ( Fazekas, T; Kiss, J; Pap, I; Rudas, L, 1994) |
| "The efficacy and safety of quinidine, as a rapid oral loading therapy, and propafenone in the conversion of atrial fibrillation of <6 months duration to sinus rhythm were compared." | 3.69 | Quinidine versus propafenone for conversion of atrial fibrillation to sinus rhythm. ( Di Benedetto, S, 1997) |
| "In order to determine the efficacy of type 1C agents (flecainide, encainide, propafenone) in patients with atrial fibrillation who have failed to maintain sinus rhythm with type 1A agents (quinidine, procainamide, disopyramide), 147 patients, that were admitted into the John Dempsey Hospital with new or recurrent atrial fibrillation between 1987-1991, were studied retrospectively." | 3.68 | Efficacy of type 1C antiarrhythmic agents for treatment of resistant atrial fibrillation. ( Grey, E; Silverman, DI, 1993) |
| "One hundred and ninety-six patients with stable atrial fibrillation of recent onset received propafenone (98 patients) or Amiodarone (98 patients) intravenously." | 3.68 | [The efficacy of intravenous propafenone and amiodarone in the conversion of recent-onset atrial fibrillation. A 1-year follow-up with oral treatment]. ( Bellandi, F; Cantini, F; Dabizzi, RP; Palchetti, R; Pedone, T, 1993) |
| "We evaluated the effects of representative class Ia (procainamide), Ic (propafenone), and III (sotalol) antiarrhythmic drugs on sustained cholinergic atrial fibrillation and atrial electrophysiological properties in anesthetized, open-chest dogs." | 3.68 | Comparative mechanisms of antiarrhythmic drug action in experimental atrial fibrillation. Importance of use-dependent effects on refractoriness. ( Bourne, GW; Nattel, S; Talajic, M; Villemaire, C; Wang, J; Wang, Z, 1993) |
| "The efficacy of propafenone in the treatment of paroxysmal atrial fibrillation was investigated in 16 patients presenting with frequent and/or poorly tolerated paroxysmal atrial fibrillation despite prophylactic treatment in 13 patients." | 3.68 | [Intravenous and oral propafenone in the treatment and prevention of paroxysmal atrial fibrillation]. ( Bru, P; Cointe, R; Gerard, R; Lévy, S; Metge, M; Paganelli, F; Vrancea, F, 1993) |
| "Propafenone efficacy in conversion of atrial fibrillation to sinus rhythm has been well documented." | 3.68 | [Efficacy of intravenous and per os propafenone in the ambulatory treatment of recent-onset atrial fibrillation]. ( Bartoli, P; Bonechi, F; Brandinelli, A; Fradella, G; Maioli, M; Margheri, M; Mazza, F; Paterni, M; Sansoni, M; Zipoli, A, 1992) |
| "A 77-year-old female with new onset atrial fibrillation occurring in the absence of structural heart disease developed torsade de pointes during therapy with quinidine bisulfate 500 mg orally every 8 hours." | 3.68 | Propafenone-induced torsade de pointes: cross-reactivity with quinidine. ( Cohen, JM; Gillis, AM; Hii, JT; Mitchell, LB; Wyse, DG, 1991) |
| "Propafenone was given to 81 patients (49 males and 32 females, mean age 61 +/- 16 years) with recurrent atrial fibrillation." | 3.68 | Long term efficacy of propafenone for prevention of atrial fibrillation. ( Kerr, CR; Kyles, AE; Murdock, CJ; Vorderbrugge, S; Yeung-Lai-Wah, JA, 1991) |
| "One hundred nine patients with recurrent episodes of symptomatic atrial fibrillation or flutter, or both, who had failed one to five previous antiarrhythmic drug trials were treated with propafenone and, subsequently, sotalol if atrial fibrillation recurred." | 3.68 | Therapy of refractory symptomatic atrial fibrillation and atrial flutter: a staged care approach with new antiarrhythmic drugs. ( Antman, EM; Beamer, AD; Cantillon, C; Friedman, PL; McGowan, N, 1990) |
| "The antiarrhythmic effect of oral propafenone was evaluated in 10 patients with Wolff-Parkinson-White syndrome presenting with non-ventricular arrhythmias (paroxysmal supraventricular tachycardia n = 7, atrial fibrillation or flutter n = 3)." | 3.68 | Propafenone in the prevention of non-ventricular arrhythmias associated with the Wolff-Parkinson-White syndrome. ( Kallikazaros, I; Papoutsakis, P; Stefanadis, C; Vassiliadis, I, 1990) |
| "We describe a case of dangerous acceleration of conduction through an accessory pathway produced by the Class IC agent propafenone during routine electrophysiological study of a patient with Wolff-Parkinson-White syndrome." | 3.68 | Acceleration of conduction within an accessory pathway with propafenone. ( Holt, P; Sowton, GE; Sulke, AN, 1990) |
| "We describe a case of acute myocardial infarction complicated by atrial and ventricular arrhythmias in which it was possible to verify the effectiveness of lidocaine, mexiletine and propafenone." | 3.67 | Lidocaine, mexiletine and propafenone in the treatment of arrhythmias complicating myocardial infarction. A case report. ( Aguglia, F; De Marzio, P; Gnecchi, M, 1985) |
| "Intravenous propafenone (1 mg/Kg in 3 min) has been administered to 14 patients with recent atrial fibrillation." | 3.67 | [Treatment of recent atrial fibrillation with intravenous propafenone]. ( Arrigo, F; Carerj, B; Carerj, S; Cavalli, G; Cento, D; Consolo, F; Magazù, A; Oreto, G, 1989) |
| "Sixty patients who had recurrent episodes of symptomatic atrial fibrillation or flutter, or both, and who had failed one to five prior drug trials were treated with open label oral propafenone hydrochloride." | 3.67 | Long-term oral propafenone therapy for suppression of refractory symptomatic atrial fibrillation and atrial flutter. ( Antman, EM; Beamer, AD; Cantillon, C; Friedman, PL; Goldman, L; McGowan, N, 1988) |
| "The safety and efficacy of intravenous Propafenone, in the treatment of atrial fibrillation (a." | 3.67 | [Fibrillation and atrial flutter. Immediate control and conversion to sinus rhythm with intravenous propafenone]. ( Bianconi, L; Boccadamo, R; Broglia, R; Pappalardo, A; Pistolese, M, 1987) |
| "The electrophysiologic effects of diprafenone were evaluated in 31 patients (9 X AV nodal reentrant tachycardia, 9 X Wolff-Parkinson-White syndrome, 4 X paroxysmal atrial fibrillation, 10 X recurrent ventricular tachycardia)." | 3.67 | [Electrophysiologic effects of diprafenone in supraventricular and ventricular tachycardia]. ( Beermann, J; Gerckens, U; Lüderitz, B; Manz, M, 1986) |
| "Forty-seven patients with chronic atrial fibrillation and (or) flutter in whom the clinical picture and the length of arrhythmia indicated that drug-mediated cardioversion should be tried were treated with a combination of lidoflazine and propafenon." | 3.66 | [Combined use of propafenon and lidoflazine in chronic atrial fibrillation and flutter (author's transl)]. ( Beck, OA; Hochrein, H, 1980) |
| "We randomly assigned 294 patients with paroxysmal atrial fibrillation and no history of antiarrhythmic drug use to an initial treatment strategy of either radiofrequency catheter ablation (146 patients) or therapy with class IC or class III antiarrhythmic agents (148 patients)." | 2.77 | Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation. ( Cosedis Nielsen, J; Englund, A; Hansen, PS; Hartikainen, J; Hindricks, G; Johannessen, A; Kongstad, O; Mortensen, LS; Pehrson, S; Raatikainen, P; Walfridsson, H, 2012) |
| "Propafenone was given to Group 1 (G1); sotalol to Group 2 (G2); amiodarone to Group 3 (G3) and diltiazem to Group 4 (G4) at doses of 300 mg/day, 80 mg/day, 400 mg/day and 180 mg/day orally respectively." | 2.73 | [The comparison between the efficiency of different anti-arrhythmic agents in preventing postoperative atrial fibrillation after open heart surgery]. ( Aytekin, S; Aytekin, V; Men, EE; Tuğcu, A; Yildirimtürk, O, 2008) |
| " Despite careful precautions, serious proarrhythmias, the major limiting side effect of dofetilide, still occurred during long-term follow-up." | 2.73 | Observations on the safety and effectiveness of dofetilide in patients with paroxysmal atrial fibrillation and normal left ventricular function. ( Bauman, JL; Kehoe, RF; Leal, S; Mykytsey, A; Razminia, M; Saleem, M; Wang, T; Zheutlin, T, 2007) |
| "Amiodarone is a slower acting alternative." | 2.72 | Single-dose oral anti-arrhythmic drugs for cardioversion of recent-onset atrial fibrillation: a systematic review and network meta-analysis of randomized controlled trials. ( Alhazzani, W; Baranchuk, A; Belley-Côté, EP; Benz, AP; Conen, D; Dalmia, S; Devereaux, PJ; Healey, JS; Ibrahim, OA; McIntyre, WF; Um, KJ; Wang, CN; Whitlock, RP, 2021) |
| "Many patients with paroxysmal atrial fibrillation (AF) become refractory to antiarrhythmic drugs (AADs)." | 2.71 | Hybrid therapy with right atrial catheter ablation and previously ineffective antiarrhythmic drugs for the management of atrial fibrillation. ( Block, JE; Calkins, H; Cher, D; Kocheril, AG; Sharma, AD; Stubbs, HA, 2005) |
| "Forty patients with paroxysmal atrial fibrillation (20 females, 20 males), aged 60-83 (mean 72." | 2.71 | Stunning of the left atrium after pharmacological cardioversion of atrial fibrillation. ( Wysokiński, A; Zapolski, T, 2005) |
| "Propafenone (PPF) is an antiarrhythmic, Class Ic agent." | 2.70 | The influence of CYP2D6 polymorphism on the antiarrhythmic efficacy of propafenone in patients with paroxysmal atrial fibrillation during 3 months propafenone prophylactic treatment. ( Dmochowska-Perz, M; Jazwinska-Tarnawska, E; Loboz-Grudzien, K; Niewinski, P; Orzechowska-Juzwenko, K; Rzemislawska, Z; Slawin, J, 2001) |
| "However, patients with no symptomatic recurrences of AF had higher scores at 3 months on measures of global well-being than those with recurrences in the first 3 months (7." | 2.70 | Quality of life improves with treatment in the Canadian Trial of Atrial Fibrillation. ( Connolly, SJ; Dorian, P; Green, M; Newman, D; Paquette, M; Roy, D; Talajic, M, 2002) |
| "Propafenone was given at a dose of 2 mg/kg body weight intravenously (i." | 2.69 | Propafenone versus procainamide for conversion of atrial fibrillation to sinus rhythm. ( Lucchi, GR; Mattioli, AV; Mattioli, G; Vivoli, D, 1998) |
| "amiodarone was not different from placebo until 8 hours when it was associated with 57% of conversions; (3) conversion to sinus rhythm at 8 hours was observed in 37% of the placebo treated patients." | 2.69 | Conversion of recent-onset atrial fibrillation to sinus rhythm: effects of different drug protocols. ( Biffi, M; Boriani, G; Botto, G; Branzi, A; Broffoni, T; Capucci, A; Magnani, B; Ongari, M; Rubino, I; Sanguinetti, M; Trisolino, G, 1998) |
| "The frequent recurrence of paroxysmal atrial fibrillation (PAF) despite the use of standard antiarrhythmic agents prompted the use of new therapeutic approaches." | 2.69 | Control of paroxysmal atrial fibrillation recurrence using combined administration of propafenone and quinidine. ( Chow, MS; Fan, C; Lau, CP; Tang, MO; Tse, HF, 2000) |
| "Pharmacological conversion of paroxysmal atrial fibrillation is frequently necessary." | 2.68 | Intravenous propafenone in paroxysmal atrial fibrillation: a randomized, placebo-controlled, double-blind, multicenter clinical trial. Paroxysmal Atrial Fibrillation Italian Trial (PAFIT)-2 Investigators. ( Buia, G; Fresco, C; Morgera, T; Pavan, A; Pavan, D; Proclemer, A; Vicentini, A, 1996) |
| "Propafenone is an effective drug for preventing supraventricular tachyarrhythmia, but the incidence of side effects during longterm therapy in patients with such arrhythmias has not been adequately reported." | 2.68 | Safety and tolerability of long-term propafenone therapy for supraventricular tachyarrhythmias. The Propafenone Multicenter Study Group. ( Anderson, JL; Podrid, PJ, 1996) |
| "Propafenone was clinically effective (complete relief of symptoms) in 26 (74%) patients." | 2.68 | The incidence of asymptomatic paroxysmal atrial fibrillation in patients treated with propranolol or propafenone. ( Ceremuzynski, L; Czepiel, A; Karczmarewicz, S; Karpinski, G; Kulakowski, P; Makowska, E; Wolk, R, 1996) |
| "Previous bradyarrhythmias or sick sinus syndrome (SSS), and concomitant use of antiarrhythmic drugs were exclusion criteria." | 2.68 | Conversion of recent onset atrial fibrillation with single loading oral dose of propafenone: is in-hospital admission absolutely necessary? ( Alfieri, G; Barone, P; Bernasconi, G; Bonini, W; Botto, GL; Broffoni, T; Ferrari, G; Lombardi, R; Molteni, S, 1996) |
| " Oral propafenone at a low dosage 150 mg 3 times daily is well tolerated and effective in maintaining sinus rhythm for 6 months after pharmacologic or electrical restoration of sinus rhythm." | 2.68 | Propafenone for conversion and prophylaxis of atrial fibrillation. Propafenone Atrial Fibrillation Trial Investigators. ( Hoebrechts, R; Stiels, B; Stroobandt, R, 1997) |
| "In case of PAF recurrence pts withdrew from the study." | 2.68 | [Comparison of anti-arrhythmic therapy guided by the transesophageal electropharmacologic test and emperic therapy in the prophylaxis of atrial fibrillation recurrence]. ( Burattini, M; Carunchio, A; Ceci, V; Coletta, C; Fera, MS; Galati, A; Mazza, A, 1997) |
| "Propafenone is a class Ic agent for the treatment of atrial arrhythmias with a main hepatic metabolism." | 2.68 | Propafenone in the conversion of atrial fibrillation in patients suffering from chronic renal failure. ( Di Benedetto, A; Di Ieso, N; Liguori, A; Napoli, C; Sorice, P, 1997) |
| "Propafenone is a class 1c antiarrhythmic agent that has an electrophysiologic profile suggesting that it might be potentially effective in recent-onset AF." | 2.67 | Clinical course of recent-onset atrial fibrillation treated with oral propafenone. ( Ganam, R; Ganem, R; Rabner, M; Weiner, P; Zidan, F, 1994) |
| " Consecutive patients were treated with P replacing previous therapy with amiodarone (A) withdrawn on account of adverse side effects occurring on average after 1." | 2.67 | [Prevention of paroxysmal atrial fibrillation with propafenone after withdrawal of amiodarone because of side effects]. ( Foscoli, M; Giofrè, R; Labriola, E; Lolli, C; Tarquinii, M; Toschi, GP, 1993) |
| "The time to first recurrence was prolonged for the overall group of 23 patients while they received propafenone (P = 0." | 2.67 | Propafenone treatment of symptomatic paroxysmal supraventricular arrhythmias. A randomized, placebo-controlled, crossover trial in patients tolerating oral therapy. ( McCarthy, EA; Pritchett, EL; Wilkinson, WE, 1991) |
| "Propafenone, 2 mg/kg was given over 15 min and blood pressure and heart rate were monitored in the following hour." | 2.66 | [Efficacy of propafenone in supraventricular arrhythmias]. ( Ayala, A; Goich, J; Kauffmann, R; Manzur, F; Parra, C, 1989) |
| "The development of a sustained-release formulation of propafenone allowed to reduce the wide fluctuations in plasma levels observed with the immediate release preparation, improving compliance and adherence to therapy, by simplifying the dosing regimen from 3 to 2 daily doses." | 2.48 | Atrial fibrillation and the pharmacological treatment: the role of propafenone. ( Molina, E; Sestito, A, 2012) |
| "Amiodarone was associated with the highest rate of patients experiencing at least one serious adverse event (OR 2." | 2.47 | Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation. ( Eckert, L; Freemantle, N; Lafuente-Lafuente, C; Mitchell, S; Reynolds, M, 2011) |
| "Atrial flutter is most often arising from a macroreentry circuit in the right atrium or around scar tissue in case or previous cardiothoracic surgery." | 2.43 | [Atrial flutter and fibrillation]. ( Scharf, C, 2005) |
| "Amiodarone has been demonstrated to be more efficacious than propafenone or sotalol in the Canadian Trial of Atrial Fibrillation." | 2.42 | Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials. ( Bhatta, L; Hynes, J; Khan, M; Luck, J; Naccarelli, GV; Samii, S; Wolbrette, DL, 2003) |
| "Procainamide is effective for stable ventricular tachycardia, and amiodarone is effective in the treatment of shock-refractory ventricular fibrillation." | 2.41 | Intravenous antiarrhythmic agents. ( Dorian, P; Pinter, A, 2001) |
| "Propafenone is a class IC antiarrhythmic agent that is suitable for oral loading as it reaches peak plasma concentrations within 2 to 4 hours of administration." | 2.41 | Oral loading with propafenone for conversion of recent-onset atrial fibrillation: a review on in-hospital treatment. ( Biffi, M; Boriani, G; Branzi, A; Capucci, A; Martignani, C, 2002) |
| "Propafenone was effective in suppressing recurrences of AF in 55." | 2.40 | Propafenone for the treatment of supraventricular tachycardia and atrial fibrillation: a meta-analysis. ( Antman, EM; Maisel, WH; Reimold, SC, 1998) |
| "Propafenone is a sodium channel blocking agent with a mild beta- and calcium channel-blocking activity." | 2.39 | Guidelines for the use of propafenone in treating supraventricular arrhythmias. ( Camm, AJ; Kishore, AG, 1995) |
| "propafenone." | 1.91 | Cardiovascular outcomes in patients with atrial fibrillation concomitantly treated with antiarrhythmic drugs and non-vitamin k antagonist oral anticoagulants. ( Chang, SH; Chen, SW; Huang, CH; Huang, YC; Huang, YT; Hung, KC; Kuo, CF; Tu, HT; Wang, CL; Wu, VC, 2023) |
| "Antazoline appears to be an efficacious agent for termination of AF in real‑world setting." | 1.72 | Efficacy and safety of antazoline for cardioversion of atrial fibrillation: propensity score matching analysis of a multicenter registry (CANT II Study). ( Balsam, P; Bula, K; Błaszczyk, R; Ceynowa-Sielawko, B; Ćwiek-Rębowska, E; Dembowski, T; Farkowski, M; Kasprzak, JD; Koziński, M; Krzowski, B; Maciąg, A; Miśkowiec, D; Mizia-Stec, K; Ozierański, K; Peller, M; Szołkiewicz, M; Szwed, H; Wańha, W; Wójcik, M; Wróbel, W; Wybraniec, MT, 2022) |
| "No sustained ventricular tachycardia, ventricular fibrillation, sudden cardiac death, or cardiovascular mortality were observed." | 1.72 | Propafenone use in coronary artery disease patients undergoing atrial fibrillation ablation. ( Aksu, T; Aras, D; Cay, S; Kara, M; Ozcan, F; Ozeke, O; Topaloglu, S, 2022) |
| "Guidelines recommend that initial trial of a "pill-in-the-pocket" (PIP) Class 1C antiarrhythmic drug (AAD) for cardioversion of atrial fibrillation (AF) be performed in a monitored setting because of the potential for adverse reactions." | 1.72 | Safety of Pill-in-the-Pocket Class 1C Antiarrhythmic Drugs for Atrial Fibrillation. ( Arkles, JS; Callans, DJ; Deo, R; Dixit, S; Epstein, AE; Frankel, DS; Guandalini, GS; Hyman, MC; Jarrah, AA; Lin, D; Marchlinski, FE; Markman, TM; Mustin, E; Nazarian, S; Riley, M; Santangeli, P; Schaller, RD; Supple, GE; Tian, Y, 2022) |
| "When verapamil treatment was stopped, the patient experienced AF recurrence." | 1.51 | Treatment with verapamil for restoration of sinus rhythm in atrial fibrillation with rapid ventricular response: A case report. ( Chen, L; Liang, D; Lin, J; Lin, Y; Qi, G; Tian, W; Wang, X, 2019) |
| " We analysed the differences between amiodarone and class IC group in terms of efficacy and safety that is conversion to sinus rhythm rates within 12 and 48 h after starting treatment, time to conversion, and adverse drug effects." | 1.46 | Efficacy and safety in pharmacological cardioversion of recent-onset atrial fibrillation: a propensity score matching to compare amiodarone vs class IC antiarrhythmic drugs. ( Bonora, A; Dilda, A; Franchi, E; Maccagnani, A; Olivieri, O; Pistorelli, C; Taioli, G; Turcato, G; Zerman, G, 2017) |
| "Recurrence was not affected by the drug used for cardioversion (P = 0." | 1.40 | Advanced interatrial block is associated with recurrence of atrial fibrillation post pharmacological cardioversion. ( Baranchuk, A; Chiale, PA; Conde, D; de Luna, AB; Enriquez, A; Hopman, W; Mondragon, I, 2014) |
| "Mirtazapine is a commonly prescribed antidepressant drug, which is also metabolized through and may modulate the CYP4502D6 pathway leading to altered metabolism of propafenone and possible adverse effects." | 1.40 | Propafenone associated severe central nervous system and cardiovascular toxicity due to mirtazapine: a case of severe drug interaction. ( Aryal, SR; Khan, MA; Rajpurohit, N; Stys, AT; Stys, TP, 2014) |
| "Amiodarone was the most widely used active compound (82%) and apparently the most effective." | 1.39 | [Predictors of reversion to sinus rhythm previous to electrical cardioversion in patients with persistent atrial fibrillation treated with anti-arrhythmic drugs]. ( Alegret, JM; Freire, F; Romero-Menor, C; Viñolas, X, 2013) |
| "Following propafenone, this type 2 Brugada ECG pattern turned to the coved type 1 Brugada pattern with ST elevation of more than 2 mm." | 1.37 | [Concealed Brugada syndrome that became apparent incidentally during atrial fibrillation therapy]. ( Işılak, Z; Kılıçaslan, F; Tokatlı, A; Yiğiner, O, 2011) |
| " Therefore, oral loading with propafenone (as "pill-in-the-pocket" treatment of recent-onset atrial fibrillation) in a patient on concurrent carvedilol treatment may lead to a pharmacokinetic interaction, with high plasma levels of propafenone and potential drug-related adverse effects." | 1.36 | Atrial fibrillation: adverse effects of "pill-in-the-pocket" treatment and propafenone-carvedilol interaction. ( Biffi, M; Boriani, G; Diemberger, I; Domenichini, G; Martignani, C; Marziali, A, 2010) |
| "Pill-in-the-pocket treatment should be prescribed only if the administration of a loading oral dose of flecainide or propafenone has been proved safe in hospital, since major adverse effects have been reported in 5% of patients during in-hospital treatment." | 1.36 | Intravenous administration of flecainide or propafenone in patients with recent-onset atrial fibrillation does not predict adverse effects during 'pill-in-the-pocket' treatment. ( Alboni, P; Boriani, G; Botto, GL; Capucci, A; Iori, M; Mancini, M; Mariconti, B; Pacchioni, F; Pasanisi, G; Russo, G, 2010) |
| "Electrocardiography (ECG) showed ventricular tachycardia." | 1.35 | A case of myotonic dystrophy presenting with ventricular tachycardia and atrial fibrillation. ( Eroğlu, S; Müderrisoğlu, H; Ozbiçer, S; Ozin, B, 2009) |
| "Propafenone toxicity can cause significant QRS widening and markedly abnormal ventricular activation pattern." | 1.34 | Cardiac memory induced by QRS widening due to propafenone toxicity. ( Josephson, ME; Shvilkin, A; Wylie, JV; Zimetbaum, P, 2007) |
| "Interventional elimination of chronic persistent atrial fibrillation (AFib) remains difficult." | 1.32 | Electrophysiological mapping and histological examinations of the swine atrium with sustained (> or =24 h) atrial fibrillation: a suitable animal model for studying human atrial fibrillation. ( Chen, SP; Du, CC; Huang, SK; Lai, LP; Lee, WC; Lien, WP; Lin, CS; Lin, JL; Tseng, YZ; Wu, TJ; Yang, PC, 2003) |
| "The amiodarone was omitted in 17 cases because of its side effects." | 1.32 | [Treatment of atrial fibrillation in a Hungarian hospital department of cardiologic internal medicine at the turn of the millennium]. ( Borbély, M; Dani, G; Erdej, F; Hajdara, I; Katona, A; Márk, L; Nagy, E; Sziklai, G, 2004) |
| "Propafenone was prescribed at the initial dose of 600 mg/day in 65% of patients." | 1.31 | [Efficacy and tolerance of propafenone after correction of atrial fibrillation: PEPS pharmaco-epidemiologic study]. ( Davy, JM; Funck-Brentano, C; Jaillon, P; Mary-Krause, M; Simon, T; Weingrod, M, 2002) |
| "Propafenone is an effective antiarrhythmic drug used widely for the treatment of supraventricular and ventricular arrhythmias." | 1.31 | Propafenone-induced ataxia: report of three cases. ( Odeh, M; Oliven, A; Seligmann, H, 2000) |
| "Ibutilide (I) has been reported to block I(k) and to delay inactivation of the slow Na(+) current (S-Na)." | 1.31 | The actions of ibutilide and class Ic drugs on the slow sodium channel: new insights regarding individual pharmacologic effects elucidated through combination therapies. ( Blitzer, M; Reiffel, JA, 2000) |
| " In this study, we prospectively investigated the effects of AFI ablation and continuation of drug therapy in patients with AF who developed AFI due to long-term administration of class IC antiarrhythmic drugs." | 1.30 | Radiofrequency ablation of atrial flutter due to administration of class IC antiarrhythmic drugs for atrial fibrillation. ( Jung, W; Lewalter, T; Lüderitz, B; Schumacher, B; Vahlhaus, C; Wolpert, C, 1999) |
| "Three patients experienced recurrence of AF in the early follow-up." | 1.29 | Role of transesophageal pacing in recurrent atrial fibrillation. Experience with propafenone. ( Bellizzi, G; Candelmo, F; Foffa, A; Guarino, P; Martino, DF; Morella, A; Parente, A; Turco, P; Viola, V, 1994) |
| "Propafenone terminated tachyarrhythmias in all patients during or within a few minutes after stopping infusion (mean conversion time: 6." | 1.28 | [Use of propafenone in emergency therapy]. ( Di Ieso, N; Guardascione, A; Liguori, A; Pellegrino, G; Piatto, A; Ruggiero, P; Scarnera, P, 1989) |
| "Propafenone was less effective (mean effect 3." | 1.27 | European experience with the antiarrhythmic efficacy of propafenone for supraventricular and ventricular arrhythmias. ( Assayag, P; Coumel, P; Leclercq, JF, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 26 (7.28) | 18.7374 |
| 1990's | 117 (32.77) | 18.2507 |
| 2000's | 128 (35.85) | 29.6817 |
| 2010's | 67 (18.77) | 24.3611 |
| 2020's | 19 (5.32) | 2.80 |
| Authors | Studies |
|---|---|
| Tsiachris, D | 1 |
| Doundoulakis, I | 1 |
| Tsioufis, P | 1 |
| Pagkalidou, E | 1 |
| Antoniou, CK | 1 |
| Zafeiropoulos, SM | 1 |
| Gatzoulis, KA | 1 |
| Tsioufis, K | 1 |
| Stefanadis, C | 3 |
| Wybraniec, MT | 3 |
| Maciąg, A | 3 |
| Miśkowiec, D | 2 |
| Ceynowa-Sielawko, B | 2 |
| Balsam, P | 3 |
| Wójcik, M | 2 |
| Wróbel, W | 2 |
| Farkowski, M | 1 |
| Ćwiek-Rębowska, E | 2 |
| Szołkiewicz, M | 2 |
| Ozierański, K | 2 |
| Błaszczyk, R | 2 |
| Bula, K | 2 |
| Dembowski, T | 2 |
| Peller, M | 2 |
| Krzowski, B | 2 |
| Wańha, W | 2 |
| Koziński, M | 2 |
| Kasprzak, JD | 2 |
| Szwed, H | 3 |
| Mizia-Stec, K | 3 |
| Cay, S | 1 |
| Kara, M | 1 |
| Ozcan, F | 1 |
| Ozeke, O | 1 |
| Aksu, T | 1 |
| Aras, D | 1 |
| Topaloglu, S | 1 |
| Topp-Zielińska, A | 1 |
| Farkowski, MM | 2 |
| Kovacs, B | 2 |
| Yakupoglu, HY | 2 |
| Eriksson, U | 2 |
| Krasniqi, N | 2 |
| Duru, F | 2 |
| Markman, TM | 1 |
| Jarrah, AA | 1 |
| Tian, Y | 1 |
| Mustin, E | 1 |
| Guandalini, GS | 1 |
| Lin, D | 2 |
| Epstein, AE | 1 |
| Hyman, MC | 1 |
| Deo, R | 1 |
| Supple, GE | 1 |
| Arkles, JS | 1 |
| Dixit, S | 1 |
| Schaller, RD | 1 |
| Santangeli, P | 1 |
| Nazarian, S | 1 |
| Riley, M | 1 |
| Callans, DJ | 1 |
| Marchlinski, FE | 3 |
| Frankel, DS | 1 |
| Chin, CG | 1 |
| Hsieh, YC | 1 |
| Lin, WS | 1 |
| Lin, YJ | 3 |
| Chiou, CW | 2 |
| Lin, TH | 1 |
| Huang, CL | 1 |
| Hung, Y | 1 |
| Lin, YK | 1 |
| Chang, SL | 3 |
| Yeh, TC | 1 |
| Lee, HC | 1 |
| Lai, WT | 1 |
| Hsieh, MH | 2 |
| Basza, M | 1 |
| Maciejewski, C | 1 |
| Bojanowicz, W | 1 |
| Grabowski, M | 1 |
| Mitkowski, P | 1 |
| Kempa, M | 1 |
| Kowalski, O | 1 |
| Kalarus, Z | 1 |
| Jaguszewski, M | 1 |
| Lubiński, A | 1 |
| Daniłowicz-Szymanowicz, L | 1 |
| Szumowski, Ł | 1 |
| Sterliński, M | 2 |
| Kołtowski, Ł | 1 |
| Wu, VC | 1 |
| Wang, CL | 1 |
| Huang, YC | 1 |
| Tu, HT | 1 |
| Huang, YT | 1 |
| Huang, CH | 1 |
| Chen, SW | 1 |
| Kuo, CF | 1 |
| Hung, KC | 1 |
| Chang, SH | 1 |
| Gagloeva, DA | 1 |
| Dzaurova, KM | 1 |
| Zelberg, MA | 1 |
| Mironov, NY | 1 |
| Yuricheva, YA | 1 |
| Sokolov, SF | 1 |
| Golitsyn, SP | 1 |
| Kampka, Z | 1 |
| Balik, M | 1 |
| Maly, M | 1 |
| Brozek, T | 1 |
| Rulisek, J | 1 |
| Porizka, M | 1 |
| Sachl, R | 1 |
| Otahal, M | 1 |
| Brestovansky, P | 1 |
| Svobodova, E | 1 |
| Flaksa, M | 1 |
| Stach, Z | 1 |
| Horejsek, J | 1 |
| Volny, L | 1 |
| Jurisinova, I | 1 |
| Novotny, A | 1 |
| Trachta, P | 1 |
| Kunstyr, J | 1 |
| Kopecky, P | 1 |
| Tencer, T | 1 |
| Pazout, J | 1 |
| Belohlavek, J | 1 |
| Duska, F | 1 |
| Krajcova, A | 1 |
| Waldauf, P | 1 |
| Przybylski, R | 1 |
| Eberly, LM | 1 |
| Alexander, ME | 1 |
| Bezzerides, VJ | 1 |
| DeWitt, ES | 1 |
| Dionne, A | 1 |
| Mah, DY | 1 |
| Triedman, JK | 1 |
| Walsh, EP | 1 |
| O'Leary, ET | 1 |
| Bergonti, M | 1 |
| Assanelli, E | 1 |
| Agostoni, P | 1 |
| Huang, R | 1 |
| Lin, J | 2 |
| Gong, K | 1 |
| Chen, L | 2 |
| Fan, L | 1 |
| Zhang, F | 1 |
| Zhang, Y | 4 |
| Chen, X | 2 |
| Xu, Z | 1 |
| Chiou, WR | 1 |
| Huang, CC | 1 |
| Lin, PL | 1 |
| Chuang, JY | 1 |
| Liu, LY | 1 |
| Su, MI | 1 |
| Liao, FC | 1 |
| Chen, CY | 1 |
| Kuo, JY | 1 |
| Tsai, CT | 1 |
| Wu, YJ | 1 |
| Lee, YH | 1 |
| Bai, J | 1 |
| Zhu, Y | 1 |
| Lo, A | 1 |
| Gao, M | 1 |
| Lu, Y | 1 |
| Zhao, J | 1 |
| Zhang, H | 1 |
| Ibrahim, OA | 1 |
| Belley-Côté, EP | 1 |
| Um, KJ | 1 |
| Baranchuk, A | 2 |
| Benz, AP | 1 |
| Dalmia, S | 1 |
| Wang, CN | 1 |
| Alhazzani, W | 1 |
| Conen, D | 1 |
| Devereaux, PJ | 1 |
| Whitlock, RP | 1 |
| Healey, JS | 1 |
| McIntyre, WF | 1 |
| Holmes, AP | 1 |
| Saxena, P | 1 |
| Kabir, SN | 1 |
| O'Shea, C | 1 |
| Kuhlmann, SM | 1 |
| Gupta, S | 1 |
| Fobian, D | 1 |
| Apicella, C | 1 |
| O'Reilly, M | 1 |
| Syeda, F | 1 |
| Reyat, JS | 1 |
| Smith, GL | 1 |
| Workman, AJ | 1 |
| Pavlovic, D | 1 |
| Fabritz, L | 1 |
| Kirchhof, P | 1 |
| Mowaswes, M | 1 |
| Biton, Y | 1 |
| Belhassen, B | 1 |
| Martignani, C | 3 |
| Diemberger, I | 2 |
| Ziacchi, M | 1 |
| Biffi, M | 7 |
| Boriani, G | 13 |
| Mattioli, AV | 3 |
| Pennella, S | 1 |
| Farinetti, A | 1 |
| Manenti, A | 1 |
| Juhász, V | 1 |
| Hornyik, T | 1 |
| Benák, A | 1 |
| Nagy, N | 1 |
| Husti, Z | 1 |
| Pap, R | 1 |
| Sághy, L | 1 |
| Virág, L | 1 |
| Varró, A | 1 |
| Baczkó, I | 1 |
| Bayram, Z | 1 |
| Güner, A | 1 |
| Doğan, C | 1 |
| Yılmaz, F | 1 |
| Özdemir, N | 1 |
| Wu, C | 1 |
| Tcherny-Lessenot, S | 1 |
| Dai, W | 1 |
| Wang, Y | 1 |
| Kechemir, H | 1 |
| Gandhi, S | 1 |
| Lin, S | 1 |
| Juhaeri, J | 1 |
| Chen, S | 1 |
| Ding, W | 1 |
| Ye, J | 1 |
| Wang, Z | 2 |
| Zhao, X | 1 |
| Cui, Y | 1 |
| Wang, X | 1 |
| Lin, Y | 1 |
| Liang, D | 1 |
| Qi, G | 1 |
| Tian, W | 1 |
| Conde, D | 5 |
| Costabel, JP | 3 |
| Aragon, M | 3 |
| Caro, M | 1 |
| Ferro, A | 1 |
| Klein, A | 2 |
| Trivi, M | 3 |
| Giniger, A | 2 |
| Yu, Z | 1 |
| Xiang, M | 1 |
| Ma, C | 2 |
| Zhang, S | 1 |
| Yang, Y | 2 |
| Duricova, J | 1 |
| Perinova, I | 1 |
| Jurckova, N | 1 |
| Kacirova, I | 1 |
| Grundmann, M | 1 |
| Bontempi, L | 1 |
| Vassanelli, F | 1 |
| Lipari, A | 1 |
| Pagnoni, C | 1 |
| Locantore, E | 1 |
| Elmaghawry, M | 1 |
| Salghetti, F | 1 |
| Cerini, M | 1 |
| Curnis, A | 1 |
| Lambardi, F | 2 |
| Corrales Barbosa, A | 1 |
| Deftereos, S | 1 |
| Giannopoulos, G | 1 |
| Kossyvakis, C | 1 |
| Efremidis, M | 1 |
| Panagopoulou, V | 1 |
| Raisakis, K | 1 |
| Kaoukis, A | 1 |
| Karageorgiou, S | 1 |
| Bouras, G | 1 |
| Katsivas, A | 1 |
| Pyrgakis, V | 1 |
| Enriquez, A | 1 |
| Hopman, W | 1 |
| Mondragon, I | 1 |
| Chiale, PA | 1 |
| de Luna, AB | 1 |
| Faggioni, M | 1 |
| Savio-Galimberti, E | 1 |
| Venkataraman, R | 1 |
| Hwang, HS | 1 |
| Kannankeril, PJ | 1 |
| Darbar, D | 1 |
| Knollmann, BC | 1 |
| Eggertson, L | 1 |
| Kiliszek, M | 1 |
| Opolski, G | 2 |
| Włodarczyk, P | 1 |
| Dąbrowski, R | 1 |
| Ponikowski, P | 2 |
| Rajpurohit, N | 1 |
| Aryal, SR | 1 |
| Khan, MA | 1 |
| Stys, AT | 1 |
| Stys, TP | 1 |
| Chun, KJ | 1 |
| Byeon, K | 1 |
| Im, SI | 1 |
| Park, KM | 1 |
| Park, SJ | 1 |
| Kim, JS | 1 |
| On, YK | 1 |
| Tesic, D | 1 |
| Kostic, M | 1 |
| Paunovic, D | 1 |
| Jankovic, SM | 1 |
| Allen LaPointe, NM | 1 |
| Dai, D | 1 |
| Thomas, L | 1 |
| Piccini, JP | 2 |
| Peterson, ED | 1 |
| Al-Khatib, SM | 1 |
| La Rocca, R | 1 |
| Ferrari-Toninelli, G | 1 |
| Patanè, S | 2 |
| Walfridsson, H | 2 |
| Walfridsson, U | 1 |
| Nielsen, JC | 1 |
| Johannessen, A | 2 |
| Raatikainen, P | 2 |
| Janzon, M | 1 |
| Levin, LA | 1 |
| Aronsson, M | 1 |
| Hindricks, G | 3 |
| Kongstad, O | 2 |
| Pehrson, S | 2 |
| Englund, A | 2 |
| Hartikainen, J | 2 |
| Mortensen, LS | 2 |
| Hansen, PS | 2 |
| Lin, CY | 1 |
| Lo, LW | 1 |
| Chen, YY | 1 |
| Chong, E | 1 |
| Chung, FP | 1 |
| Chao, TF | 1 |
| Hu, YF | 1 |
| Tuan, TC | 1 |
| Liao, JN | 1 |
| Chang, Y | 1 |
| Chien, KL | 1 |
| Chen, SA | 7 |
| Nawrocka, I | 1 |
| Kaczyńska, A | 1 |
| Abramczyk, P | 1 |
| Carbone, V | 1 |
| Pia Calabrò, M | 1 |
| Marafioti, V | 2 |
| Oreto, G | 3 |
| Lip, GY | 7 |
| Fauchier, L | 1 |
| Freedman, SB | 1 |
| Van Gelder, I | 1 |
| Natale, A | 1 |
| Gianni, C | 1 |
| Nattel, S | 7 |
| Potpara, T | 1 |
| Rienstra, M | 1 |
| Tse, HF | 2 |
| Lane, DA | 1 |
| Żurawska, M | 1 |
| Pytkowski, M | 1 |
| Kowalik, I | 1 |
| Woźniak, J | 1 |
| Bonora, A | 1 |
| Turcato, G | 1 |
| Franchi, E | 1 |
| Taioli, G | 1 |
| Dilda, A | 1 |
| Zerman, G | 1 |
| Maccagnani, A | 1 |
| Pistorelli, C | 1 |
| Olivieri, O | 1 |
| Chouchoulis, K | 1 |
| Chiladakis, J | 1 |
| Koutsogiannis, N | 1 |
| Davlouros, P | 1 |
| Kaza, M | 1 |
| Alexopoulos, D | 1 |
| Stoschitzky, K | 1 |
| Stoschitzky, G | 1 |
| Lercher, P | 1 |
| Brussee, H | 1 |
| Li, X | 1 |
| Liu, H | 1 |
| Jiang, H | 1 |
| Ge, H | 1 |
| Men, EE | 1 |
| Yildirimtürk, O | 1 |
| Tuğcu, A | 1 |
| Aytekin, V | 1 |
| Aytekin, S | 1 |
| Garcia, A | 1 |
| Palardy, M | 1 |
| Ducharme, A | 1 |
| Tardif, JC | 1 |
| White, M | 1 |
| Racine, N | 1 |
| Tétreault, K | 1 |
| Dabouz, F | 1 |
| Talajic, M | 8 |
| Roy, D | 7 |
| Milicevic, G | 1 |
| Gavranovic, Z | 1 |
| Bakula, M | 1 |
| Pazur, V | 1 |
| Frank, B | 1 |
| Stanaitiene, G | 1 |
| Babarskiene, RM | 1 |
| Catapano-Minotti, G | 1 |
| Corsonello, A | 1 |
| Antonelli Incalzi, R | 1 |
| Domenichini, G | 1 |
| Marziali, A | 1 |
| Tsiperfal, A | 1 |
| Scheibly, K | 1 |
| Matsuda, K | 1 |
| Jastrzebski, M | 1 |
| De Clercq, D | 1 |
| van Loon, G | 1 |
| Tavernier, R | 1 |
| Verbesselt, R | 1 |
| Deprez, P | 1 |
| Watson, T | 1 |
| Dogan, A | 2 |
| Akcay, S | 1 |
| Karabacak, M | 1 |
| Turker, Y | 1 |
| Ozaydin, M | 2 |
| Erdogan, D | 1 |
| Burashnikov, A | 3 |
| Antzelevitch, C | 3 |
| Mihálcz, A | 1 |
| Földesi, C | 1 |
| Kardos, A | 1 |
| Ladunga, K | 1 |
| Szili-Török, T | 1 |
| Niu, G | 1 |
| Scherlag, BJ | 1 |
| Lu, Z | 1 |
| Ghias, M | 1 |
| Patterson, E | 1 |
| Dasari, TW | 1 |
| Zacharias, S | 1 |
| Lazzara, R | 1 |
| Jackman, WM | 1 |
| Po, SS | 1 |
| Eroğlu, S | 1 |
| Ozin, B | 1 |
| Ozbiçer, S | 1 |
| Müderrisoğlu, H | 1 |
| Khavandi, A | 1 |
| Walker, SK | 1 |
| Daubert, JP | 1 |
| Kosior, DA | 1 |
| Kochanowski, J | 1 |
| Scisło, P | 1 |
| Piatkowski, R | 1 |
| Postuła, M | 1 |
| Rabczenko, D | 1 |
| Akhmedov, VA | 1 |
| Dolgikh, VT | 1 |
| Naumov, DV | 1 |
| Dvornikov, VE | 1 |
| Kowey, PR | 3 |
| Breithardt, G | 2 |
| Camm, J | 1 |
| Crijns, H | 1 |
| Dorian, P | 7 |
| Le Heuzey, JY | 1 |
| Pedrazzini, L | 1 |
| Prystowsky, EN | 1 |
| Salette, G | 1 |
| Schwartz, PJ | 1 |
| Torp-Pedersen, C | 1 |
| Weintraub, W | 1 |
| Alboni, P | 5 |
| Botto, GL | 11 |
| Russo, G | 1 |
| Pacchioni, F | 1 |
| Iori, M | 1 |
| Pasanisi, G | 1 |
| Mancini, M | 1 |
| Mariconti, B | 1 |
| Capucci, A | 15 |
| Stiefelhagen, P | 1 |
| Tsai, CF | 1 |
| Sia, SK | 1 |
| Lin, MC | 1 |
| Wu, DJ | 1 |
| Ueng, KC | 1 |
| Anusionwu, O | 1 |
| Wali, A | 1 |
| Ito, N | 1 |
| Tashiro, T | 1 |
| Morishige, N | 1 |
| Nishimi, M | 1 |
| Hayashida, Y | 1 |
| Takeuchi, K | 1 |
| Minematsu, N | 1 |
| Kuwahara, G | 1 |
| Sukehiro, Y | 1 |
| Conti, A | 1 |
| Del Taglia, B | 1 |
| Mariannini, Y | 1 |
| Pepe, G | 1 |
| Vanni, S | 1 |
| Grifoni, S | 1 |
| Abbate, R | 1 |
| Michelucci, A | 2 |
| Padeletti, L | 2 |
| Gensini, GF | 2 |
| Samaan, RA | 1 |
| Sobamowo, HO | 1 |
| Tamburrino, F | 1 |
| Grodman, R | 1 |
| Isber, N | 1 |
| Walsh, KB | 1 |
| Alexoudis, A | 1 |
| Spyridonidou, A | 1 |
| Kirchhof, CJ | 1 |
| Crijns, HJ | 2 |
| van Gelder, IC | 2 |
| Freemantle, N | 1 |
| Lafuente-Lafuente, C | 1 |
| Mitchell, S | 1 |
| Eckert, L | 1 |
| Reynolds, M | 1 |
| Kong, DF | 1 |
| Bellone, A | 1 |
| Etteri, M | 1 |
| Vettorello, M | 1 |
| Bonetti, C | 1 |
| Clerici, D | 1 |
| Gini, G | 1 |
| Maino, C | 1 |
| Mariani, M | 1 |
| Natalizi, A | 1 |
| Nessi, I | 1 |
| Rampoldi, A | 1 |
| Colombo, L | 1 |
| Yiğiner, O | 1 |
| Kılıçaslan, F | 1 |
| Tokatlı, A | 1 |
| Işılak, Z | 1 |
| O'Hara, GE | 2 |
| Philippon, F | 1 |
| Gilbert, M | 1 |
| Champagne, J | 1 |
| Michaud, V | 1 |
| Charbonneau, L | 1 |
| Pruneau, G | 1 |
| Hamelin, BA | 1 |
| Geelen, P | 2 |
| Turgeon, J | 2 |
| Apostolakis, S | 1 |
| Dragios, TD | 1 |
| Manolis, AG | 1 |
| Kyriakides, ZS | 1 |
| Okutucu, S | 1 |
| Sabanov, C | 1 |
| Abdulhayoğlu, E | 1 |
| Aksu, NM | 1 |
| Erbil, B | 1 |
| Aytemir, K | 1 |
| Ozkutlu, H | 1 |
| Daniell, HW | 1 |
| Balla, I | 1 |
| Petrela, E | 1 |
| Kondili, A | 2 |
| Wang, AH | 1 |
| Pu, JL | 1 |
| Qi, XY | 1 |
| Miao, WL | 1 |
| Hou, ZS | 1 |
| Cong, HL | 1 |
| Zhou, JZ | 1 |
| Liu, XF | 1 |
| Li, SM | 1 |
| Han, QH | 1 |
| Liu, YJ | 1 |
| Yang, XC | 1 |
| Belardinelli, L | 2 |
| Rodríguez-Suárez, S | 1 |
| García-Morillo, S | 1 |
| Gómez-Morales, L | 1 |
| Romero-Rodriguez, N | 1 |
| Beltran-Romero, L | 1 |
| Gonzalez-Estrada, A | 1 |
| Bash, LD | 1 |
| Buono, JL | 1 |
| Davies, GM | 1 |
| Martin, A | 1 |
| Fahrbach, K | 1 |
| Phatak, H | 1 |
| Avetisyan, R | 1 |
| Mwamburi, M | 1 |
| Sestito, A | 1 |
| Molina, E | 1 |
| Blecher, GE | 1 |
| Stiell, IG | 1 |
| Rowe, BH | 1 |
| Lang, E | 1 |
| Brison, RJ | 1 |
| Perry, JJ | 1 |
| Clement, CM | 1 |
| Borgundvaag, B | 1 |
| Langhan, T | 1 |
| Magee, K | 1 |
| Stenstrom, R | 1 |
| Birnie, D | 1 |
| Wells, GA | 1 |
| Kupriianova, OG | 1 |
| Pavlov, AV | 1 |
| Vaniev, SB | 1 |
| Doshchitsin, VL | 1 |
| Viñolas, X | 1 |
| Freire, F | 1 |
| Romero-Menor, C | 1 |
| Alegret, JM | 1 |
| Cosedis Nielsen, J | 1 |
| Kuo, CE | 1 |
| Liang, SF | 1 |
| Lu, SS | 1 |
| Kuan, TC | 1 |
| Lin, CS | 2 |
| Chock, JG | 1 |
| Gill, MR | 1 |
| Simon, T | 1 |
| Mary-Krause, M | 1 |
| Funck-Brentano, C | 1 |
| Davy, JM | 1 |
| Weingrod, M | 1 |
| Jaillon, P | 1 |
| Hrovatin, E | 1 |
| Piazza, R | 1 |
| Brieda, M | 1 |
| Dametto, E | 1 |
| Zardo, F | 1 |
| Burelli, C | 1 |
| Cassin, M | 1 |
| Nicolosi, GL | 1 |
| Khairy, P | 1 |
| Meinertz, T | 1 |
| Lombardi, F | 1 |
| Sadowski, ZP | 1 |
| Kalsch, B | 1 |
| Camez, A | 1 |
| Hewkin, A | 1 |
| Eberle, S | 1 |
| Peciuliene, I | 1 |
| Lukoseviciūte, A | 1 |
| Bonatti, S | 1 |
| Bonetti, L | 1 |
| Mattioli, G | 2 |
| Soucier, R | 1 |
| Silverman, D | 1 |
| Abordo, M | 1 |
| Jaagosild, P | 1 |
| Abiose, A | 1 |
| Madhusoodanan, KP | 1 |
| Therrien, M | 1 |
| Lippman, N | 1 |
| Dalamagas, H | 1 |
| Berns, E | 1 |
| Cocozzella, D | 1 |
| Curciarello, J | 1 |
| Corallini, O | 1 |
| Olivera, A | 1 |
| Alburquerque, MM | 1 |
| Fraquelli, E | 1 |
| Zamagna, L | 1 |
| Olenchuck, A | 1 |
| Cremona, A | 1 |
| Naccarelli, GV | 2 |
| Wolbrette, DL | 2 |
| Khan, M | 1 |
| Bhatta, L | 1 |
| Hynes, J | 1 |
| Samii, S | 1 |
| Luck, J | 1 |
| Yan, GX | 1 |
| Winkel, E | 1 |
| Kao, W | 1 |
| Friberg, J | 1 |
| Gadsbøll, N | 1 |
| Lin, JL | 2 |
| Lai, LP | 2 |
| Du, CC | 1 |
| Wu, TJ | 1 |
| Chen, SP | 1 |
| Lee, WC | 1 |
| Yang, PC | 1 |
| Tseng, YZ | 2 |
| Lien, WP | 2 |
| Huang, SK | 2 |
| Pritchett, EL | 2 |
| Page, RL | 1 |
| Carlson, M | 1 |
| Undesser, K | 1 |
| Fava, G | 1 |
| Lee, JK | 2 |
| Klein, GJ | 5 |
| Krahn, AD | 2 |
| Yee, R | 5 |
| Zarnke, K | 2 |
| Simpson, C | 2 |
| Skanes, A | 2 |
| Villani, GQ | 3 |
| Piepoli, MF | 2 |
| Lumer, G | 1 |
| Mangat, I | 1 |
| Sung, RJ | 1 |
| Kochiadakis, GE | 6 |
| Igoumenidis, NE | 6 |
| Hamilos, MI | 1 |
| Tzerakis, PG | 2 |
| Klapsinos, NC | 2 |
| Zacharis, EA | 1 |
| Vardas, PE | 6 |
| Márk, L | 1 |
| Erdej, F | 1 |
| Dani, G | 1 |
| Borbély, M | 1 |
| Sziklai, G | 1 |
| Nagy, E | 1 |
| Hajdara, I | 1 |
| Katona, A | 1 |
| Amit, G | 1 |
| Rosen, A | 1 |
| Wagshal, AB | 1 |
| Bonneh, DY | 1 |
| Liss, T | 1 |
| Grosbard, A | 1 |
| Ilia, R | 1 |
| Katz, A | 1 |
| Ergene, O | 3 |
| Nazli, C | 3 |
| Kinay, O | 2 |
| Altinbas, A | 1 |
| Ucarci, Y | 1 |
| Ergene, U | 3 |
| Gedikli, O | 1 |
| Chandra, P | 1 |
| Rosen, TS | 1 |
| Yeom, ZH | 1 |
| Lee, K | 1 |
| Kim, HY | 1 |
| Danilo, P | 1 |
| Rosen, MR | 1 |
| Chiladakis, JA | 1 |
| Kalogeropoulos, A | 1 |
| Patsouras, N | 1 |
| Manolis, AS | 1 |
| Hongo, RH | 1 |
| Themistoclakis, S | 2 |
| Raviele, A | 2 |
| Bonso, A | 2 |
| Rossillo, A | 1 |
| Glatter, KA | 1 |
| Scheinman, MM | 1 |
| Yannicelli, D | 1 |
| Amsterdam, E | 1 |
| Humphries, KH | 1 |
| Kerr, CR | 4 |
| Steinbuch, M | 1 |
| Beldner, S | 1 |
| Bertaglia, E | 1 |
| Zoppo, F | 1 |
| Proclemer, A | 2 |
| Verlato, R | 2 |
| Corò, L | 1 |
| Mantovan, R | 1 |
| Pascotto, P | 1 |
| Freestone, B | 2 |
| Baldi, N | 2 |
| Luzi, M | 1 |
| Russo, V | 1 |
| Gianfranchi, L | 1 |
| Marchi, P | 1 |
| Calzolari, M | 1 |
| Solano, A | 1 |
| Baroffio, R | 1 |
| Gaggioli, G | 1 |
| Hamilos, ME | 2 |
| Chlouverakis, GI | 3 |
| Antonelli, D | 2 |
| Freedberg, NA | 2 |
| Feldman, A | 1 |
| Darawsha, A | 2 |
| Rosenfeld, T | 2 |
| Wittkowsky, AK | 1 |
| Konety, SH | 1 |
| Olshansky, B | 1 |
| Varma, N | 1 |
| Gilkeson, RC | 1 |
| Waldo, AL | 1 |
| Kocheril, AG | 1 |
| Calkins, H | 1 |
| Sharma, AD | 2 |
| Cher, D | 1 |
| Stubbs, HA | 1 |
| Block, JE | 1 |
| Zhang, HC | 1 |
| Guo, JH | 2 |
| Fang, Q | 1 |
| Zheng, YA | 1 |
| Sun, YM | 1 |
| Zhu, WQ | 1 |
| Wan, Z | 1 |
| Guo, JX | 1 |
| Ge, JB | 1 |
| Han, SM | 1 |
| Martínez-Sellés, M | 1 |
| Castillo, I | 1 |
| Montenegro, P | 1 |
| Martín, ML | 1 |
| Almendral, J | 1 |
| Sanjurjo, M | 1 |
| Wiesfeld, AC | 1 |
| Ansink, JM | 1 |
| van Veldhuisen, DJ | 1 |
| Korantzopoulos, P | 1 |
| Kolettis, TM | 1 |
| Papathanasiou, A | 1 |
| Naka, KK | 1 |
| Kolios, P | 1 |
| Leontaridis, I | 1 |
| Draganigos, A | 1 |
| Katsouras, CS | 1 |
| Goudevenos, JA | 1 |
| Fragakis, N | 1 |
| Papadopoulos, N | 1 |
| Papanastasiou, S | 1 |
| Kozirakis, M | 1 |
| Maligkos, G | 1 |
| Tsaritsaniotis, E | 1 |
| Katsaris, G | 1 |
| Zapolski, T | 1 |
| Wysokiński, A | 1 |
| Bjerregaard, P | 2 |
| Gussak, I | 1 |
| Wyse, DG | 2 |
| Scharf, C | 1 |
| Gorenek, B | 1 |
| Cavusoglu, Y | 1 |
| Goktekin, O | 1 |
| Birdane, A | 1 |
| Kudaiberdieva, G | 1 |
| Ata, N | 1 |
| Unalir, A | 1 |
| Timuralp, B | 1 |
| Zhang, N | 1 |
| Zhang, HCh | 1 |
| Li, XB | 1 |
| Zhang, P | 1 |
| Xn, Y | 1 |
| Wongcharoen, W | 1 |
| Tai, CT | 6 |
| Chen, DY | 1 |
| Cao, J | 1 |
| Zhu, BP | 1 |
| Schwartzman, D | 1 |
| Harvey, MN | 1 |
| Hoyt, RH | 1 |
| Koehler, JL | 1 |
| Ujhelyi, MR | 1 |
| Euler, DE | 1 |
| Janko, S | 1 |
| Hoffmann, E | 1 |
| Narayan, G | 1 |
| Akhtar, M | 1 |
| Sra, J | 1 |
| Liu, X | 3 |
| Long, D | 1 |
| Dong, J | 1 |
| Hu, F | 1 |
| Yu, R | 1 |
| Tang, R | 1 |
| Fang, D | 1 |
| Hao, P | 1 |
| Lu, C | 1 |
| He, X | 1 |
| Camm, AJ | 4 |
| Savelieva, I | 1 |
| Marte, F | 2 |
| Di Bella, G | 2 |
| Patane', S | 1 |
| Pugliatti, P | 1 |
| Mykytsey, A | 1 |
| Bauman, JL | 1 |
| Razminia, M | 1 |
| Zheutlin, T | 1 |
| Wang, T | 1 |
| Saleem, M | 1 |
| Leal, S | 1 |
| Kehoe, RF | 1 |
| Marketou, ME | 3 |
| Wylie, JV | 1 |
| Zimetbaum, P | 2 |
| Josephson, ME | 2 |
| Shvilkin, A | 1 |
| Grecu, M | 1 |
| Olteanu, RO | 1 |
| Olteanu, SS | 1 |
| Georgescu, CA | 1 |
| Regan, CP | 1 |
| Kiss, L | 1 |
| Stump, GL | 1 |
| McIntyre, CJ | 1 |
| Beshore, DC | 1 |
| Liverton, NJ | 1 |
| Dinsmore, CJ | 1 |
| Lynch, JJ | 1 |
| Kanjwal, Y | 2 |
| Imran, N | 2 |
| Grubb, B | 2 |
| Gulizia, M | 1 |
| Mangiameli, S | 1 |
| Orazi, S | 1 |
| Chiarandà, G | 1 |
| Piccione, G | 1 |
| Di Giovanni, N | 1 |
| Colletti, A | 1 |
| Pensabene, O | 1 |
| Lisi, F | 1 |
| Vasquez, L | 1 |
| Grammatico, A | 1 |
| Mörike, K | 1 |
| Kivistö, KT | 1 |
| Schaeffeler, E | 1 |
| Jägle, C | 1 |
| Igel, S | 1 |
| Drescher, S | 1 |
| Fux, R | 1 |
| Marx, C | 1 |
| Hofmann, U | 1 |
| Engel, C | 1 |
| Wagner, F | 1 |
| Delabar, U | 1 |
| Meisner, C | 1 |
| Bail, D | 1 |
| Böhm, JO | 1 |
| Gleiter, CH | 1 |
| Ziemer, G | 1 |
| Rein, JG | 1 |
| Hellberg, KD | 1 |
| Eichelbaum, M | 1 |
| Schwab, M | 1 |
| Chutani, S | 1 |
| Riccardi, A | 1 |
| Lerza, R | 1 |
| Fogari, R | 1 |
| Zoppi, A | 1 |
| Mugellini, A | 1 |
| Corradi, L | 1 |
| Lazzari, P | 1 |
| Preti, P | 1 |
| Derosa, G | 1 |
| Di Diego, JM | 1 |
| Zygmunt, AC | 1 |
| Leclercq, JF | 2 |
| Georgiopoulos, G | 1 |
| Halkidis, H | 1 |
| Attuel, P | 1 |
| Maisonblanche, P | 1 |
| Coumel, P | 2 |
| Gmeiner, R | 1 |
| Sterz, H | 1 |
| Beck, OA | 1 |
| Hochrein, H | 1 |
| Assayag, P | 1 |
| Kulbertus, H | 1 |
| Grey, E | 1 |
| Silverman, DI | 1 |
| Borggrefe, M | 1 |
| Martinez-Rubio, A | 1 |
| Hief, C | 1 |
| Haverkamp, W | 1 |
| Carbonieri, E | 1 |
| Zardini, P | 1 |
| Lenzi, T | 2 |
| Sanguinetti, M | 5 |
| Magnani, B | 7 |
| Jones, RJ | 1 |
| Brace, SR | 1 |
| Vander Tuin, EL | 1 |
| Reimold, SC | 3 |
| Lamas, GA | 1 |
| Cantillon, CO | 2 |
| Antman, EM | 7 |
| Scarfò, S | 1 |
| Fucà, G | 1 |
| Paparella, N | 1 |
| Pedini, I | 1 |
| Mele, D | 1 |
| Bonini, W | 4 |
| Broffoni, T | 7 |
| Cappelletti, G | 2 |
| Falcone, C | 2 |
| Lombardi, R | 4 |
| Paulesu, A | 1 |
| Pedraglio, E | 2 |
| Ferrari, G | 4 |
| Treglia, A | 1 |
| Alfano, C | 1 |
| Rossini, E | 1 |
| Minutiello, L | 1 |
| Rubino, I | 5 |
| Trisolino, G | 2 |
| Della Casa, S | 4 |
| Binetti, N | 1 |
| Cavazza, M | 1 |
| Cobbe, SM | 1 |
| Fazekas, T | 1 |
| Kiss, J | 1 |
| Pap, I | 1 |
| Rudas, L | 1 |
| Turco, P | 3 |
| Guarino, P | 1 |
| Parente, A | 1 |
| Viola, V | 1 |
| Candelmo, F | 1 |
| Bellizzi, G | 1 |
| Foffa, A | 1 |
| Morella, A | 1 |
| Martino, DF | 1 |
| Weiner, P | 1 |
| Ganam, R | 1 |
| Ganem, R | 1 |
| Zidan, F | 1 |
| Rabner, M | 1 |
| Furlanello, F | 1 |
| Bertoldi, A | 1 |
| Leather, RA | 1 |
| Murdoch, C | 1 |
| Leitch, JW | 1 |
| Cowan, JC | 1 |
| Manz, M | 2 |
| Lüderitz, B | 3 |
| Koenig, A | 1 |
| Theolade, R | 1 |
| Chauvin, M | 1 |
| Brechenmacher, C | 1 |
| Bellandi, F | 6 |
| Cantini, F | 5 |
| Pedone, T | 2 |
| Dabizzi, RP | 6 |
| Palchetti, R | 4 |
| Tarquinii, M | 1 |
| Lolli, C | 1 |
| Foscoli, M | 1 |
| Giofrè, R | 1 |
| Labriola, E | 1 |
| Toschi, GP | 1 |
| Wang, J | 1 |
| Bourne, GW | 1 |
| Villemaire, C | 1 |
| Friedman, PL | 5 |
| Cointe, R | 1 |
| Metge, M | 1 |
| Bru, P | 1 |
| Vrancea, F | 1 |
| Gerard, R | 1 |
| Paganelli, F | 1 |
| Lévy, S | 1 |
| Kishore, AG | 1 |
| Di Biasi, P | 1 |
| Scrofani, R | 1 |
| Paje, A | 1 |
| Cappiello, E | 1 |
| Mangini, A | 1 |
| Santoli, C | 1 |
| Bamoshmoosh, M | 1 |
| Telichowski, A | 1 |
| Banasiak, W | 1 |
| Wiech, K | 1 |
| Zebrowski, J | 1 |
| Pieróg, M | 1 |
| Kałka, D | 1 |
| Lacheta, W | 1 |
| Fuglewicz, A | 1 |
| Molenda, W | 1 |
| Chimienti, M | 2 |
| Cullen, MT | 2 |
| Casadei, G | 2 |
| Aliot, E | 1 |
| Denjoy, I | 1 |
| Niccoli, L | 2 |
| Fresco, C | 1 |
| Pavan, A | 1 |
| Buia, G | 1 |
| Vicentini, A | 1 |
| Pavan, D | 1 |
| Morgera, T | 1 |
| Aouate, P | 1 |
| Frank, R | 1 |
| Fontaine, G | 1 |
| Tonet, J | 1 |
| Tageddine, R | 1 |
| Benassar, A | 1 |
| Turlure, A | 1 |
| Jacquemin, M | 1 |
| Laborde, JP | 1 |
| Podrid, PJ | 1 |
| Anderson, JL | 1 |
| Satullo, G | 1 |
| Arrigo, F | 2 |
| Cavallaro, L | 1 |
| Coglitore, A | 1 |
| Fazio, F | 1 |
| Saporito, F | 1 |
| Sorrenti, S | 1 |
| Lee, SH | 4 |
| Chiang, CE | 4 |
| Wen, ZC | 3 |
| Wang, SP | 1 |
| Chang, MS | 5 |
| Bianconi, L | 5 |
| Mennuni, M | 2 |
| Lukic, V | 1 |
| Castro, A | 2 |
| Chieffi, M | 1 |
| Santini, M | 2 |
| Wolk, R | 1 |
| Kulakowski, P | 1 |
| Karczmarewicz, S | 1 |
| Karpinski, G | 1 |
| Makowska, E | 1 |
| Czepiel, A | 1 |
| Ceremuzynski, L | 1 |
| Gosselink, AT | 1 |
| Lie, KI | 2 |
| Natale, MD | 1 |
| Larbuisson, R | 1 |
| Venneman, I | 1 |
| Stiels, B | 2 |
| Molteni, S | 3 |
| Alfieri, G | 1 |
| Barone, P | 2 |
| Bernasconi, G | 1 |
| Doni, F | 1 |
| Staffiere, E | 1 |
| Manfredi, M | 1 |
| Piemonti, C | 1 |
| Todd, S | 1 |
| Rimondini, A | 1 |
| Fiorentini, C | 1 |
| Lardoux, H | 1 |
| Maison Blanche, P | 1 |
| Marchand, X | 1 |
| Canler, A | 1 |
| Rouesnel, P | 1 |
| Bleinc, D | 1 |
| Péraudeau, P | 1 |
| Scheck, F | 1 |
| Bleyer, FL | 1 |
| Quattromani, A | 1 |
| Caracciolo, EA | 1 |
| Espureo, M | 2 |
| Stroobandt, R | 1 |
| Hoebrechts, R | 1 |
| Chen, YJ | 2 |
| Yu, WC | 3 |
| Huang, JL | 1 |
| Fong, AN | 1 |
| Cheng, JJ | 1 |
| Oltrona, L | 1 |
| Broccolino, M | 1 |
| Merlini, PA | 1 |
| Spinola, A | 1 |
| Pezzano, A | 1 |
| Mannucci, PM | 1 |
| Fera, MS | 1 |
| Carunchio, A | 1 |
| Burattini, M | 1 |
| Mazza, A | 1 |
| Coletta, C | 1 |
| Galati, A | 1 |
| Ceci, V | 1 |
| Di Benedetto, S | 1 |
| Girona, J | 1 |
| Domingo, A | 1 |
| Albert, D | 1 |
| Casaldàliga, J | 1 |
| Mont, L | 1 |
| Brugada, J | 1 |
| Brugada, R | 1 |
| Hughes, C | 1 |
| Sunderji, R | 1 |
| Gin, K | 1 |
| Azpitarte, J | 1 |
| Alvarez, M | 1 |
| Baún, O | 1 |
| García, R | 1 |
| Moreno, E | 1 |
| Martín, F | 1 |
| Tercedor, L | 1 |
| Fernández, R | 1 |
| Mugnaioni, G | 1 |
| Ding, YA | 3 |
| Huang, DT | 1 |
| Monahan, KM | 1 |
| Papageorgiou, P | 1 |
| Epstein, LM | 1 |
| Feng, AN | 2 |
| Kuo, BI | 1 |
| Iwasa, A | 1 |
| Okumura, K | 1 |
| Tabuchi, T | 1 |
| Tsuchiya, T | 1 |
| Tsunoda, R | 1 |
| Matsunaga, T | 1 |
| Tayama, S | 1 |
| Yasue, H | 1 |
| Lucchi, GR | 1 |
| Vivoli, D | 1 |
| el-Harari, MB | 1 |
| Adams, PC | 1 |
| Rae, AP | 1 |
| Maisel, WH | 1 |
| Branzi, A | 4 |
| Botto, G | 1 |
| Ongari, M | 1 |
| Simantirakis, EN | 1 |
| Parthenakis, FI | 2 |
| Mezilis, NE | 1 |
| Pandozi, C | 1 |
| Toscano, S | 1 |
| Altamura, G | 1 |
| Jesi, AP | 1 |
| Gentilucci, G | 1 |
| Villani, M | 1 |
| Scianaro, MC | 1 |
| Cete, Y | 2 |
| Fowler, J | 2 |
| Oktay, C | 2 |
| Ciolli, A | 1 |
| De Sisti, A | 1 |
| Montenero, AS | 1 |
| Sanna, T | 1 |
| Lo Sardo, G | 1 |
| Palamara, A | 1 |
| Aschieri, D | 2 |
| Schumacher, B | 1 |
| Jung, W | 1 |
| Lewalter, T | 1 |
| Vahlhaus, C | 1 |
| Wolpert, C | 1 |
| Nabar, A | 2 |
| Rodriguez, LM | 2 |
| Timmermans, C | 2 |
| Smeets, JL | 1 |
| Wellens, HJ | 2 |
| Piepoli, M | 1 |
| Carrel, T | 1 |
| Meyer, B | 1 |
| Candinas, R | 1 |
| Turina, M | 1 |
| Schmid, ER | 1 |
| Bronzetti, G | 1 |
| Napoli, C | 1 |
| Sorice, P | 1 |
| Di Benedetto, A | 1 |
| Di Ieso, N | 2 |
| Liguori, A | 2 |
| De Simone, A | 1 |
| Stabile, G | 1 |
| Vitale, DF | 1 |
| Di Stasio, M | 1 |
| Petrazzuoli, F | 1 |
| Gasparini, M | 3 |
| De Matteis, C | 1 |
| Rotunno, R | 1 |
| Di Napoli, T | 1 |
| Roy, N | 1 |
| Plante, S | 1 |
| Blanc, JJ | 1 |
| Voinov, C | 1 |
| Maarek, M | 1 |
| Antonielli, E | 1 |
| Pizzuti, A | 1 |
| Bassignana, A | 1 |
| Tanga, M | 1 |
| Baralis, G | 1 |
| Rovere, ME | 1 |
| Di Leo, M | 1 |
| Connolly, S | 1 |
| Eisenberg, MJ | 1 |
| Green, M | 2 |
| Kus, T | 1 |
| Lambert, J | 2 |
| Dubuc, M | 2 |
| Gagné, P | 2 |
| Thibault, B | 2 |
| Moretti, R | 1 |
| Torre, P | 1 |
| Antonello, RM | 1 |
| Zorzon, M | 1 |
| Cazzato, G | 1 |
| Dell'Orfano, JT | 1 |
| Patel, HM | 1 |
| Luck, JC | 1 |
| Madonia, S | 1 |
| De Simone, M | 1 |
| Brai, G | 1 |
| Gozzo, D | 1 |
| Gristina, A | 1 |
| Luciano, L | 1 |
| Maisano, S | 1 |
| Migliore, G | 1 |
| Mineo, R | 1 |
| Muzzo, MP | 1 |
| Nicchi, F | 1 |
| Randazzo, A | 1 |
| Raspanti, G | 1 |
| Rotolo, G | 1 |
| Russo, A | 1 |
| Sagona, F | 1 |
| Schirosa, M | 1 |
| Spinello, M | 1 |
| Stancampiano, R | 1 |
| Geraci, E | 1 |
| Vergara, G | 1 |
| Catanzariti, D | 1 |
| Cozzi, F | 1 |
| Accardi, R | 1 |
| Spagnolli, W | 1 |
| Cammilli, L | 1 |
| Berkowitsch, A | 2 |
| Carlsson, J | 1 |
| Erdogan, A | 1 |
| Neuzner, J | 1 |
| Pitschner, HF | 2 |
| Rimbrot, S | 1 |
| Aggarwal, A | 1 |
| Odeh, M | 1 |
| Seligmann, H | 1 |
| Oliven, A | 1 |
| Paquette, M | 2 |
| Newman, D | 2 |
| Couturier, A | 2 |
| Yang, C | 1 |
| Martínez-Marcos, FJ | 1 |
| García-Garmendia, JL | 1 |
| Ortega-Carpio, A | 1 |
| Fernández-Gómez, JM | 1 |
| Santos, JM | 1 |
| Camacho, C | 1 |
| Spindler, B | 1 |
| Lau, CP | 2 |
| Chow, MS | 2 |
| Tang, MO | 2 |
| Fan, C | 2 |
| Pinter, A | 1 |
| Coltorti, F | 1 |
| Mantica, M | 1 |
| Galimberti, P | 1 |
| Ceriotti, C | 1 |
| Beatty, G | 1 |
| Chrysostomakis, SI | 1 |
| Mavrakis, HE | 1 |
| Kaleboubas, MD | 1 |
| White, CM | 1 |
| Reiffel, JA | 1 |
| Blitzer, M | 1 |
| Vágó, H | 1 |
| Merkely, B | 1 |
| Szabolcs, Z | 1 |
| Moravcsik, E | 1 |
| Gellér, L | 1 |
| Szabó, T | 1 |
| Turbók, E | 1 |
| Matkó, I | 1 |
| Bodor, E | 1 |
| Romano, S | 1 |
| Fattore, L | 1 |
| Toscano, G | 1 |
| Corsini, F | 1 |
| Coppo, A | 1 |
| Catanzaro, M | 1 |
| Romano, A | 1 |
| Martone, A | 1 |
| Caccavale, F | 1 |
| Iodice, E | 1 |
| Di Maggio, O | 1 |
| Corsini, G | 1 |
| Khan, IA | 1 |
| Wirth, KJ | 1 |
| Knobloch, K | 1 |
| van Mechelen, R | 1 |
| Lazzeri, C | 1 |
| Bagliani, G | 1 |
| Colella, A | 1 |
| Sabini, A | 1 |
| Zipoli, R | 1 |
| Costoli, A | 1 |
| Pieragnoli, P | 1 |
| Franchi, F | 1 |
| Jazwinska-Tarnawska, E | 1 |
| Orzechowska-Juzwenko, K | 1 |
| Niewinski, P | 1 |
| Rzemislawska, Z | 1 |
| Loboz-Grudzien, K | 1 |
| Dmochowska-Perz, M | 1 |
| Slawin, J | 1 |
| Simonetti, I | 1 |
| Leoncini, M | 1 |
| Frascarelli, F | 1 |
| Giovannini, T | 1 |
| Maioli, M | 2 |
| SoRelle, R | 1 |
| Zadura, M | 1 |
| Grossmann, G | 1 |
| Modrzewska, A | 1 |
| Klecha, T | 1 |
| Klepacka, H | 1 |
| Rumiński, W | 1 |
| Brignole, M | 1 |
| Menozzi, C | 1 |
| Bongiorni, MG | 1 |
| Ometto, R | 1 |
| Bruna, C | 1 |
| Vincenti, A | 1 |
| Connolly, SJ | 2 |
| Krahn, A | 1 |
| Klein, G | 1 |
| Skanes, AC | 1 |
| Lumer, GB | 1 |
| Frasure-Smith, N | 1 |
| Gillor, A | 1 |
| Korsch, E | 1 |
| Margheri, M | 1 |
| Fradella, G | 1 |
| Paterni, M | 1 |
| Bartoli, P | 1 |
| Bonechi, F | 1 |
| Brandinelli, A | 1 |
| Mazza, F | 1 |
| Sansoni, M | 1 |
| Zipoli, A | 1 |
| Katritsis, D | 1 |
| Nunain, SO | 1 |
| Kingma, JH | 2 |
| Suttorp, MJ | 2 |
| Auricchio, A | 1 |
| Gentili, C | 2 |
| Giordano, F | 1 |
| Alois, A | 1 |
| Massa, E | 1 |
| Richiardi, E | 1 |
| Gaita, F | 1 |
| Greco, C | 1 |
| Gaschino, G | 1 |
| Comba Costa, G | 1 |
| Rosettani, E | 1 |
| Brusca, A | 1 |
| Hii, JT | 1 |
| Gillis, AM | 1 |
| Cohen, JM | 1 |
| Mitchell, LB | 1 |
| Kumagai, K | 1 |
| Yamanouchi, Y | 1 |
| Hiroki, T | 1 |
| Arakawa, K | 1 |
| O'Nunain, S | 1 |
| Garratt, CJ | 1 |
| Linker, NJ | 1 |
| Gill, J | 1 |
| Ward, DE | 1 |
| Kyles, AE | 2 |
| Murdock, CJ | 2 |
| Yeung-Lai-Wah, JA | 2 |
| Vorderbrugge, S | 2 |
| Zeng, ZQ | 1 |
| Zhu, L | 1 |
| Goy, JJ | 1 |
| Métrailler, JC | 1 |
| Humair, L | 1 |
| de Torrenté, A | 1 |
| McCarthy, EA | 1 |
| Wilkinson, WE | 1 |
| Santinelli, V | 1 |
| De Paola, M | 1 |
| Smimmo, D | 1 |
| Giasi, M | 1 |
| Santinelli, C | 1 |
| Chiariello, M | 1 |
| Condorelli, M | 1 |
| Marcus, FI | 1 |
| Jessurun, ER | 1 |
| Lie-A-Huen, L | 1 |
| van Hemel, NM | 1 |
| Kastrati, A | 1 |
| Popa, Y | 1 |
| Boahene, KA | 1 |
| Fujimura, O | 1 |
| Beamer, AD | 2 |
| Cantillon, C | 3 |
| McGowan, N | 2 |
| Bauernfeind, RA | 1 |
| Welch, WJ | 1 |
| Vassiliadis, I | 1 |
| Papoutsakis, P | 1 |
| Kallikazaros, I | 1 |
| Sulke, AN | 1 |
| Holt, P | 1 |
| Sowton, GE | 1 |
| Qi, A | 1 |
| Li, ZS | 1 |
| Liusov, VA | 1 |
| Borodkin, VV | 1 |
| Volov, NA | 1 |
| Dudaev, VA | 1 |
| Kauffmann, R | 1 |
| Goich, J | 1 |
| Parra, C | 1 |
| Ayala, A | 1 |
| Manzur, F | 1 |
| Pellegrino, G | 1 |
| Piatto, A | 1 |
| Ruggiero, P | 1 |
| Scarnera, P | 1 |
| Guardascione, A | 1 |
| Aguglia, F | 1 |
| Gnecchi, M | 1 |
| De Marzio, P | 1 |
| Hoffert, DL | 1 |
| Boccadamo, R | 2 |
| Pappalardo, A | 2 |
| Pistolese, M | 2 |
| Vita, JA | 1 |
| Carerj, S | 1 |
| Cavalli, G | 1 |
| Magazù, A | 1 |
| Carerj, B | 1 |
| Cento, D | 1 |
| Consolo, F | 1 |
| Porterfield, JG | 1 |
| Porterfield, LM | 1 |
| Barbieri, O | 1 |
| Cammalleri, G | 1 |
| Gruttadauria, G | 1 |
| Rugiano, A | 1 |
| Vancheri, F | 1 |
| Allen, BJ | 1 |
| Brodsky, MA | 1 |
| Doria, R | 1 |
| Luckett, CR | 1 |
| Thomas, R | 1 |
| Henry, WL | 1 |
| Ludmer, PL | 1 |
| McGowan, NE | 1 |
| Hammill, SC | 1 |
| Wood, DL | 1 |
| Gersh, BJ | 1 |
| Osborn, MJ | 1 |
| Holmes, DR | 1 |
| Axelson, JE | 1 |
| Cooper, JC | 1 |
| Goldman, L | 1 |
| Gubelli, S | 1 |
| Carini, G | 1 |
| Frabetti, L | 1 |
| Broglia, R | 1 |
| Palumbo, E | 1 |
| Svetoni, N | 1 |
| Casini, M | 1 |
| Spargi, T | 1 |
| Biagi, G | 1 |
| Martelli, F | 1 |
| Lanzetta, T | 1 |
| Beermann, J | 1 |
| Gerckens, U | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparison of (R) and (S) Propafenone for Prevention of Atrial Fibrillation Induction[NCT02710669] | Phase 1/Phase 2 | 193 participants (Actual) | Interventional | 2016-10-31 | Terminated (stopped due to Study halted/terminated prematurely due to COVID.) | ||
| Efficacy of Propafenone Versus Dronedarone for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation After DC Cardioversion[NCT01991119] | 98 participants (Actual) | Interventional | 2011-05-31 | Completed | |||
| First-line Cryoablation for Early Treatment of Persistent Atrial Fibrillation - a Randomized Study Comparing Early Trigger Isolation Using the Cryoballoon Versus Antiarrhythmic Medication[NCT05939076] | Phase 3 | 220 participants (Anticipated) | Interventional | 2023-08-21 | Not yet recruiting | ||
| Medical Antiarrhythmic Treatment or Radiofrequency Ablation in Paroxysmal Atrial Fibrillation: A Randomized Prospective Multicentre Study (MANTRA-PAF)[NCT00133211] | Phase 3 | 294 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
| Using Time-dependent Intravenous Infusions of Amiodarone for Conversions to Sinus Rhythms in Patients With Paroxysmal Atrial Fibrillation[NCT03432663] | Phase 4 | 60 participants (Actual) | Interventional | 2008-08-01 | Completed | ||
| Efficacy and Safety of Electrical Versus Pharmacological Cardioversion in Early Atrial Fibrillation: a Randomized Controlled Trial[NCT00933634] | 247 participants (Anticipated) | Interventional | 2006-01-31 | Completed | |||
| Atrial Fibrillation Registry at the Emergency Department of the Medical University of Vienna: A Tool for Structured Diagnosis and Treatment[NCT03272620] | 3,000 participants (Anticipated) | Observational [Patient Registry] | 2014-10-22 | Recruiting | |||
| Dual Shock Versus Single Shock Synchronized External Direct Current Cardioversion for Atrial Fibrillation - A Double-blinded Randomized Trial[NCT03943693] | Phase 4 | 100 participants (Actual) | Interventional | 2019-04-01 | Terminated (stopped due to Poor enrollment) | ||
| Inhibition of Atrial Fibrillation by Elimination of Transitional Mechanisms[NCT02758002] | 0 participants (Actual) | Interventional | 2016-01-28 | Withdrawn | |||
| Radiofrequency vs Cryoballoon Catheter Ablation for Pulmonary Vein Isolation in Patients With Atrial Fibrillation - Effect on Atrial Fibrillation Burden Assessed by Implantable Cardiac Monitor (RACE-AF Trial)[NCT03805555] | 105 participants (Actual) | Interventional | 2015-06-30 | Completed | |||
| Antiarrhythmic Drugs Assessment in Preventing Atrial Fibrillation[NCT02145546] | Phase 4 | 600 participants (Anticipated) | Interventional | 2014-05-31 | Not yet recruiting | ||
| A Single-center, Observational, 12-months Study to Examine the Predictive Factors for Successful Outcome After Pulmonary Veins Ablation to Treat Patients With Paroxysmal Atrial Fibrillation.[NCT02614521] | 0 participants (Actual) | Observational | 2017-01-31 | Withdrawn | |||
| Home-based Videoplethysmographic Detection of Atrial Fibrillation[NCT04267133] | 256 participants (Actual) | Interventional | 2018-05-24 | Completed | |||
| Hybrid Ablation Plus Medical Therapy for Persistent Atrial Fibrillation (HYBRID AF)[NCT04190186] | 90 participants (Anticipated) | Interventional | 2020-06-25 | Recruiting | |||
| Modeling of Amiodarone Effect on Heart Rate Control in Critically Ill Patients With Atrial Tachyarrhythmias[NCT03413150] | 80 participants (Actual) | Observational | 2007-01-31 | Completed | |||
| Pragmatic Randomized Clinical Trial of Early Dronedarone Versus Usual Care to Change and Improve Outcomes in Persons With First-Detected Atrial Fibrillation[NCT05130268] | Phase 4 | 3,000 participants (Anticipated) | Interventional | 2021-10-29 | Active, not recruiting | ||
| Subclinical Postoperative Atrial Fibrillation[NCT02522364] | 150 participants (Anticipated) | Interventional | 2015-08-31 | Recruiting | |||
| [NCT00005237] | 0 participants | Observational | 1988-12-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Inducibility of atrial fibrillation (AF) or atrial flutter (AFL) expressed as an ordinal variable based on stage of the induction protocol.~Stage 1 measured the AV block (Wenckebach) cycle length (AVBCL), AV node effective refractory period (AVN ERP) and atrial ERP (AERP). AVN ERP and AERP were measured at drive trains (S1) of 600 ms and 450 ms. Extrastimuli (S2) were introduced starting at a coupling interval of 500ms and decremented by 10ms with each pacing train.~Stage 2 consisted of 15-beat bursts from the CS proximal electrode. The starting cycle length was 250ms, which was decremented by 10ms with each burst. A 10-second rest period was used between bursts. Step 2 was complete when 1:1 atrial capture was lost or a minimum cycle length of 180ms was reached.~Stage 3 consisted of 15-second bursts. The cycle length used for the bursts was the fastest cycle length achieved during Step 2 that maintained 1:1 atrial conduction." (NCT02710669)
Timeframe: Twenty minutes post-dosage to end of induction protocol (approximately 10 minutes)
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Stage 1 | Stage 2 | Stage 3 | Non-inducible AF/AFL | |
| (R)-Propafenone | 5 | 28 | 27 | 11 |
| (S)-Propafenone | 5 | 31 | 24 | 15 |
| Placebo | 1 | 3 | 8 | 7 |
A rapid atrial pacing protocol was used to attempt to induce atrial fibrillation/atrial flutter. Twenty minutes after start of the study drug, participants underwent placement of a decapolar coronary sinus catheter. Pacing was performed from the proximal electrode at 20 milliamps and a pulse width of 2 ms. Bursts from the CS proximal electrode were induced to attempt atrial fibrillation. (NCT02710669)
Timeframe: Twenty minutes post-dosage to end of induction protocol (approximately 10 minutes)
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Sustained AF and/or AFL induced | Non-sustained AF and/or AFL induced | |
| (R)-Propafenone | 60 | 11 |
| (S)-Propafenone | 60 | 15 |
| Placebo | 12 | 7 |
A rapid atrial pacing protocol was used to attempt to induce atrial flutter. Twenty minutes after start of the study drug, participants underwent placement of a decapolar coronary sinus catheter. Pacing was performed from the proximal electrode at 20 milliamps and a pulse width of 2 ms. Bursts from the CS proximal electrode were induced to attempt atrial flutter. (NCT02710669)
Timeframe: Twenty minutes post-dosage to end of induction protocol (approximately 10 minutes)
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Sustained AFL | Non-Sustained AFL | |
| (R)-Propafenone | 23 | 48 |
| (S)-Propafenone | 26 | 49 |
| Placebo | 1 | 18 |
The outcome measure is the AUC of the curve obtained from the ROC analysis. The curve is a combination of specificity and sensitivity of detecting atrial fibrillation. The range of the curve is 0.5-1.0 where 0.5 would be random detection of atrial fibrillation and 1.0 would be perfect performance. (NCT04267133)
Timeframe: 2 weeks
| Intervention | probability (Number) |
|---|---|
| All Participants | 0.74 |
38 reviews available for propafenone and Atrial Fibrillation
| Article | Year |
|---|---|
Reappraising the role of class Ic antiarrhythmics in atrial fibrillation.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Flecainide; Humans; Propafenone; | 2022 |
Flecainide in clinical practice.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Child; Female; Flecainide; Humans; Pregnancy; Propafeno | 2023 |
Pharmacological cardioversion of atrial fibrillation: practical considerations.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Heart Diseases; Heart Failure; H | 2023 |
Single-dose oral anti-arrhythmic drugs for cardioversion of recent-onset atrial fibrillation: a systematic review and network meta-analysis of randomized controlled trials.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Humans; Network Meta | 2021 |
Propafenone-associated Gross Hematuria: A Case Report and Review of the Literature.
Topics: Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Hematuria; Humans; Male; Propafenone | 2019 |
Atrial fibrillation.
Topics: Ablation Techniques; Anticoagulants; Aspirin; Atrial Fibrillation; Dizziness; Dyspnea; Electric Coun | 2016 |
Atrial fibrillation (acute onset).
Topics: Acute Disease; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Propafenone; Sotalol | 2008 |
New pharmacological strategies for the treatment of atrial fibrillation.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Drugs, Investigational; Enzyme Inhibitors; Hum | 2009 |
Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Female; Flecainide; Huma | 2011 |
Atrial fibrillation (acute onset).
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Propafenone; Sotalol | 2011 |
Systematic review and meta-analysis of the efficacy of cardioversion by vernakalant and comparators in patients with atrial fibrillation.
Topics: Aged; Anisoles; Anti-Arrhythmia Agents; Atrial Fibrillation; Bayes Theorem; Electric Countershock; F | 2012 |
Atrial fibrillation and the pharmacological treatment: the role of propafenone.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmia, Sinus; Atrial Fibrillation; Delayed-Action Preparations | 2012 |
New insights into the mechanisms and management of atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Cardiac Catheterization; Hu | 2002 |
Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Australia; Canada; Controlled Clinical Tria | 2003 |
Pharmacologic and nonpharmacologic options to maintain sinus rhythm: guideline-based and new approaches.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing, Artificial; Catheter Ablati | 2003 |
Cost evaluation of rhythm control methods for atrial fibrillation: evidence from CTAF.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Cost-Benefit Anal | 2003 |
Facilitating electrical cardioversion of persistant atrial fibrillation by antiarrhythmic drugs: update on clinical trial results.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Humans; Propafenone; Randomized | 2003 |
Atrial fibrillation (acute).
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Digoxin; Diltiazem; Flecainide; Humans; Pro | 2003 |
Atrial fibrillation (acute).
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Digoxin; Diltiazem; Flecainide; Humans; Pro | 2004 |
Short QT syndrome: mechanisms, diagnosis and treatment.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Death, Sudden, Cardiac; Electric Countershock; Electroc | 2005 |
[Atrial flutter and fibrillation].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Amiodarone; Anti-Arrhythmia | 2005 |
Atrial fibrillation (recent onset).
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Digoxin; Diltiazem; Flecainide; Humans; Pro | 2005 |
[Drug treatment of atrial fibrillation].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti | 2006 |
Some patients with paroxysmal atrial fibrillation should carry flecainide or propafenone to self treat.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Flecainide; Humans; Propafenone; Self Care | 2007 |
Drug therapy of supraventricular tachyarrhythmias--based on efficacy or futility?
Topics: Atrial Fibrillation; Catheter Ablation; Chronic Disease; Humans; Propafenone; Tachycardia, Supravent | 1994 |
[Role of propafenone in anti-arrhythmia treatment].
Topics: Arrhythmias, Cardiac; Atrial Fibrillation; Drug Interactions; Electrophysiology; Humans; Propafenone | 1993 |
Supraventricular tachycardia and pre-excitation syndromes: pharmacological therapy.
Topics: Ajmaline; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Disopyramide; Fle | 1993 |
[Antiarrhythmic treatment after reduction of atrial fibrillation by external shock].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Combined Modality Therapy; Disopyramide; El | 1993 |
Guidelines for the use of propafenone in treating supraventricular arrhythmias.
Topics: Adult; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Cardiac Surgical Procedure | 1995 |
[Supraventricular tachycardia with wide QRS complexes during Vaughan-Williams class I anti-arrhythmic treatment. Diagnostic and therapeutic implications].
Topics: Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Drug Th | 1995 |
Oral propafenone for rapid conversion of recent onset atrial fibrillation--a review.
Topics: Administration, Oral; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Propafenone | 1997 |
Placebo-controlled evaluations of propafenone for atrial tachyarrhythmias.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Controlled Clinic | 1998 |
Propafenone for the treatment of supraventricular tachycardia and atrial fibrillation: a meta-analysis.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Propafenone; Research Design; Tachycardia, Supr | 1998 |
The role of oral 1C antiarrhythmic drugs in terminating atrial fibrillation.
Topics: Administration, Oral; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Flecainide; | 1999 |
Cost-effective management of acute atrial fibrillation: role of rate control, spontaneous conversion, medical and direct current cardioversion, transesophageal echocardiography, and antiembolic therapy.
Topics: Algorithms; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Cost-Benefit An | 2000 |
Intravenous antiarrhythmic agents.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Infusions, Intravenous; Procainamid | 2001 |
Single oral loading dose of propafenone for pharmacological cardioversion of recent-onset atrial fibrillation.
Topics: Administration, Oral; Atrial Fibrillation; Clinical Trials as Topic; Dose-Response Relationship, Dru | 2001 |
Oral loading with propafenone for conversion of recent-onset atrial fibrillation: a review on in-hospital treatment.
Topics: Administration, Oral; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Heart R | 2002 |
132 trials available for propafenone and Atrial Fibrillation
| Article | Year |
|---|---|
An open-label randomized noninferior study of generic name and brand name of propafenone for rhythm control in patients with paroxysmal atrial fibrillation.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; Humans; Propafenone; Taiwan; Treat | 2023 |
Propafenone versus amiodarone for supraventricular arrhythmias in septic shock: a randomised controlled trial.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Propafenone; Prospective Studies; S | 2023 |
Comparison of Amiodarone and Propafenone in Blanking Period after Radiofrequency Catheter Ablation in Patients with Atrial Fibrillation: A Propensity Score-Matched Study.
Topics: Aged; Amiodarone; Atrial Fibrillation; Catheter Ablation; Female; Humans; Male; Middle Aged; Propafe | 2020 |
[Efficacy and safety of ibutilide for conversion of atrial fibrillation/flutter].
Topics: Adolescent; Adult; Aged; Atrial Fibrillation; Atrial Flutter; Female; Humans; Male; Middle Aged; Pro | 2013 |
Propafenone versus vernakalant for conversion of recent-onset atrial fibrillation.
Topics: Aged; Anisoles; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Humans; Length of Stay; Male; M | 2013 |
Effectiveness of moxonidine to reduce atrial fibrillation burden in hypertensive patients.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin Receptor Antagonists; Angiotensin-Convert | 2013 |
Efficacy of dronedarone versus propafenone in the maintenance of sinus rhythm in patients with atrial fibrillation after electrical cardioversion.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Combined Modality Therapy; Dronedaron | 2014 |
Efficacy of dronedarone versus propafenone in the maintenance of sinus rhythm in patients with atrial fibrillation after electrical cardioversion.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Combined Modality Therapy; Dronedaron | 2014 |
Efficacy of dronedarone versus propafenone in the maintenance of sinus rhythm in patients with atrial fibrillation after electrical cardioversion.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Combined Modality Therapy; Dronedaron | 2014 |
Efficacy of dronedarone versus propafenone in the maintenance of sinus rhythm in patients with atrial fibrillation after electrical cardioversion.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Combined Modality Therapy; Dronedaron | 2014 |
Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation: results on health-related quality of life and symptom burden. The MANTRA-PAF trial.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Cost of Illness; Female | 2015 |
[The comparison between the efficiency of different anti-arrhythmic agents in preventing postoperative atrial fibrillation after open heart surgery].
Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Surgical Proc | 2008 |
Absence of protective effect of renin-angiotensin system inhibitors on atrial fibrillation development: insights from the Canadian Trial of Atrial Fibrillation (CTAF).
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Canada; Female; Humans; Male; Middle | 2008 |
[Impact of electrical shock waveform and paddle positions on efficacy of direct current cardioversion for atrial fibrillation].
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Body Mass Index; Chi-Square Distribut | 2008 |
Use of propafenone for conversion of chronic atrial fibrillation in horses.
Topics: Analysis of Variance; Animals; Atrial Fibrillation; Echocardiography; Electrocardiography; Horse Dis | 2009 |
Efficacy and tolerability of oral propafenone versus quinidine in the treatment of recent onset atrial fibrillation: A randomized, prospective study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; B | 2009 |
Physician stated atrial fibrillation management in light of treatment guidelines: data from an international, observational prospective survey.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium Channe | 2010 |
Management of patients with acute atrial fibrillation in the ED.
Topics: Acute Disease; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; | 2010 |
Cardioversion of acute atrial fibrillation in the emergency department: a prospective randomised trial.
Topics: Acute Disease; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Counte | 2012 |
Cardioversion of acute atrial fibrillation in the emergency department: a prospective randomised trial.
Topics: Acute Disease; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Counte | 2012 |
Cardioversion of acute atrial fibrillation in the emergency department: a prospective randomised trial.
Topics: Acute Disease; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Counte | 2012 |
Cardioversion of acute atrial fibrillation in the emergency department: a prospective randomised trial.
Topics: Acute Disease; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Counte | 2012 |
Combined administration of quinidine and propafenone for atrial fibrillation: the CAQ-PAF study.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 | 2012 |
Pharmacological conversion of recent atrial fibrillation: a randomized, placebo-controlled study of three antiarrhythmic drugs.
Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; | 2011 |
[Evaluation of shensongyangxin capsules in the treatment of paroxysmal atrial fibrillation: a randomized, double-blind and controlled multicenter trial].
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Double-Blind Method; Drugs, Chinese Herbal; Femal | 2011 |
Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Cost of Illnes | 2012 |
Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Cost of Illnes | 2012 |
Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Cost of Illnes | 2012 |
Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Cost of Illnes | 2012 |
Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Cost of Illnes | 2012 |
Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Cost of Illnes | 2012 |
Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Cost of Illnes | 2012 |
Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Cost of Illnes | 2012 |
Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Cost of Illnes | 2012 |
Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Cost of Illnes | 2012 |
Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Cost of Illnes | 2012 |
Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Cost of Illnes | 2012 |
Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Cost of Illnes | 2012 |
Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Cost of Illnes | 2012 |
Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Cost of Illnes | 2012 |
Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Cost of Illnes | 2012 |
Efficacy and safety of propafenone sustained release in the prophylaxis of symptomatic paroxysmal atrial fibrillation (The European Rythmol/Rytmonorm Atrial Fibrillation Trial [ERAFT] Study).
Topics: Acute Disease; Anti-Arrhythmia Agents; Atrial Fibrillation; Delayed-Action Preparations; Double-Blin | 2002 |
Left atrial size after cardioversion for atrial fibrillation: effect of external direct current shock.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Function, Left; Blood Flow Velocity | 2003 |
Propafenone versus ibutilide for post operative atrial fibrillation following cardiac surgery: neither strategy improves outcomes compared to rate control alone (the PIPAF study).
Topics: Adrenergic beta-Antagonists; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Surgical Pro | 2003 |
Intracardiac low-energy versus transthoracic high-energy direct-current cardioversion of atrial fibrillation: a randomised comparison.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Biomarkers; Creatine Kinase; Electric | 2003 |
Efficacy and safety of sustained-release propafenone (propafenone SR) for patients with atrial fibrillation.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Anti-Arrhythmia Agents; Atrial Fibrillation; C | 2003 |
Rate-control versus conversion strategy in postoperative atrial fibrillation: trial design and pilot study results.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmia, Sinus; Atrial Fib | 2003 |
Quality of life variables in the selection of rate versus rhythm control in patients with atrial fibrillation: observations from the Canadian Trial of Atrial Fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Health Status Indicators; Humans; Propafeno | 2003 |
Long-term maintenance of normal sinus rhythm in patients with current symptomatic atrial fibrillation: amiodarone vs propafenone, both in low doses.
Topics: Aged; Amiodarone; Analysis of Variance; Anti-Arrhythmia Agents; Atrial Fibrillation; Dose-Response R | 2004 |
Efficacy of propafenone for maintaining sinus rhythm in patients with recent onset or persistent atrial fibrillation after conversion: a randomized, placebo-controlled study.
Topics: Anti-Arrhythmia Agents; Arrhythmia, Sinus; Atrial Fibrillation; Chronic Disease; Electric Countersho | 2004 |
Ibutilide added to propafenone for the conversion of atrial fibrillation and atrial flutter.
Topics: Administration, Oral; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Drug Administrati | 2004 |
Use of ibutilide in cardioversion of patients with atrial fibrillation or atrial flutter treated with class IC agents.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Drug Administration Schedule; Dru | 2004 |
Effectiveness of oral propafenone for the prevention of atrial fibrillation after coronary artery bypass grafting.
Topics: Administration, Oral; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Coronary Artery Bypass; Dou | 2004 |
Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach.
Topics: Administration, Oral; Ambulatory Care; Anti-Arrhythmia Agents; Atrial Fibrillation; Feasibility Stud | 2004 |
Sotalol versus propafenone for long-term maintenance of normal sinus rhythm in patients with recurrent symptomatic atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Humans; Male; Middle Aged; Propafenone; P | 2004 |
[Intravenous propafenone for conversion of atrial fibrillation in the emergency room].
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Emergencies; Heart Rate; Humans; Infusions, Intravenous | 2004 |
Hybrid therapy with right atrial catheter ablation and previously ineffective antiarrhythmic drugs for the management of atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Combined Modality Therap | 2005 |
[Immediate cardioversion of atrial fibrillation and atrial flutter lasting less than 90 days by ibutilide versus propafenone: a multicenter study].
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Electrocardiog | 2005 |
[Outpatient treatment of recurrent atrial fibrillation with the "pill-in-the-pocket" approach: practical aspects].
Topics: Administration, Oral; Adolescent; Adult; Aged; Ambulatory Care; Anti-Arrhythmia Agents; Atrial Fibri | 2005 |
Propafenone added to ibutilide increases conversion rates of persistent atrial fibrillation.
Topics: Administration, Oral; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Drug Therapy, Combination; | 2006 |
Stunning of the left atrium after pharmacological cardioversion of atrial fibrillation.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Function, L | 2005 |
Amiodarone versus Sotalol and Propafenone for prevention of immediate recurrence of atrial fibrillation after internal cardioversion: importance of P wave analysis.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Female; Humans; Male | 2006 |
Comparison of intravenous ibutilide vs. propafenone for rapid termination of recent onset atrial fibrillation.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Dose-Response Relationship, Drug; Epidemio | 2005 |
Utility of adjunctive single oral bolus propafenone therapy in patients with atrial defibrillators.
Topics: Administration, Oral; Anti-Arrhythmia Agents; Atrial Fibrillation; Combined Modality Therapy; Cross- | 2006 |
Is circumferential pulmonary vein isolation preferable to stepwise segmental pulmonary vein isolation for patients with paroxysmal atrial fibrillation?
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ab | 2006 |
Observations on the safety and effectiveness of dofetilide in patients with paroxysmal atrial fibrillation and normal left ventricular function.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flut | 2007 |
A comparative study of the efficacy and safety of procainamide versus propafenone versus amiodarone for the conversion of recent-onset atrial fibrillation.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Hum | 2007 |
Does treatment with ACE inhibitors prevent the long term recurrences of lone atrial fibrillation after cardioversion?
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Atrial Fibrillation; Drug Th | 2007 |
A randomized comparison of amiodarone and class IC antiarrhythmic drugs to treat atrial fibrillation in patients paced for sinus node disease: the Prevention Investigation and Treatment: A Group for Observation and Research on Atrial arrhythmias (PITAGORA
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Arrhythmia, Sinus; Atrial Fibrillation; | 2008 |
Propafenone for the prevention of atrial tachyarrhythmias after cardiac surgery: a randomized, double-blind placebo-controlled trial.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Cytochrome P-450 CYP2D6; Double-Blind Method; Fem | 2008 |
Comparative evaluation of effect of valsartan/amlodipine and atenolol/amlodipine combinations on atrial fibrillation recurrence in hypertensive patients with type 2 diabetes mellitus.
Topics: Aged; Amlodipine; Anti-Arrhythmia Agents; Antihypertensive Agents; Atenolol; Atrial Fibrillation; Bl | 2008 |
Efficacy of ajmaline and propafenone in patients with accessory pathways: a prospective randomized study.
Topics: Accessory Nerve; Adolescent; Adult; Aged; Ajmaline; Atrial Fibrillation; Electrophysiology; Female; | 1994 |
A randomized, placebo-controlled trial of propafenone in the prophylaxis of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation. UK Propafenone PSVT Study Group.
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Humans; Male; Middle A | 1995 |
Propafenone for conversion of recent-onset atrial fibrillation. A controlled comparison between oral loading dose and intravenous administration.
Topics: Administration, Oral; Adult; Aged; Atrial Fibrillation; Chi-Square Distribution; Electrocardiography | 1995 |
Risk factors for the development of recurrent atrial fibrillation: role of pacing and clinical variables.
Topics: Atrial Fibrillation; Cardiac Pacing, Artificial; Chronic Disease; Female; Heart Atria; Heart Disease | 1995 |
Regular ventricular rhythms before conversion of recent onset atrial fibrillation to sinus rhythm.
Topics: Atrial Fibrillation; Digoxin; Electrocardiography; Electrocardiography, Ambulatory; Female; Flecaini | 1994 |
[A comparison between propafenone and amiodarone in the conversion to sinus rhythm of atrial fibrillation of recent onset].
Topics: Adult; Aged; Amiodarone; Atrial Fibrillation; Electrocardiography, Ambulatory; Female; Heart Rate; H | 1994 |
Clinical course of recent-onset atrial fibrillation treated with oral propafenone.
Topics: Administration, Oral; Aged; Atrial Fibrillation; Heart Rate; Humans; Middle Aged; Propafenone; Verap | 1994 |
A controlled study on oral propafenone versus digoxin plus quinidine in converting recent onset atrial fibrillation to sinus rhythm.
Topics: Administration, Oral; Adult; Aged; Atrial Fibrillation; Digoxin; Drug Combinations; Electrocardiogra | 1994 |
The inefficacy of intravenous propafenone for rate control in atrial fibrillation.
Topics: Adult; Aged; Atrial Fibrillation; Blood Pressure; Electrocardiography; Female; Humans; Infusions, In | 1994 |
[Prevention of paroxysmal atrial fibrillation with propafenone after withdrawal of amiodarone because of side effects].
Topics: Adult; Aged; Amiodarone; Atrial Fibrillation; Drug Evaluation; Female; Humans; Male; Middle Aged; Pr | 1993 |
Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation.
Topics: Aged; Atrial Fibrillation; Electrocardiography, Ambulatory; Female; Follow-Up Studies; Humans; Male; | 1993 |
Intravenous amiodarone vs propafenone for atrial fibrillation and flutter after cardiac operation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Coronary Disease; Dos | 1995 |
Effectiveness of intravenous propafenone for conversion of recent-onset atrial fibrillation: a placebo-controlled study.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Double-Blind Method; Female; Hemodynamics; | 1995 |
[Effect of propafenone hydrochloride on atrial signal-averaged ECG in patients with paroxysmal atrial fibrillation].
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Echocardiography; Electrocardiography; Electrocar | 1995 |
Safety of long-term flecainide and propafenone in the management of patients with symptomatic paroxysmal atrial fibrillation: report from the Flecainide and Propafenone Italian Study Investigators.
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Flecainide; Follow-Up | 1996 |
Comparison of the safety and efficacy of flecainide versus propafenone in hospital out-patients with symptomatic paroxysmal atrial fibrillation/flutter. The Flecainide AF French Study Group.
Topics: Adult; Aged; Ambulatory Care; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Female; F | 1996 |
Safety of flecainide versus propafenone for the long-term management of symptomatic paroxysmal supraventricular tachyarrhythmias. Report from the Flecainide and Propafenone Italian Study (FAPIS) Group.
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Dose-Res | 1995 |
[Propafenone and sotalol: long-term efficacy and tolerability in the prevention of paroxysmal atrial fibrillation. A placebo-controlled double-blind study].
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Double-Blind Method; Electrocardiography; | 1996 |
Intravenous propafenone in paroxysmal atrial fibrillation: a randomized, placebo-controlled, double-blind, multicenter clinical trial. Paroxysmal Atrial Fibrillation Italian Trial (PAFIT)-2 Investigators.
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Double-Blind Method; Echocardi | 1996 |
Safety and tolerability of long-term propafenone therapy for supraventricular tachyarrhythmias. The Propafenone Multicenter Study Group.
Topics: Administration, Oral; Adult; Age Factors; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial | 1996 |
[A comparison between propafenone and hydroquinidine perorally in the treatment of recent-onset atrial fibrillation].
Topics: Administration, Oral; Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Drug Evaluation; Fem | 1996 |
Comparisons of oral propafenone and quinidine as an initial treatment option in patients with symptomatic paroxysmal atrial fibrillation: a double-blind, randomized trial.
Topics: Administration, Oral; Anti-Arrhythmia Agents; Atrial Fibrillation; Double-Blind Method; Electrocardi | 1996 |
Effects of oral propafenone administration before electrical cardioversion of chronic atrial fibrillation: a placebo-controlled study.
Topics: Administration, Oral; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Chron | 1996 |
The incidence of asymptomatic paroxysmal atrial fibrillation in patients treated with propranolol or propafenone.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography, Ambulatory; Evaluation Studi | 1996 |
Propafenone versus disopyramide for maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation: a randomized, double-blind study. PRODIS Study Group.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Chronic Disease; Disopyramide; Do | 1996 |
Intravenous propafenone: efficacy and safety in the conversion to sinus rhythm of recent onset atrial fibrillation--a single-blind placebo-controlled study.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; Female; Humans; Infus | 1996 |
The efficacy and safety of intravenous propafenone versus intravenous amiodarone in the conversion of atrial fibrillation or flutter after cardiac surgery.
Topics: Adolescent; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Fe | 1996 |
Conversion of recent onset atrial fibrillation with single loading oral dose of propafenone: is in-hospital admission absolutely necessary?
Topics: Administration, Oral; Age Factors; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Function; Atr | 1996 |
Type II atrial flutter interruption with transesophageal pacing: use of propafenone and possible change of the substrate.
Topics: Administration, Oral; Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Atri | 1996 |
[Cibenzoline versus propafenone by the oral route for preventing recurrence of atrial arrhythmia: multicenter, randomized, double-blind study].
Topics: Administration, Oral; Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation | 1996 |
Conversion of recent onset atrial fibrillation to sinus rhythm using a single oral loading dose of propafenone: comparison of two regimens.
Topics: Administration, Oral; Adult; Aged; Analysis of Variance; Anti-Arrhythmia Agents; Atrial Fibrillation | 1997 |
Propafenone for conversion and prophylaxis of atrial fibrillation. Propafenone Atrial Fibrillation Trial Investigators.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; D | 1997 |
Oral propafenone to convert recent-onset atrial fibrillation in patients with and without underlying heart disease. A randomized, controlled trial.
Topics: Administration, Oral; Anti-Arrhythmia Agents; Atrial Fibrillation; Heart Diseases; Humans; Hypertens | 1997 |
Comparisons of oral propafenone and sotalol as an initial treatment in patients with symptomatic paroxysmal atrial fibrillation.
Topics: Administration, Oral; Anti-Arrhythmia Agents; Atrial Fibrillation; Double-Blind Method; Evaluation S | 1997 |
[Comparison of anti-arrhythmic therapy guided by the transesophageal electropharmacologic test and emperic therapy in the prophylaxis of atrial fibrillation recurrence].
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Echocardiography, Transesophageal; Female; Flecainide; | 1997 |
Is hospitalisation necessary for recent-onset atrial fibrillation?
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Digoxin; Double-Blind Method; Heart Rate; Hospitalizati | 1997 |
Value of single oral loading dose of propafenone in converting recent-onset atrial fibrillation. Results of a randomized, double-blind, controlled study.
Topics: Acute Disease; Administration, Oral; Anti-Arrhythmia Agents; Atrial Fibrillation; Dose-Response Rela | 1997 |
Effects of antiarrhythmic drugs on variability of ventricular rate and exercise performance in chronic atrial fibrillation complicated with ventricular arrhythmias.
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Blood Pressure; Chi-Square | 1998 |
Tachycardia-induced change of atrial refractory period in humans: rate dependency and effects of antiarrhythmic drugs.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; Electroph | 1998 |
Comparison between propafenone and digoxin administered intravenously to patients with acute atrial fibrillation. PAFIT-3 Investigators. The Propafenone in Atrial Fibrillation Italian Trial.
Topics: Acute Disease; Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Digoxin; Electrocardiograph | 1998 |
Propafenone versus procainamide for conversion of atrial fibrillation to sinus rhythm.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Drug Tolerance; Female; Humans; Infusions, Intrav | 1998 |
Oral loading with propafenone: a placebo-controlled study in elderly and nonelderly patients with recent onset atrial fibrillation.
Topics: Administration, Oral; Age Factors; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiog | 1998 |
Conversion of recent-onset atrial fibrillation to sinus rhythm: effects of different drug protocols.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dose-Response Relationship, Drug; Electroca | 1998 |
Intravenous propafenone versus intravenous amiodarone in the management of atrial fibrillation of recent onset: a placebo-controlled study.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Digoxin; Female; Humans; Infusions, Intrave | 1998 |
Randomized, crossover, controlled comparison of oral loading versus intravenous infusion of propafenone in recent-onset atrial fibrillation.
Topics: Administration, Oral; Anti-Arrhythmia Agents; Atrial Fibrillation; Cross-Over Studies; Electrocardio | 1998 |
Low energy intracardiac cardioversion of persistent atrial fibrillation.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Cat | 1998 |
Amiodarone versus propafenone for conversion of chronic atrial fibrillation: results of a randomized, controlled study.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Chronic Disease; Electrocardiography; | 1999 |
Safety of oral propafenone in the conversion of recent onset atrial fibrillation to sinus rhythm: a prospective parallel placebo-controlled multicentre study.
Topics: Administration, Oral; Anti-Arrhythmia Agents; Atrial Fibrillation; Digitalis Glycosides; Drug Therap | 1999 |
Propafenone in the conversion of atrial fibrillation in patients suffering from chronic renal failure.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Blood Urea Nitrogen; Female; Humans; Injections, Intrav | 1997 |
Pretreatment with verapamil in patients with persistent or chronic atrial fibrillation who underwent electrical cardioversion.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Chronic Disease; Combined Modality Therapy; Elect | 1999 |
Comparison of propafenone versus procainamide for the acute treatment of atrial fibrillation after cardiac surgery.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Surgical Procedures; Coronary Artery Bypa | 1999 |
Comparison of oral loading dose of propafenone and amiodarone for converting recent-onset atrial fibrillation. PARSIFAL Study Group.
Topics: Administration, Oral; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dose-Response R | 1999 |
Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease-Free Survival; Female; Humans | 2000 |
Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease-Free Survival; Female; Humans | 2000 |
Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease-Free Survival; Female; Humans | 2000 |
Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease-Free Survival; Female; Humans | 2000 |
Intravenous versus oral initial load of propafenone for conversion of recent-onset atrial fibrillation in the emergency room: a randomized trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; B | 2000 |
[Propafenone dose for emergency room conversion of paroxysmal atrial fibrillation].
Topics: Administration, Oral; Anti-Arrhythmia Agents; Atrial Fibrillation; Emergency Medical Services; Femal | 1999 |
Role of gender and personality on quality-of-life impairment in intermittent atrial fibrillation.
Topics: Age Factors; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Double-Blind Method; Fem | 2000 |
Comparison of intravenous flecainide, propafenone, and amiodarone for conversion of acute atrial fibrillation to sinus rhythm.
Topics: Aged; Amiodarone; Analysis of Variance; Anti-Arrhythmia Agents; Atrial Fibrillation; Confidence Inte | 2000 |
Rate-control versus conversion strategy in postoperative atrial fibrillation: a prospective, randomized pilot study.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Surgical Procedures; Digoxin; | 2000 |
Control of paroxysmal atrial fibrillation recurrence using combined administration of propafenone and quinidine.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Anti-Arrhythmia Agents; Atrial Fibrillation; Cross-Ov | 2000 |
Noncontact system-guided simplified right atrial linear lesions using radiofrequency transcatheter ablation for treatment of refractory atrial fibrillation.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Electrocardiography; Female; Flecain | 2000 |
Amiodarone, sotalol, or propafenone in atrial fibrillation: which is preferred to maintain normal sinus rhythm?
Topics: Administration, Oral; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Heart R | 2000 |
[Effectiveness and side effects of the treatment with propafenone and flecainide for recent-onset atrial fibrillation].
Topics: Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Flecainide; Hum | 2001 |
The influence of CYP2D6 polymorphism on the antiarrhythmic efficacy of propafenone in patients with paroxysmal atrial fibrillation during 3 months propafenone prophylactic treatment.
Topics: Administration, Oral; Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Cytochrome P-450 CYP | 2001 |
Long-term efficacy and safety of propafenone and sotalol for the maintenance of sinus rhythm after conversion of recurrent symptomatic atrial fibrillation.
Topics: Administration, Oral; Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease-Free Surviva | 2001 |
[Comparison of efficacy, safety and cost-effectiveness of intravenous versus oral propafenone in paroxysmal atrial fibrillation].
Topics: Administration, Oral; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Cost-Benefit Analysis; Fema | 2001 |
An evaluation of the strategy of maintenance of sinus rhythm by antiarrhythmic drug therapy after ablation and pacing therapy in patients with paroxysmal atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrioventricular Node; Catheter Ablat | 2002 |
Quality of life improves with treatment in the Canadian Trial of Atrial Fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Canada; Female; Health Status Indicat | 2002 |
Amiodarone reduces procedures and costs related to atrial fibrillation in a controlled clinical trial.
Topics: Aged; Amiodarone; Analysis of Variance; Anti-Arrhythmia Agents; Atrial Fibrillation; Costs and Cost | 2002 |
Effects of flecainide on atrial electrophysiology in the Wolff-Parkinson-White syndrome.
Topics: Atrial Fibrillation; Atrial Function; Cardiac Catheterization; Cardiac Pacing, Artificial; Flecainid | 1992 |
Acute pharmacologic conversion of atrial fibrillation and flutter: the role of flecainide, propafenone, and verapamil.
Topics: Atrial Fibrillation; Atrial Flutter; Drug Evaluation; Female; Flecainide; Humans; Male; Middle Aged; | 1992 |
Reversible protective effect of propafenone or flecainide during atrial fibrillation in patients with an accessory atrioventricular connection.
Topics: Adult; Atrial Fibrillation; Atrioventricular Node; Cardiac Pacing, Artificial; Exercise; Exercise Te | 1992 |
[Propafenone versus hydroquinidine in long-term pharmacological prophylaxis of atrial fibrillation].
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Follow-Up Studies; Humans; Male; M | 1992 |
A comparison of intravenous propafenone and flecainide in the treatment of tachycardias associated with the Wolff-Parkinson-White syndrome.
Topics: Adult; Atrial Fibrillation; Cardiac Pacing, Artificial; Female; Flecainide; Humans; Male; Propafenon | 1991 |
Propafenone treatment of symptomatic paroxysmal supraventricular arrhythmias. A randomized, placebo-controlled, crossover trial in patients tolerating oral therapy.
Topics: Adult; Aged; Aged, 80 and over; Atrial Fibrillation; Dose-Response Relationship, Drug; Female; Follo | 1991 |
Propafenone in Wolff-Parkinson-White syndrome at risk.
Topics: Administration, Oral; Adolescent; Adult; Atrial Fibrillation; Dose-Response Relationship, Drug; Fema | 1990 |
The value of class IC antiarrhythmic drugs for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm.
Topics: Atrial Fibrillation; Atrial Flutter; Electrocardiography; Female; Flecainide; Humans; Male; Middle A | 1990 |
Comparative evaluation of verapamil, flecainide and propafenone for the acute conversion of atrial fibrillation to sinus rhythm.
Topics: Adult; Aged; Atrial Fibrillation; Electrocardiography; Female; Flecainide; Heart Rate; Humans; Infus | 1990 |
Termination of acute atrial fibrillation in the Wolff-Parkinson-White syndrome by procainamide and propafenone: importance of atrial fibrillatory cycle length.
Topics: Adolescent; Adult; Aged; Atrial Fibrillation; Echocardiography; Female; Humans; Male; Middle Aged; P | 1990 |
[Efficacy of propafenone in supraventricular arrhythmias].
Topics: Adult; Aged; Atrial Fibrillation; Atrial Flutter; Blood Pressure; Electrocardiography; Female; Heart | 1989 |
Usefulness of propafenone for recurrent paroxysmal atrial fibrillation.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Double-Blind Method; Humans; | 1989 |
Effectiveness of intravenous propafenone for conversion of atrial fibrillation and flutter of recent onset.
Topics: Adult; Aged; Aged, 80 and over; Atrial Fibrillation; Atrial Flutter; Clinical Trials as Topic; Elect | 1989 |
Efficacy of propafenone in Wolff-Parkinson-White syndrome: electrophysiologic findings and long-term follow-up.
Topics: Adolescent; Adult; Atrial Fibrillation; Clinical Trials as Topic; Electrophysiology; Female; Follow- | 1987 |
187 other studies available for propafenone and Atrial Fibrillation
| Article | Year |
|---|---|
Efficacy and safety of antazoline for cardioversion of atrial fibrillation: propensity score matching analysis of a multicenter registry (CANT II Study).
Topics: Aged; Amiodarone; Antazoline; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Fe | 2022 |
Propafenone use in coronary artery disease patients undergoing atrial fibrillation ablation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Coronary Artery Disease; Death, Sudden, Car | 2022 |
Pharmacological Cardioversion in Patients with Recent-Onset Atrial Fibrillation and Chronic Kidney Disease Subanalysis of the CANT II Study.
Topics: Amiodarone; Antazoline; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Female; | 2022 |
Medical therapy with flecainide and propafenone in atrial fibrillation: Long-term clinical experience in the tertiary care setting.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrioventricular Node; Flecainide; Humans; | 2023 |
Medical therapy with flecainide and propafenone in atrial fibrillation: Long-term clinical experience in the tertiary care setting.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrioventricular Node; Flecainide; Humans; | 2023 |
Medical therapy with flecainide and propafenone in atrial fibrillation: Long-term clinical experience in the tertiary care setting.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrioventricular Node; Flecainide; Humans; | 2023 |
Medical therapy with flecainide and propafenone in atrial fibrillation: Long-term clinical experience in the tertiary care setting.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrioventricular Node; Flecainide; Humans; | 2023 |
Safety of Pill-in-the-Pocket Class 1C Antiarrhythmic Drugs for Atrial Fibrillation.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Bradycardia; Female; Flecainide; Humans; H | 2022 |
Cardiovascular outcomes in patients with atrial fibrillation concomitantly treated with antiarrhythmic drugs and non-vitamin k antagonist oral anticoagulants.
Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Brain | 2023 |
Early initiation of anti-relapse antiarrhythmic therapy in patients with atrial fibrillation and flutter after pharmacological cardioversion with refralon.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Electric Countershock; Humans; Long QT | 2023 |
Medical cardioversion of atrial fibrillation and flutter with class IC antiarrhythmic drugs in young patients with and without congenital heart disease.
Topics: Adolescent; Adult; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Electric Countershoc | 2023 |
The Wrong Drug That Led to the Right Diagnosis.
Topics: Action Potentials; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; D | 2019 |
Safety and Effectiveness of Rivaroxaban in Combination with Various Antiarrhythmic Drugs in Patients with Non-Permanent Atrial Fibrillation.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiovascular Dis | 2021 |
In Silico Assessment of Class I Antiarrhythmic Drug Effects on
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Computer Simulation; Dis | 2021 |
Atrial resting membrane potential confers sodium current sensitivity to propafenone, flecainide and dronedarone.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease Models, Animal; Dro | 2021 |
Type 1 Brugada-Electrocardiogram: A Rare Presentation in a 57-Year-Old Woman with Paroxysmal Atrial Fibrillation Treated with a Therapeutic Dose of Propafenone.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Brugada Syndrome; Clinical Decision-Making; Drug Substi | 2021 |
Oral loading of propafenone: restoring its role before restoring rhythm.
Topics: Administration, Oral; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Propafenone | 2017 |
Energy Drinks and atrial fibrillation in young adults.
Topics: Adult; Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; Energy Drinks; Follow-Up St | 2018 |
Comparison of the effects of I
Topics: Action Potentials; Animals; Atrial Fibrillation; Atrial Remodeling; Bee Venoms; Consciousness; Dogs; | 2018 |
Severe cardiac toxicity following alcohol intake in a patient using therapeutic dose of propafenone.
Topics: Adult; Alcohol Drinking; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrioventricular Block; Cardio | 2017 |
Assessing the Risk for Peripheral Neuropathy in Patients Treated With Dronedarone Compared With That in Other Antiarrhythmics.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cohort Stud | 2018 |
Treatment with verapamil for restoration of sinus rhythm in atrial fibrillation with rapid ventricular response: A case report.
Topics: Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Comorbidity; Female; Hum | 2019 |
Flecainide or propafenone vs. vernakalant for conversion of recent-onset atrial fibrillation.
Topics: Anisoles; Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; Europe; Flecainide; Huma | 2013 |
Clinically important interaction between metoprolol and propafenone.
Topics: Aged; Anti-Arrhythmia Agents; Antihypertensive Agents; Atrial Fibrillation; Cytochrome P-450 CYP2D6; | 2013 |
[Role of antiarrhythmic therapy for atrial fibrillation].
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Humans; Propafenone | 2013 |
Conversion of recent onset atrial fibrillation: which drug is faster?
Topics: Administration, Oral; Amiodarone; Anisoles; Anti-Arrhythmia Agents; Atrial Fibrillation; Flecainide; | 2013 |
Vernakalant: Perception of state of health in patients with a recent-onset atrial fibrillation.
Topics: Administration, Oral; Aged; Anisoles; Atrial Fibrillation; Dose-Response Relationship, Drug; Drug Th | 2014 |
Advanced interatrial block is associated with recurrence of atrial fibrillation post pharmacological cardioversion.
Topics: Aged; Anisoles; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease-Free Survival; Electrocardiogra | 2014 |
Suppression of spontaneous ca elevations prevents atrial fibrillation in calsequestrin 2-null hearts.
Topics: Animals; Atrial Fibrillation; Calcium; Calsequestrin; Cardiac Pacing, Artificial; Disease Models, An | 2014 |
Three heart medications in short supply in Canada.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Canada; Flecainide; Humans; Phenethylamines; Propafenon | 2014 |
Cardioversion of Atrial Fibrillation (RHYTHM-AF) International Registry in Poland.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Female; Heart | 2014 |
Propafenone associated severe central nervous system and cardiovascular toxicity due to mirtazapine: a case of severe drug interaction.
Topics: Aged; Anti-Arrhythmia Agents; Antidepressive Agents, Tricyclic; Atrial Fibrillation; Bradycardia; Di | 2014 |
Analysis of the cost-effectiveness of dronedarone versus amiodarone, propafenone, and sotalol in patients with atrial fibrillation: results for Serbia.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cost-Benefit Analysis; Disease-Free Surviva | 2015 |
Antiarrhythmic drug use in patients <65 years with atrial fibrillation and without structural heart disease.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cohort Studies; Databases, Factual; Droneda | 2015 |
Widened QRS interval and left ventricular systolic depression after propafenone and promazine exposure.
Topics: Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Dementia; Dopamine Antagonists; Dose | 2014 |
Factors predisposing to ventricular proarrhythmia during antiarrhythmic drug therapy for atrial fibrillation in patients with structurally normal heart.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Echocardiography; Electrocardiography; Female; He | 2015 |
Electric cardioversion of atrial fibrillation resulting in pulmonary oedema in patient with apical hypertrophic cardiomyopathy.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiomyopathy, Hypertrophic; Diuretics; Electric Count | 2015 |
Atrial tachycardia with Wenckebach atrioventricular conduction mechanism: What is the origin of the beat following the pause?
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrioventricular Node; Electrocardiography; Elect | 2016 |
Comparative effectiveness and safety of antazoline‑based and propafenone‑based strategies for pharmacological cardioversion of short‑duration atrial fibrillation in the emergency department.
Topics: Aged; Aged, 80 and over; Antazoline; Anti-Arrhythmia Agents; Atrial Fibrillation; Emergency Service, | 2016 |
Efficacy and safety in pharmacological cardioversion of recent-onset atrial fibrillation: a propensity score matching to compare amiodarone vs class IC antiarrhythmic drugs.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countersh | 2017 |
Impact of QT interval prolongation following antiarrhythmic drug therapy on left ventricular function.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Echocardiography; Electrocardiography | 2017 |
Oral loading of propafenone: restoring its role before restoring rhythm-authors' reply.
Topics: Administration, Oral; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Propafenone | 2017 |
Efficacy of Intravenous Sotalol for Treatment of Incessant Tachyarrhythmias in Children.
Topics: Adolescent; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Child; Child, Preschool; Dr | 2017 |
Adverse effects of propafenone after long-term therapy with the addition of citalopram.
Topics: Accidental Falls; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Citalopram; Dizzin | 2008 |
Successful conversion of recent-onset atrial fibrillation by sequential administration of up to three antiarrhythmic drugs.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Drug Admini | 2008 |
Giant P waves after pharmacological cardioversion of atrial fibrillation.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Echocardiography; Female; Humans; Hypertrophy, Right Ve | 2009 |
Atrial fibrillation: adverse effects of "pill-in-the-pocket" treatment and propafenone-carvedilol interaction.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Atrial Fibrillation; Carbazoles; Carvedilol; Dr | 2010 |
Can QRS Widening be a result of propafenone overdose?
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Consciousness Disorders; Drug Ove | 2008 |
[Proarrhythmic effect of propafenone in patients with atrial fibrillation and atrial flutter].
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Bundle-Branch Blo | 2008 |
I was diagnosed with paroxysmal atrial fibrillation three years ago, ablation proved unsuccessful. My blood pressure and cholesterol are in a healthy range and I have experienced no AFib manifestations since beginning a medication regimen that includes Ry
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Propafenone | 2008 |
The effect of pretreatment with renin-angiotensin-aldosterone system blockers on cardioversion success and acute recurrence of atrial fibrillation.
Topics: Acute Disease; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease-Free Survival; Elect | 2009 |
[Effectiveness of D,L-sotalol in post-ablative atrial arrhythmias in patients with atrial fibrillation treated with radiofrequency ablation].
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Case-Control Studies; Catheter | 2009 |
An acute experimental model demonstrating 2 different forms of sustained atrial tachyarrhythmias.
Topics: Acetylcholine; Acute Disease; Animals; Anti-Arrhythmia Agents; Atrial Appendage; Atrial Fibrillation | 2009 |
A case of myotonic dystrophy presenting with ventricular tachycardia and atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Defibrillators, Implantable | 2009 |
Atrial tachycardia with 1:1 atrioventricular conduction precipitated by propafenone.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Bundle of His; Electric Countershock; Electrocardiograp | 2009 |
Is newer better? Propafenone versus quinidine for conversion of atrial fibrillation.
Topics: Administration, Oral; Anti-Arrhythmia Agents; Atrial Fibrillation; Digoxin; Drug Therapy, Combinatio | 2009 |
[Preventive strategy for atrial fibrillation in arterial hypertension].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia A | 2009 |
Intravenous administration of flecainide or propafenone in patients with recent-onset atrial fibrillation does not predict adverse effects during 'pill-in-the-pocket' treatment.
Topics: Administration, Oral; Adolescent; Adult; Aged; Ambulatory Care; Anti-Arrhythmia Agents; Atrial Fibri | 2010 |
[Instead of long-term antiarrhythmia drug treatment--stand-by therapy for atrial fibrillation].
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Atrial Fibrillation; Diagnosis, Differential; D | 2010 |
Unstable wide complex tachycardia during propafenone therapy.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Electrocardiography; Female; Hear | 2010 |
'Pill-in-the-pocket' treatment for recent-onset atrial fibrillation.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Flecainide; Humans; Infusions, Intravenous; Mal | 2010 |
Efficacy of propafenone hydrochloride in preventing postoperative atrial fibrillation after coronary artery bypass grafting.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Coronary Artery Bypass; Female; Humans; Incidence | 2010 |
Syncope, widened QRS interval, and left ventricular systolic depression: coincident with propafenone therapy for atrial fibrillation.
Topics: Alcohol Drinking; Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; Heart Conduction | 2010 |
A real-time screening assay for GIRK1/4 channel blockers.
Topics: Acetylcholine; Amiloride; Animals; Atrial Fibrillation; Barbiturates; Biological Assay; Biological T | 2010 |
Images in emergency medicine. Reversible QRS complex widening after oral administration of propafenone.
Topics: Administration, Oral; Aged; Atrial Fibrillation; Diagnosis, Differential; Dizziness; Electrocardiogr | 2010 |
Propafenone contraindicated in the elderly?
Topics: Age Factors; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Contraindications | 2011 |
Mixed treatment comparisons for atrial fibrillation: evidence network or bewildering entanglement?
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Evidence-Based Medicine; Fleca | 2011 |
[Concealed Brugada syndrome that became apparent incidentally during atrial fibrillation therapy].
Topics: Adult; Anti-Arrhythmia Agents; Atrial Fibrillation; Brugada Syndrome; Cardiac Electrophysiology; Car | 2011 |
Likelihood of Brugada ECG pattern confirmed after propafenone administration for atrial fibrillation cardioversion.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Brugada Syndrome; Electric Countershock; Electrocardiog | 2011 |
A rare cause of atrial fibrillation: a European hornet sting.
Topics: Adult; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Diagnosis, Differential; Echocardiograp | 2011 |
Syncope following 'pill-in-the-pocket' treatment of atrial fibrillation with propafenone plus quinidine.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Flecainide; Humans; Propafenone | 2011 |
Atrial-selective sodium channel block strategy to suppress atrial fibrillation: ranolazine versus propafenone.
Topics: Acetanilides; Action Potentials; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Diastole; Dog | 2012 |
Variegate porphyria and atrial fibrillation: acute attack induced by propafenone.
Topics: Adult; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Inappropriate ADH Syndrome; Male; Porphy | 2012 |
Use of rate control medication before cardioversion of recent-onset atrial fibrillation or flutter in the emergency department is associated with reduced success rates.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; | 2012 |
[Termination of paroxysm of atrial fibrillation conversion using oral propafenone after unsuccessful electrical cardioversion].
Topics: Administration, Oral; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Dose-Response Rel | 2012 |
[Predictors of reversion to sinus rhythm previous to electrical cardioversion in patients with persistent atrial fibrillation treated with anti-arrhythmic drugs].
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Body Mass Index; Comorbidity; Diabete | 2013 |
Estimation and prediction of drug therapy on the termination of atrial fibrillation by autoregressive model with exogenous inputs.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Computer Simulation; Female; Heart Conduction | 2013 |
Paroxysmal supraventricular tachycardia induced by oral stimulation: a case report and review of swallow-induced dysrhythmias.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Deglutition; Electrocardiography; Humans; Male; Mastica | 2002 |
[Efficacy and tolerance of propafenone after correction of atrial fibrillation: PEPS pharmaco-epidemiologic study].
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Cohort Studies; Female; Humans; Male; Middle Aged | 2002 |
[Proarrhythmic effects of propafenone in a woman with hepatopathy: is it always a simple drug in clinical practice?].
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Digoxin; Drug Therapy, Comb | 2002 |
[Pharmacological cardioversion of atrial fibrillation with intravenous and oral propafenone].
Topics: Administration, Oral; Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Humans; Infu | 2002 |
Propafenone hepatotoxicity: report of two new cases.
Topics: Aged; Atrial Fibrillation; Biopsy, Needle; Chemical and Drug Induced Liver Injury; Dose-Response Rel | 2003 |
Electrophysiological mapping and histological examinations of the swine atrium with sustained (> or =24 h) atrial fibrillation: a suitable animal model for studying human atrial fibrillation.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Body Surface Potential Mapping; Cardiac Pacing | 2003 |
Reproducible efficacy of loading oral propafenone in restoring sinus rhythm in patients with paroxysmal atrial fibrillation.
Topics: Administration, Oral; Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Humans; Male | 2003 |
Atrial fibrillation: rate control often better than rhythm control.
Topics: Adult; Aged; Amiodarone; Anticoagulants; Arrhythmia, Sinus; Atrial Fibrillation; Canada; Disopyramid | 2004 |
[Treatment of atrial fibrillation in a Hungarian hospital department of cardiologic internal medicine at the turn of the millennium].
Topics: Acute Disease; Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrill | 2004 |
Efficacy of substituting innovator propafenone for its generic formulation in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Cohort Studies; Drugs, Generic | 2004 |
Evaluation of KCB-328, a new IKr blocking antiarrhythmic agent in pacing induced canine atrial fibrillation.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease Models, Animal; Dog | 2004 |
Limitations to antiarrhythmic drug use in patients with atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Canada; Contraindications; Female; Fl | 2004 |
Flecainide and propafenone induced ST-segment elevation in patients with atrial fibrillation: clue to specificity of Brugada-type electrocardiographic changes.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Bundle-Branch Block; Dose-Response Relationship, Drug; | 2004 |
Different clinical courses and predictors of atrial fibrillation occurrence after transisthmic ablation in patients with preablation lone atrial flutter, coexistent atrial fibrillation, and drug induced atrial flutter.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Co | 2004 |
The "pill-in-the-pocket" approach to atrial fibrillation.
Topics: Administration, Oral; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Digoxin; Drug Int | 2005 |
The "pill-in-the-pocket" approach to atrial fibrillation.
Topics: Administration, Oral; Anti-Arrhythmia Agents; Atrial Fibrillation; Control Groups; Flecainide; Human | 2005 |
Typical counterclockwise atrial flutter occurring despite absence of the inferior vena cava.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Electrophysiol | 2004 |
[Pharmacogenetic study of the response to flecainide and propafenone in patients with atrial fibrillation].
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Cytochrome P-450 CYP2D6; Female; Flecainid | 2005 |
Broad complex tachycardia during treatment of atrial fibrillation with a 1c antiarrhythmic drug: ventricular or supraventricular proarrhythmia?
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Drug Thera | 2006 |
Efficacy and safety of ibutilide for cardioversion of atrial flutter and fibrillation in patients receiving amiodarone or propafenone.
Topics: Adult; Aged; Amiodarone; Analysis of Variance; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial F | 2005 |
Can recent-onset atrial fibrillation be safely and successfully treated with self-administered antiarrhythmic drugs?
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; Flecainid | 2005 |
"Pseudosinus rhythm": what is the mechanism?
Topics: Amiodarone; Atrial Fibrillation; Catheter Ablation; Female; Humans; Middle Aged; Propafenone; Pulmon | 2005 |
Drug therapy of paroxysmal atrial fibrillation in the elderly over 75 years old.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bradycardia; Cardi | 2006 |
Combined use of 1C and III agents for highly symptomatic, refractory atrial fibrillation.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Chronic Disease; Drug Combinations; Female | 2006 |
Transient syncope, left bundle branch block and first degree atrioventricular block after "pill-in-the-pocket" administration.
Topics: Aged; Atrial Fibrillation; Atrioventricular Block; Bundle-Branch Block; Carbazoles; Carvedilol; Drug | 2008 |
Atrial fibrillation, pharmacological cardioversion and topical ophthalmic beta-blocker use.
Topics: Administration, Topical; Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Atrial Fibrillation; C | 2008 |
Cardiac memory induced by QRS widening due to propafenone toxicity.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Humans; Propafenone; Ventricular Fibrilla | 2007 |
Atrial antifibrillatory effects of structurally distinct IKur blockers 3-[(dimethylamino)methyl]-6-methoxy-2-methyl-4-phenylisoquinolin-1(2H)-one and 2-phenyl-1,1-dipyridin-3-yl-2-pyrrolidin-1-yl-ethanol in dogs with underlying heart failure.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Benzopyrans; Cell Line; Dogs; Female; Heart At | 2008 |
Deglutition induced atrial tachycardia and atrial fibrillation.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Deglutition; Electrocardiography; Female; Humans; Middl | 2007 |
Propafenone-induced Brugada-like ECG changes mistaken as acute myocardial infarction.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Brugada Syndrome; Catheter Ablati | 2008 |
Controversies in the "pill in the pocket" approach to atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Humans; Male; Propafenone | 2008 |
Atrial-selective sodium channel block as a strategy for suppression of atrial fibrillation.
Topics: Acetanilides; Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Dogs; Electrophysiol | 2008 |
[Effects of anti-arrhythmia agents on heart rate. Significance and importance].
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibril | 1981 |
[Conservative therapy of supraventricular tachycardias].
Topics: Adrenergic beta-Antagonists; Ajmaline; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; | 1984 |
[Combined use of propafenon and lidoflazine in chronic atrial fibrillation and flutter (author's transl)].
Topics: Atrial Fibrillation; Atrial Flutter; Cardiac Complexes, Premature; Chronic Disease; Drug Therapy, Co | 1980 |
European experience with the antiarrhythmic efficacy of propafenone for supraventricular and ventricular arrhythmias.
Topics: Adolescent; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillati | 1984 |
[How and why treat supraventricular tachycardias].
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing, Artificial; Drug Evaluation; Humans; Pr | 1984 |
Efficacy of type 1C antiarrhythmic agents for treatment of resistant atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Disopyramide; Encainide; Female; Flecainide; Hear | 1993 |
Cases in electrocardiography.
Topics: Atrial Fibrillation; Electrocardiography; Female; Humans; Middle Aged; Propafenone; Tachycardia, Par | 1995 |
Probable propafenone-induced transient global amnesia.
Topics: Amnesia; Atrial Fibrillation; Humans; Male; Middle Aged; Propafenone; Sick Sinus Syndrome | 1995 |
Hemodynamic effects of oral propafenone during both sinus rhythm and atrial fibrillation.
Topics: Administration, Oral; Atrial Fibrillation; Electrophysiology; Female; Heart Rate; Hemodynamics; Huma | 1995 |
[Efficacy of intravenous propafenone in the management of arterial flutter and fibrillation of recent onset].
Topics: Adult; Aged; Aged, 80 and over; Atrial Fibrillation; Atrial Flutter; Echocardiography; Female; Human | 1994 |
Conversion of recent-onset atrial fibrillation by a single oral loading dose of propafenone or flecainide.
Topics: Administration, Oral; Aged; Atrial Fibrillation; Female; Flecainide; Humans; Male; Middle Aged; Prop | 1994 |
[Persistent atrial flutter induced by propafenone (Rytmonorm)].
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Female; Humans; Propafenone | 1994 |
Role of transesophageal pacing in recurrent atrial fibrillation. Experience with propafenone.
Topics: Administration, Oral; Adult; Aged; Atrial Fibrillation; Cardiac Pacing, Artificial; Echocardiography | 1994 |
Antiarrhythmic drugs in the management of atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Digoxin; Flecainide; Heart; Humans; Propafe | 1993 |
[The efficacy of intravenous propafenone and amiodarone in the conversion of recent-onset atrial fibrillation. A 1-year follow-up with oral treatment].
Topics: Administration, Oral; Adult; Aged; Amiodarone; Atrial Fibrillation; Drug Evaluation; Female; Follow- | 1993 |
Comparative mechanisms of antiarrhythmic drug action in experimental atrial fibrillation. Importance of use-dependent effects on refractoriness.
Topics: Animals; Atrial Fibrillation; Atrial Function; Cardiac Pacing, Artificial; Dogs; Electric Stimulatio | 1993 |
[Intravenous and oral propafenone in the treatment and prevention of paroxysmal atrial fibrillation].
Topics: Administration, Oral; Adolescent; Adult; Aged; Atrial Fibrillation; Dizziness; Drug Evaluation; Fema | 1993 |
An aggressive approach in converting resistant atrial fibrillation.
Topics: Adult; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Atrial Fibrillation; Electric Countershock; | 1996 |
Activation of the hemostatic mechanism after pharmacological cardioversion of acute nonvalvular atrial fibrillation.
Topics: Acute Disease; Amiodarone; Anti-Arrhythmia Agents; Antithrombin III; Atrial Fibrillation; Biomarkers | 1997 |
Quinidine versus propafenone for conversion of atrial fibrillation to sinus rhythm.
Topics: Administration, Oral; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Heart Rate; Humans; | 1997 |
[Familial auricular fibrillation].
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Anticoagulants; Atenolol; Atrial Fibrillation; Digo | 1997 |
[Pharmacological cardioversion of isolated atrial fibrillation: recovery of atrial mechanical function and correlation with duration of arrhythmia].
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Function; Data Interpretation, Stat | 1997 |
Quinidine versus propafenone for conversion of atrial fibrillation to sinus rhythm.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Heart Rate; Humans; Propafenone; Quinidine; Treatment O | 1998 |
Hybrid pharmacologic and ablative therapy: a novel and effective approach for the management of atrial fibrillation.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flut | 1998 |
Effects of pilsicainide and propafenone on vagally induced atrial fibrillation: role of suppressant effect in conductivity.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Output; Dogs; Electric Conductivity; E | 1998 |
Atrial flutter with 1:1 atrioventricular conduction caused by propafenone.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Atrioventricular Node; Coronary Artery | 1998 |
Predictors of success in the conversion of new-onset atrial fibrillation using oral propafenone.
Topics: Acute Disease; Administration, Oral; Analysis of Variance; Anti-Arrhythmia Agents; Atrial Fibrillati | 1998 |
[Idiopathic atrial fibrillation of recent onset and atrial stunning: the echocardiographic evidence after pharmacological cardioversion].
Topics: Adult; Aged; Analysis of Variance; Anti-Arrhythmia Agents; Atrial Fibrillation; Echocardiography, Do | 1998 |
Radiofrequency ablation of atrial flutter due to administration of class IC antiarrhythmic drugs for atrial fibrillation.
Topics: Administration, Oral; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation | 1999 |
Radiofrequency ablation of "class IC atrial flutter" in patients with resistant atrial fibrillation.
Topics: Administration, Oral; Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Cath | 1999 |
Intravenous amiodarone versus propafenone for atrial fibrillation and flutter after cardiac surgery: a note of caution.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Cardiac Surgical Procedures | 1996 |
Electrophysiological effects of flecainide and propafenone on atrial fibrillation cycle and relation with arrhythmia termination.
Topics: Adrenergic beta-Agonists; Adult; Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; F | 1999 |
Persistent atrial flutter in patients treated for atrial fibrillation with amiodarone and propafenone: electrophysiologic characteristics, radiofrequency catheter ablation, and risk prediction.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; El | 1999 |
Transesophageal echocardiographic evidence of more pronounced left atrial stunning after chemical (propafenone) rather than electrical attempts at cardioversion from atrial fibrillation.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Blood Flow Velocity; Echocardiography, Dop | 1999 |
Must antidysrhythmic agents be given to all patients with new-onset atrial fibrillation?
Topics: Administration, Oral; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Drug Monitoring; Emergency | 1999 |
Recurrent atrial fibrillation associated with pulse administration of high doses of methylprednysolone: a possible prophylactic treatment.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Digoxin; Electrocardiography; Humans; Male; Methylpredn | 2000 |
Pharmacological atrial defibrillation via temporarily occluded coronary sinus: first clinical experience and implications for an implantable device.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Humans; Infusion Pumps, Implantabl | 2000 |
Electrophysiological heterogeneity of atrial fibrillation and local effect of propafenone in the human right atrium: analysis based on symbolic dynamics.
Topics: Algorithms; Anti-Arrhythmia Agents; Atrial Fibrillation; Body Surface Potential Mapping; Electrophys | 2000 |
Amiodarone to prevent recurrence of atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Coronary Disease; Humans; Hypertrophy, Left | 2000 |
Propafenone-induced ataxia: report of three cases.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Ataxia; Atrial Fibrillation; Brain; Fem | 2000 |
Evaluation of CYP2D6 oxidation of dextromethorphan and propafenone in a Chinese population with atrial fibrillation.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; China; Cytochrome P-450 CYP2D6; Dextromethorphan; Dextr | 2001 |
The actions of ibutilide and class Ic drugs on the slow sodium channel: new insights regarding individual pharmacologic effects elucidated through combination therapies.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Drug Therapy, Combination; Electrocardiogr | 2000 |
[Atrial fibrillation after open-heart surgery--incidence, prevention and treatment].
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2000 |
Differential effects of dofetilide, amiodarone, and class lc drugs on left and right atrial refractoriness and left atrial vulnerability in pigs.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Atrial Function, L | 2001 |
Class IC antiarrhythmic drug induced atrial flutter: electrocardiographic and electrophysiological findings and their importance for long term outcome after right atrial isthmus ablation.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Electro | 2001 |
Altered values of heart rate variability in patients with relapse of atrial fibrillation during the first week after electrical cardioversion: preliminary data.
Topics: Aged; Amiodarone; Atrial Fibrillation; Circadian Rhythm; Electric Countershock; Electrocardiography, | 2001 |
Global distribution of atrial ectopic foci triggering recurrence of atrial tachyarrhythmia after electrical cardioversion of long-standing atrial fibrillation: a bi-atrial basket mapping study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; | 2001 |
Late-breaking clinical trials at the American Heart Association's scientific sessions 2001.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Coronary Artery Bypass; Coron | 2001 |
Algorithmic complexity. A new approach of non-linear algorithms for the analysis of atrial signals from multipolar basket catheter.
Topics: Algorithms; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Catheterization; Female; Humans; Ma | 2001 |
Amiodarone: pearl or peril?
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cost-Benefit Analysis; Humans; Propafenone; | 2002 |
[Familial manifestation of idiopathic atrial flutter].
Topics: Adolescent; Atrial Fibrillation; Atrial Flutter; Cardiac Complexes, Premature; Child; Digoxin; Drug | 1992 |
[Efficacy of intravenous and per os propafenone in the ambulatory treatment of recent-onset atrial fibrillation].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Ambulatory Care; Atrial Fibrillation; Clinical | 1992 |
Efficacy of intravenous propafenone in acute atrial fibrillation complicating open-heart surgery.
Topics: Acute Disease; Aged; Atrial Fibrillation; Blood Pressure; Cardiac Output; Cardiac Surgical Procedure | 1992 |
Propafenone-induced torsade de pointes: cross-reactivity with quinidine.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Cross Reactions; Electrocardiography; Female; Hum | 1991 |
Effects of transcatheter cardioversion on chronic lone atrial fibrillation.
Topics: Atrial Fibrillation; Cardiac Catheterization; Cardiac Pacing, Artificial; Chronic Disease; Disopyram | 1991 |
Long term efficacy of propafenone for prevention of atrial fibrillation.
Topics: Atrial Fibrillation; Female; Follow-Up Studies; Humans; Male; Middle Aged; Propafenone; Recurrence; | 1991 |
[Hemolytic reaction resulting from propafenone administration].
Topics: Anemia, Hemolytic; Atrial Fibrillation; Female; Humans; Injections, Intravenous; Male; Middle Aged; | 1991 |
Restoration of sinus rhythm in atrial fibrillation of recent onset using intravenous propafenone.
Topics: Aged; Atrial Fibrillation; Drug Evaluation; Female; Heart Rate; Humans; Infusions, Intravenous; Male | 1991 |
The hazards of using type 1C antiarrhythmic drugs for the treatment of paroxysmal atrial fibrillation.
Topics: Anilides; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Encainide; Flecainide; Hemodynamics; | 1990 |
Therapy of refractory symptomatic atrial fibrillation and atrial flutter: a staged care approach with new antiarrhythmic drugs.
Topics: Adult; Aged; Atrial Fibrillation; Atrial Flutter; Data Interpretation, Statistical; Drug Administrat | 1990 |
New hope in atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Propafenone; Quinidine; Sotalol | 1990 |
Propafenone in the prevention of non-ventricular arrhythmias associated with the Wolff-Parkinson-White syndrome.
Topics: Adult; Atrial Fibrillation; Drug Administration Schedule; Echocardiography; Electrocardiography; Ele | 1990 |
Acceleration of conduction within an accessory pathway with propafenone.
Topics: Adult; Atrial Fibrillation; Atrial Flutter; Cardiac Pacing, Artificial; Electrocardiography; Electro | 1990 |
Atrial flutter in patients treated for atrial fibrillation with propafenone.
Topics: Atrial Fibrillation; Atrial Flutter; Electrocardiography; Follow-Up Studies; Heart Rate; Humans; Pro | 1990 |
[Antiarrhythmic effect and blood levels of propafenone].
Topics: Adult; Aged; Atrial Fibrillation; Cardiac Complexes, Premature; Chromatography, High Pressure Liquid | 1987 |
[Use of prolecofen in the treatment of arrhythmia in patients with ischemic heart disease].
Topics: Adult; Aged; Atrial Fibrillation; Cardiac Complexes, Premature; Coronary Disease; Female; Hemostasis | 1989 |
[Use of propafenone in emergency therapy].
Topics: Adult; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Drug Evaluation; Electrocardiograp | 1989 |
Lidocaine, mexiletine and propafenone in the treatment of arrhythmias complicating myocardial infarction. A case report.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Cardiac Complexes, Premature; Dru | 1985 |
Efficacy of intravenous propafenone for the acute management of atrial fibrillation.
Topics: Adult; Aged; Aged, 80 and over; Arrhythmia, Sinus; Atrial Fibrillation; Double-Blind Method; Echocar | 1989 |
[Treatment of recent atrial fibrillation with intravenous propafenone].
Topics: Atrial Fibrillation; Drug Evaluation; Electrocardiography; Female; Humans; Injections, Intravenous; | 1989 |
Therapeutic efficacy and safety of oral propafenone for atrial fibrillation.
Topics: Administration, Oral; Aged; Atrial Fibrillation; Electrocardiography; Female; Follow-Up Studies; Hum | 1989 |
[I.v. propafenone in supraventricular paroxysmal tachyarrhythmias in patients with Wolff-Parkinson-White syndrome. 2 clinical cases].
Topics: Adult; Atrial Fibrillation; Electrocardiography; Female; Humans; Infusions, Intravenous; Propafenone | 1988 |
Oral propafenone therapy for patients with paroxysmal supraventricular tachyarrhythmia.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Atrial Fibrillation; Female; Humans; Male; Mid | 1988 |
Propafenone for paroxysmal atrial fibrillation.
Topics: Atrial Fibrillation; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Middle Aged; Prop | 1988 |
Propafenone for prevention of recurrent atrial fibrillation.
Topics: Adult; Aged; Atrial Fibrillation; Female; Follow-Up Studies; Humans; Male; Middle Aged; Propafenone; | 1988 |
Propafenone: new therapy for a tough, old arrhythmia.
Topics: Atrial Fibrillation; Atrial Flutter; Electric Countershock; Humans; Propafenone; Recurrence | 1988 |
Long-term oral propafenone therapy for suppression of refractory symptomatic atrial fibrillation and atrial flutter.
Topics: Actuarial Analysis; Administration, Oral; Atrial Fibrillation; Atrial Flutter; Female; Humans; Male; | 1988 |
[Pharmacologic cardioversion with propafenone of stable atrial fibrillation of recent onset].
Topics: Adult; Aged; Amiodarone; Atrial Fibrillation; Electrocardiography; Female; Humans; Injections, Intra | 1987 |
[Fibrillation and atrial flutter. Immediate control and conversion to sinus rhythm with intravenous propafenone].
Topics: Adult; Aged; Aged, 80 and over; Atrial Fibrillation; Atrial Flutter; Female; Humans; Hypotension; In | 1987 |
[Digoxin-propafenone interaction: values and limitations of plasma determination of the 2 drugs. Anti-arrhythmia effectiveness of propafenone].
Topics: Adult; Aged; Arrhythmias, Cardiac; Atrial Fibrillation; Digoxin; Drug Interactions; Drug Therapy, Co | 1986 |
[Electrophysiologic effects of diprafenone in supraventricular and ventricular tachycardia].
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Bundle of His; Cardiomyopathy, Dilated; Coronary Diseas | 1986 |